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Cytochromes P450 are of potential synthetic value because they hydroxylate a large array 
of substrates, often with high regio- and enantioselectivity.  In contrast to most P450s, the 
BM-3 variant from Bacillus megaterium is soluble, easily expressed in E. coli, and does 
not require additional electron transfer proteins.  A highly efficient enzyme for its 
preferred reaction, hydroxylation of medium-chain (C12 to C18) fatty acids, BM-3 is a 
good candidate for engineering for applications requiring activity on other substrates.  
Using iterations of random mutagenesis, recombination, and high throughput screening, 
we engineered P450 BM-3 mutants to hydroxylate linear alkanes as short as propane.  
Activity towards linear alkanes was further increased by changing two key active site 
residues. The resulting mutants hydroxylate linear alkanes with high regioselectivity and, 
notably, enantioselectivity.  
We further engineered these enzymes with guidance from the crystal structure of 
substrate-bound P450 BM-3.  Eleven active-site residues were chosen for saturation 
mutagenesis, and the resulting mutants were screened for improved activity towards 
alkanes, as measured by total product formation.  Substitutions at these positions 
generally did not affect correct folding of the enzyme, and a large fraction of folded 
proteins retained similar levels of activity as their predecessor.  Moreover, several of the 
11 selected amino acid substitutions yielded mutants that were both more active and 




Recombination of these beneficial active-site mutations generated BM-3 variants that 
catalyze: (a) regio- and enantioselective hydroxylation of linear alkanes; (b) terminal 
hydroxylation of linear alkanes; (c) regio- and enantioselective hydroxylation of 
heterocyclic compounds; and (d) ethane hydroxylation.   
The selective conversion of ethane to ethanol, not previously reported for any P450, is 
catalyzed by the most active mutant from this library.  In nature, this reaction is solely 
observed for methane monooxygenases (MMOs) and related enzymes in alkane-
assimilating bacteria. 
Additionally, we have found that the reductase domain can be engineered to increase the 
efficiency of these reactions.  Our progress in converting BM-3 from a fatty-acid 
hydroxylase into an enzyme able to selectively hydroxylate smaller alkanes, including 
ethane, is an important step towards our ultimate goal, achieving selective BM-3 





Methane is a potent greenhouse gas that is emitted from natural and human-influenced 
sources. Reducing methane emissions by increasing its recovery in the form of chemicals, 
such as methanol, would have significant economic and environmental benefits. Methane 
is currently converted to methanol via the syngas reaction, an energy-intensive steam 
reformation process that is economically feasible only on a large scale. The most 
common source of methane is excavation of subterraneous raw natural gas or petroleum. 
In many instances, transportation limitations prevent methane recovery, and methane is 
therefore typically burned on-site or vented directly to the atmosphere.   
Oxidation of n-alkanes to n-alcohols is extremely difficult, due to the high alkane C-H 
bond strength, and the fact that the catalyst must control the oxidation to stop at the 
alcohol and not continue further to the thermodynamically favoured oxidation products, 
e.g., aldehydes, ketones, carboxylic acids or carbon dioxide. Despite decades of research, 
this transformation continues to pose a great challenge to classic chemistry. The solutions 
nature has found for this reaction are monooxygenases. These enzymes catalyze the 
selective insertion of one oxygen atom into a C-H bond of a non-activated carbon atom, 
while reducing the second oxygen atom to H2O with electrons from NADH or NADPH.  
These enzymes perform this reaction at room temperature, and utilize dioxygen as a 
cheap and non-toxic oxidant. The methane monooxygenases (MMO), for example, 
enable methanotrophic bacteria to use methane as a source of carbon and energy. 
Microorganisms that grow on C2 to C4 gaseous alkanes are dependent on non-heme (di-




a source of inspiration for designers of synthetic catalysts. That they are not yet used in 
large-scale industrial oxidation processes reflects their large size and complexity: despite 
much effort, these multi-component enzymes have never been functionally expressed in a 
heterologous organism.  Thus it has been extremely difficult to use modern metabolic and 
protein engineering tools to generate optimized industrial strains of MMO-utilizing 
microorganisms for biological production of chemicals or fuels from methane or ethane. 
We therefore chose to follow a completely different strategy by trying to convert a 
cytochrome P450 into a methane hydroxylating catalyst.   
Cytochromes P450 are a large superfamily of heme-containing monooxygenases that 
catalyze the oxidation of a vast array of substrates, including n-alkanes.  Chapter 1 of this 
thesis provides an introduction to cytochromes P450 and a detailed review of progress 
made in the engineering of these enzymes.  In particular, the diversity of P450-catalyzed 
reactions is illustrated, and site-directed mutagenesis studies that provide much of our 
present knowledge about how these systems work are presented.  P450s are now a 
relatively well understood class of proteins, making them a good target for engineering 
approaches.  Rational design and directed evolution have been applied to engineer these 
proteins. The engineering of a select group of P450s to accept novel substrates, to change 
their regio- and enantioselectivity of substrate hydroxylation, and to alter protein-protein 
interactions and electron transfer processes are described.  
Although the hydroxylation of non-activated C-H bonds is the most common P450 
catalyzed reaction, none of the thousand-plus members of this family are known to 




hydroxylating these substrates is the focus of this thesis.  For several reasons, cytochrome 
P450 BM-3, a bacterial P450 from Bacillus megaterium was chosen as the starting point 
for this effort: the enzyme is robust and soluble; it presents one of the rare cases in which 
heme and FAD- and FMN-containing NADPH dependent reductase domain are fused to 
form a single polypeptide; and it catalyzes the hydroxylation of a range (C12 to C18) of 
fatty acids with a kcat of 17,100 min-1, which is the highest catalytic activity reported 
amongst P450 monooxygenases.  
Three postdoctoral scholars in our laboratory (Ulrich Schwaneberg, Edgardo T. Farinas, 
and Anton Glieder) initiated the work on P450 BM-3 in our laboratory.  Their first step in 
converting this P450 into a methane monooxygenase was to engineer variants active 
towards linear alkanes lacking the carboxylate moiety. Directed evolution – iterations of 
random mutagenesis, recombination, and screening – was applied to generate P450 
variants with improved alkane hydroxylation activity. A colorimetric screening system 
employing p-nitrophenoxy octane as a surrogate substrate was chosen. In addition, 
NADPH oxidation in presence of the linear alkane substrate was monitored. This 
approach had important limitations: the surrogate substrate does not resemble the linear 
alkane structure very well, and electron transfer from NADPH to the heme is not 
necessarily coupled to product formation. Nevertheless, variants exhibiting high activity 
towards octane were identified. Limited activity towards propane, a substrate not 
hydroxylated at all by the wild-type enzyme, was also observed.  At this point, I took 




Chapter 2 describes the further steps in elevating the activity towards linear alkanes.  
Directed evolution was used to identify mutants with increased activity towards these 
substrates.  Initially, the selection of mutants was based on monitoring NADPH depletion 
in the presence of an alkane substrate. To overcome the problem of identifying mutants in 
which cofactor oxidation is not coupled to product formation, a new screening system 
(developed by Matthew W. Peters) that employs methyl ether derivatives of linear 
alkanes. Upon hydroxylation of the methoxy group, formaldehyde is released, which is 
readily detectable in high-throughput format using a commercially available dye. 
Initially, random mutagenesis was applied to the heme domain. Improvements in activity, 
however, were hard to achieve, and mutations were repeatedly identified in the active site.  
This led us to investigate further the active site.  At first, two active-site residues were 
chosen based on the crystal structure and prior research for saturation mutagenesis and 
site-directed mutagenesis. The resulting mutants oxidize n-alkanes, including propane, to 
the corresponding alcohols at high rates (up to 660 min-1) and product turnovers 
(thousands per active site).  It was further observed that the regioselectivity of these 
mutants was significantly altered by introducing mutations in the active site, with the 2-
alkanol being the major product isomer.  Matthew W. Peters made the remarkable 
observations that linear alkanes were hydroxylated enantioselectively; this was the first 
report of enantioselective hydroxylation of linear alkanes.   
The success of applying mutagenesis directly to the active site encouraged us to 
investigate further the role of specific active site residues. Chapter 3 describes the 




chosen for their proximity to the bound fatty acid substrates co-crystallized with BM-3 
heme domain in published crystal structures.  Unexpectedly, a large fraction of mutants 
remained folded and active towards at least one of two screening substrates, hexyl methyl 
ether and dimethyl ether.  The most active mutants were then recombined to generate a 
library of approximately 9,000 P450 BM-3 variants, each of which contains a 
characteristic active site. 17 mutants with significantly increased alkane hydroxylation 
activity were further analysed. Each of these mutants produced a distinct mixture of 
product regioisomers.  Remarkably, and this is detailed in Chapter 4, one of the mutants 
was able to catalyze the terminal hydroxylation of octane.  This had never before been 
observed in a P450 BM-3 variant.  
The regio- and enantioselective hydroxylation of non-activated carbon atoms is a highly 
useful reaction in organic chemistry.  The synthesis of chiral alcohols that can be used as 
synthons or pharmaceutical intermediates has received much attention in recent years, but 
still remains a challenge in synthetic chemistry.  Cytochromes P450 catalyze the selective 
hydroxylation of a wide variety of substrates, often with high regio- and 
enantioselectivity. The fact that P450s are involved in the degradation of most drug 
compounds currently on the market makes them well-suited candidates for this 
application.  To access these activities, it is necessary to identify a highly active and 
robust P450 with the desired substrate specificity. These demands, however, were not 
targeted during the natural evolution of enzymes, therefore making it necessary to 
improve upon existing ones.  In Chapter 5, the application of active site variants of P450 




remarkably from linear alkanes is described.  P450 mutants with modified active sites 
were tested for their ability to hydroxylate the achiral carboxylic acid derivative 2-
cyclopentanebenzoxazole.  This work was done in collaboration with Anna de Raadt (TU 
Graz, Austria) who had previously used this derivative to make carboxylic acid 
compounds amenable to enzymatic hydroxylation reactions.  Mutants previously 
identified for the efficient and selective conversion of linear alkanes also proved to be 
useful hydroxylation catalysts for this compound.  We anticipate that a vast variety of 
substrates can be hydroxylated regioselectively by at least one of the variants.  
The main goal of this research, selective hydroxylation of methane or ethane, was 
partially achieved:  The active site variant with the highest activity towards propane was 
subsequently examined for its ability to hydroxylate ethane.  In Chapter 6, the first 
cytochrome P450 that selectively converts ethane to ethanol is described. This is also the 
first report of a porphyrin-based catalyst for this reaction. The limited productivity of the 
enzyme (50 turnovers per active site) was further improved by evolving the reductase 
domain.  The resulting enzyme catalyzes at least 250 turnovers of ethane to ethanol, with 
no overoxidation, at room temperature and pressure, using oxygen from the air.  This is a 
key step towards P450-catalyzed methane oxidation that would open new opportunities 
the bioconversion methane to fuels and chemicals. 
Chapter 7 provides a discussion of the protein engineering strategy chosen for this 
research and proposes future experiments aimed at overcoming some of the problems and 
limitations associated with it.  Finally, Chapter 8 details experimental procedures used 
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Petroleum and natural gas compounds are the cheapest and most abundant hydrocarbons 
available.  Due to the lack of catalysts for the selective activation of the notoriously inert C-
H bonds, these hydrocarbon sources cannot be converted directly into more valuable 
products.  Instead, they are either used as fuels to produce energy, or are converted to more 
reactive alkenes by energy-intensive high temperature, endothermic processes, such as 
dehydrogenation or cracking.  These processes also produce unwanted and often 
environmentally hazardous side products [1-3].  The ability to perform direct and selective 
activation of alkanes to high value products such as alcohols, ketones, amines or acids 
would allow more efficient utilization of the hydrocarbon feedstocks.   
Natural gas reserves, including methane hydrates, are thought to be twice as large as known 
oil reserves [4].  In addition to these reservoirs, methane is constantly produced by 
methanogenic organisms capable of reducing carbon dioxide to methane.  A large portion 
of gaseous methane cannot be used as fuel due to the economic and practical limitations of 
current methods of safe transport and storage on a large scale.  Some of these problems 
could be solved by the efficient conversion of these methane resources into liquid 
methanol.  Existing methods to do this on a large scale are energy-intensive, multi-step 
processes that are uneconomical for use of methanol as a fuel.  Efficient methods for direct 
conversion of methane to methanol are intensively sought after because these would be 
energetically much more efficient [3,5].   
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Alkanes are among the least reactive of organic compounds, and are inert even to common 
acids or bases, or common oxidizing or reducing agents [6].  This lack of chemical 
reactivity arises from the high bond energy of C-C and C-H bonds.  Alkanes do, however, 
react with oxygen at high temperature, yielding carbon dioxide and water.  This reaction is 
thermodynamically favored over selective oxidation stopping at one of the first stages of 
the reaction (e.g., at the alcohol), because the oxidation products have more reactive C-H 
bonds than the alkane itself [7].  The regioselectivity of the oxidation reaction is typically 
governed by the relative bond dissociation energies; i.e., tertiary and secondary carbon 
atoms are favored over primary carbon atoms.  Therefore, the terminal (i.e., methyl carbon) 
hydroxylation of linear alkanes is disfavored and regioselective oxidation (i.e., oxidation of 
a specific C-H bond) of alkanes is difficult because the C-H bonds of the methylene groups 
are very similar in energy.  Functionalization of alkane C-H bonds to yield the respective 
alcohols or acids is highly desirable and would have far reaching economic implications.  
Such methods are, however, are not generally available. 
The functionalization of alkanes has received much attention in recent years.  Major 
advances toward transformation of alkane C-H bonds have been achieved using transition 
metal catalysts [8], but these reactions are generally only possible in organic solvents and 
are water and/or air sensitive.  Nature has provided examples of efficient alkane 
functionalization achievable under environmentally benign conditions.  The advantages of 
such biological processes lie in the ability of enzymes to catalyze selective alkane oxidation 
reactions under mild temperatures and pressures, using dioxygen or peroxide as the 
oxidant, and producing no side-products other than water.  A biotechnological process in 
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which enzymes are used as catalysts to activate alkanes would lead to reductions in energy 
and toxic waste products while simultaneously increasing the safety of the process.  
Several enzymes abundant throughout nature have been reported that are able to catalyze 
these difficult reactions.  Monooxygenases are a class of enzymes capable of inserting an 
oxygen atom into a wide variety of substrates.  Three distinct types of monooxygenases are 
utilized by a variety of organisms to active alkanes: diiron monooxygenase enzymes, such 
as soluble methane monooxygenase (sMMO) and alkane hydroxylase (AlkB); copper 
containing monooxygenases, such as the particulate methane monooxygenase; and 
cytochromes P450.  Several recent review articles focus on the biochemistry and 
mechanism of these enzymes [9-12].  In this chapter, we will briefly review the organisms 
that utilize these enzymes for alkane assimilation and the enzymes themselves.  Particular 
emphasis will be placed on cytochromes P450, especially bacterial ones and prior work 
focused on engineering cytochromes P450.   
 
B. Organisms that Grow Aerobically on Alkanes  
Several microorganisms have been found to aerobically utilize alkanes of various chain 
lengths. In the first step, they oxidize n-alkanes to the corresponding primary or secondary 
alcohols by terminal (i.e., methyl carbon), subterminal (i.e., methylene carbon) or 
biterminal (i.e., methyl carbons at both ends) oxidation.  Methane-oxidizing bacteria, 
methanotrophs, are capable of utilizing methane as a growth-supporting alkane [13].  The 
other gaseous alkanes (C2-C4) also support growth of alkane–oxidizing bacteria [14], as do 
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medium (C5-C12) to long chain (C10-C20) alkanes [10].  The groups of alkane utilizing 
organisms are briefly reviewed below.  Most previous studies in this area have focused on 
the isolation and characterization of the organisms themselves.  Considerably less is known 
about the enzymes involved in the first alkane oxidation step.  
 
B.1. Methanotrophs 
Methanotrophic bacteria are unique in their ability to utilize methane as their sole carbon 
and energy source.  Methanotrophs have been classified in six different genera: 
Methylococcus, Methylomicrobium, Methylobacter, Methylomonas, Methylocystis, and 
Methylosinus [13].  Their defining characteristic is the use of enzymes known as methane 
monooxygenases to catalyze the oxidation of methane to methanol.  All methanotrophs can 
produce a membrane-bound particulate form of MMO (pMMO) while only some 
methanotrophs can additionally produce a soluble form of MMO (sMMO) under conditions 
of copper limitation [15].  Methanol is further oxidized to formaldehyde, formate and 
finally CO2 (Figure 1.1), generating two equivalents of NADPH, one of which is utilized 
by MMO, the other of which is fed into the respiratory chain to support generation of ATP.  
A fraction of the formaldehyde is not further oxidized but instead used to synthesize cell 
material [16].   
 6 




+ H2ONAD+ + + H+NADH +
CH3OH HCHO
HCHO HCOOH






Figure 1.1. Metabolism of methane by methanotrophs.  Methane is oxidized by a methane 
monooxygenase, forming methanol (1).  The second oxidation step involves oxidation of 
methanol to formaldehyde, which is catalyzed by a pyrroloquinoline (PQQ) dependent 
methanol dehydrogenase (2).  Formaldehyde is further oxidized to formate by 
formaldehyde dehydrogenase (3), and formate is finally oxidized to carbon dioxide by 
formate dehydrogenase (4).   
 
B.2. Gaseous Alkane Utilizers   
Microorganisms that assimilate gaseous hydrocarbons other than methane (ethane, 
propane, butane) as a source of carbon and energy have been known for a long time.  Initial 
interest arose due to the possibility of producing biomass from natural gas components 
other than methane.  In the 1970s and 1980s, substantial research focused on isolating 
bacterial strains capable of growing on gaseous alkanes.  Since then, several such 
microorganisms have been isolated, and are reviewed in [14].  These are mainly species 
belonging to the Gram positive bacteria Corynebacterium, Nocardia, Mycobacterium, 
Rhodococcus, Arthrobacter, Brevibacterium [17-21], but Gram negative bacteria such as 
certain Pseudomonas species have also been isolated [18].  Fungi that utilize gaseous 
alkane have been reported as well.  Species of Acremonium, Allescheria, Candida, 
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Fusarium, Graphium, Penicillium and Phialaphora have been shown to utilize C2 to C4 n-
alkanes [22-25].  
Fundamental knowledge of the monooxygenases involved in the first alkane oxidation step 
of C2 to C4 gaseous alkanes remains scant.  Propane monooxygenases from Rhodococcus 
species have been described and evidence exists that these enzymes are not a cytochrome 
P450 monooxygenase [20,26-28].  Propane oxidation in a Gordonia strain is catalyzed by 
an NADH-dependent multi-component enzyme system belonging to the family of non-
heme diiron monooxygenases [29].  Also, in at least three cases, the sequences of butane 
monooxygenases have been found to align most closely with non-heme diiron 
monooxygenases [30-32]. 
A variety of degradative pathways for gaseous alkanes hydroxylated by a monooxygenase 
at the terminal and subterminal carbon have been proposed.  Ethane, propane and butane 
are each metabolized differently, also depending on whether the alkane is oxidized 
terminally or subterminally (Figure 1.2).  Pathways originating from terminal alcohols are 
well understood.  In general, the primary alcohol is oxidized to an aldehyde, which is then 
subsequently converted to acetyl- or propionyl-CoA.  Subterminal oxidation of propane 
and butane has also been observed.  The pathways for metabolizing these molecules are not 
well understood.  In the case of 2-propanol, for example, several pathways have been 
proposed for the further metabolism [14].   
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Figure 1.2. Metabolism of gaseous alkanes.  The alkane (C2 to C4) is hydroxylated by a 
monooxygenase to form a terminal alcohol (1) which is subsequently oxidized by an 
alcohol dehydrogenase to the aldehyde (2).  Depending on the carbon length, further 
metabolism proceeds differently.  a) Acetaldehyde is directly converted to acetyl-CoA (3) 
and then oxidized further via the Krebs-cycle. b) Propionaldehyde is converted to 
propionyl-CoA (4).  Several pathways have been proposed for propionyl-CoA [33].  One of 
them involves conversion to pyruvate via the methylcitrate cycle (5) [34].  c) 
Butyraldehyde is converted to butyryl-CoA (6) and subsequently oxidized via the β-
oxidation pathway to yield two molecules of acetyl-CoA (7). 
 
B.3. Microorganisms that Grow on Liquid Alkanes  
Organisms that utilize liquid alkanes (C5 to C12) and their corresponding enzyme systems 
have been studied in more detail.  Pseudomonas putida is capable of growing on n-alkanes 
and was found to contain an alkane hydroxylase system [35,36].  The substrate range 
includes straight-chain, branched, and cyclic alkanes and fatty acids [37].  The hydroxylase 
part of this system is a non-heme diiron monooxygenase.  Homologous proteins have been 
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identified in species of alkane utilizing bacteria of the genera Acinetobacter, Alcanivorax, 
Burkholderia, Mycobacterium, Pseudomonas and Rhodococcus.  While the Pseudomonas 
putida alkane hydroxylase system primarily acts on C5 to C12 alkanes, most of these 
homologous enzymes hydroxylate alkanes of more than 10 carbon atoms [38]. 
Several alkane assimilating yeasts have been reported, such as Candida maltosa, C. 
tropicalis, C. apicola, Yarrowia lipolytica and Debaryomyces hansenii, that utilize a 
cytochrome P450 for the oxidation of n-alkanes [39-41].  These yeasts utilize cytochromes 
P450 of the CYP52 family for alkane degradation by ω-hydroxylation.  Reports of bacteria 
that utilize P450s for the degradation of n-alkanes are not as frequent.  An octane 
assimilating Corynebacterium was reported by Cardini et al. that utilizes a P450 system for 
the first oxidation step [42].  And a new bacterial class of P450s was cloned from 
Acinetobacter calcoaceticus grown on n-hexadecane [43].  The further metabolism of 
alkanes is described in Figure 1.3 (see captions for details) [16].  
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Scheme 1.3. Metabolism of liquid alkanes.  a) The alkane is hydroxylated by a 
monooxygenase to form a terminal alcohol (1) which is subsequently oxidized to the 
aldehyde (2) and the carboxylic acid (3) by an alcohol dehydrogenase and an aldehyde 
dehydrogenase, respectively.  The carboxylic acid is then metabolised via the β-oxidation 
pathway.  b) The alkane is hydroxylated by a monooxygenase to form subterminal 
oxidation products (4).  These are further oxidized to a ketone by a alcohol dehydrogenase 
(5) and subsequently converted into an acetylester by a second monooxygenase (6).  The 
acetylester is hydrolyzed by an acetylesterase to form acetate, which is further converted to 
acetyl-CoA and oxidized via the Krebs cycle, and a primary alcohol, which is oxidized as 
in (1).  
 
C. Alkane Oxidizing Enzymes 
The enzymes utilized by the organisms described above have generally not been purified, 
cloned or characterized.  Previous research has focused on four distinct enzymes, listed in 
Table 1.1.  Enzyme systems identified in other alkane assimilating microorganisms appear 
to be homologs of these.   
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Table 1.1. Alkane hydroxylating enzymes [44]. 
  
Enzyme 
(EC number) Microorganism Substrates Active Site 
pMMO 
(1.14.13.25) All methanotrophs 
C1-C5 linear 
alkanes Copper cluster 
sMMO 
(1.14.13.25) 





C1-C7 linear and 










C5-C24 alkanes Diiron cluster 
Cytochrome 
P450 (1.14.14.1) 
Bacillus megaterium,  






C.1. Methane Monooxygenases 
Methane monooxygenases (MMO) are the only enzymes known capable of efficiently 
catalyzing oxidative cleavage of the extremely stable C-H bond of methane.  All 
methanotrophs can produce a membrane-bound, particulate form of MMO (pMMO) while 
only a subset of methanotrophs can produce a soluble form of MMO (sMMO) which is 
produced under conditions of copper limitation  [15].  
Soluble methane monooxygenase has been purified and is well characterized.  It consists of 
three protein components: a hydroxylase (245 kDa) containing a binuclear iron cluster that 
is the active site of MMO, an NADH-dependent reductase (40kDa), containing FAD and a 
[2Fe-2S] cluster, and a regulatory subunit (16 kDa). It exhibits broader substrate specificity 
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than pMMO, and can accept substrates such as alkenes, aromatic and heterocyclic 
compounds [45].  In contrast to sMMO, pMMO is produced under conditions of copper 
sufficiency in methanotrophs.  It has a narrower substrate range than sMMO, but can still 
catalyze the co-oxidation of alternative substrates, including propane and butane [10,11].  
pMMO consists of three polypeptides with molecular masses of 47, 27 and 25 kDa and is 
arranged as an α3β3γ3 trimer.  The crystal structure of pMMO was solved recently [46] and 
revealed two metal centers, modelled as mononuclear and a dinclear copper centers.  The 
active site in which methane is oxidized was, however, not identified.  
 
C.2. Alkane Hydroxylase 
Biochemical and genetic studies have thus far focused on a very limited number of alkane 
hydroxylases, such as the Pseudomonas putida GPo1 alkane hydroxylase [47], which 
facilitates growth on C4 to C12 n-alkanes by oxidizing them to terminal alcohols, thereby 
allowing the host to grow on these compounds.  Only recently has it become apparent 
that this enzyme is the prototype of a very diverse collection of related non-heme iron 
integral membrane oxygenases, reviewed in [10].  The P. putida GPo1 alkane 
hydroxylase system consists of three components: alkane hydroxylase (AlkB), rubredoxin 
(AlkG), and rubredoxin reductase (AlkT).  AlkB is a non-heme iron integral membrane 
protein that carries out the hydroxylation reaction [37,48,49].  Rubredoxin transfers 
electrons from the NADH-dependent flavoprotein rubredoxin reductase to AlkB.  The 
molecular genetics of this enzyme system has been reviewed recently [50].  Genes that 
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related to the alkane hydroxylase gene (alkB) of GPo1 have been detected in several 
species of Gram-positive and negative bacteria [51,52].  
 
C.3. Cytochrome P450 
Cytochromes P450 are a large superfamily of heme proteins found in all domains of life 
that, as a whole, perform a diverse array of redox chemistries on an extremely wide variety 
of substrates.  Most P450s are NADPH-dependent monooxygenases, introducing an 
oxygen atom from dioxygen into non activated carbon atoms to yield often optically pure 
products according to reaction: 
RH + O2 + NAD(P)H + H+ → ROH + H2O + NAD(P)+
Less common reactions catalyzed by these versatile enzymes include, but are not limited to, 
alkene epoxidation, amine and thioether oxidations, dealkylation of amines, ethers, and 
thioethers, oxidative and reductive dehalogenations, and dehydrogenations.  P450s are used 
for the catabolic degradation of alkanes and aromatics in bacteria, drugs and xenobiotics in 
animals, and herbicides (both natural and synthetic) in plants.  Additionally, key steps in 
the biosynthesis of physiologically important compounds, such as steroids, fatty and bile 
acids, eicosanoids, and fat-soluble vitamins, are catalyzed by P450s.  The ability of the 
P450 platform to accommodate different substrates and chemistries has been repeatedly 
demonstrated by nature, providing much inspiration both to biochemists trying to 
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understand how these systems work, and to protein engineers trying to introduce new 
activities into this malleable platform.   
Cytochrome P450s (CYPs) were first discovered in the 1960s.  Since then more than 3,000 
different P450 genes have been described (updated regularly at 
http://drnelson.utmem.edu/CytochromeP450.html) and much has been learned about the 
catalytic cycle of dioxygen activation and substrate oxidation, although structure-function 
relationships are far from being well understood.  Despite their catalytic variety, P450s all 
share the same reaction center: a protoporphyrin-IX-coordinated iron (i.e., heme) with a 
distal cysteinate as its fifth ligand.  The sixth coordination site on the iron is used to bind 
molecular oxygen upon the reduction of the iron to its ferrous state upon substrate binding 
[53].  Carbon monoxide bound to this iron center (reduced in vitro with dithionite) has an 
absorption maximum at 450 nm, giving P450s (pigment 450) their name.  The superfamily 
of P450 proteins (and their respective genes) is divided into families, subfamilies and 
individual members according to the similarity in their primary structure.  A new 
nomenclature has been introduced where CYP is used to characterize the respective P450 
as a heme protein.  The first Arabic number defines the gene family, the following letter the 
subfamily and the second number the individual enzyme, e.g., CYP1A1 for cytochrome 
P4501A1 (previously P450c).  Members of the same gene family are defined as usually 
having < 40% sequence identity to a P450 protein from any other family.  Mammalian 
sequences within the same subfamily are always > 55 % identical.  The numbers of 
individual P450s in a species differs widely.   
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The mechanism of dioxygen activation at the heme is the same in most P450s, the chemical 
promiscuity of this family being determined mostly by the shape and polarity of the 
substrate-binding pocket used to position the substrate above the heme.  In this chapter, the 
diversity of P450-catalyzed reactions is illustrated and site-directed mutagenesis studies 
that have provided much of our present knowledge about how these systems work are 
detailed.  In light of these facts, the engineering of a few P450s to accept novel substrates, 
to change their regio- and stereoselectivity of substrate hydroxylation, and to alter their 
protein-protein interactions and electron transfer processes are described.  Recent review 
articles provide detailed discussions on protein engineering of P450s [54], and their general 
application [55] and utilization as biocatalysts [56,57]. 
 
C.3.1. The Catalytic Cycle 
The catalytic cycle of cytochromes P450 generally starts with binding of substrate (Figure 
1.4), inducing a change in spin state of the ferric heme iron from low to high spin and 
leaving the heme iron in a pentacoordinated state with higher reduction potential.  This 
makes possible the introduction of the first electron from NAD(P)H via an electron 
transport chain, reducing the heme iron to ferrous iron.  Next, oxygen binds, yielding an 
unstable ferrous-dioxy species, which is capable of accepting the second electron to 
produce a ferric peroxy anion.  In the next steps, the ferric peroxy anion is protonated to 

























































































Figure 1.4. The cytochrome P450 catalytic cycle.  See main text for details. 
 17 
formation of a putative ferryl species, formally equivalent to a Fe(V)=O species 
(Compound I).  Crystallographic measurements of P450 intermediates are consistent with 
the formation of an oxyferryl intermediate [58].  This species (or a similar reactive, 
electrophilic iron-oxo intermediate) then attacks the substrate, yielding the hydroxylated 
product which dissociates to let the cycle start again.  Interestingly, in many, but not all 
P450s, a so-called "shunt" reaction can proceed, where the substrate can be hydroxylated 
directly by peroxides such as hydrogen peroxide, cumene hydroperoxide and tert-butyl 
hydroperoxide without the necessity of stepwise activation of molecular oxygen and  
interaction with an electron donating systems [59].  Most reactions catalyzed by P450s 
appear to be consistent with this catalytic cycle and are briefly presented below. 
 
C.3.2. Common P450 Catalyzed Reactions  
The iron-oxo species described above is responsible for most P450 catalyzed reactions 
(Table 1.2).  This electron deficient intermediate is sufficiently reactive to insert its oxygen 
into inert C-H bonds, yielding an alcohol from an alkane in the most common case.   The 
similar hydroxylation of a carbon atom α to a heteroatom leads to O-, N-, or S-
dealkylations.   The active oxygen can also be used for the two-electron oxidation of S, N, 
P, and I atoms in organic compounds to form sulfoxides, N-oxides and hydroxides, 
phosphine oxides and iodoso-compounds.  Another common P450 reaction on which a lot 
of research and engineering effort has focused is oxidation of C=C double bonds to 
epoxides from olefins, and arene oxides from aromatic compounds.  The identity of the 
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oxidizing species (iron-oxo or iron-peroxo) for this reaction is still being debated.  P450s 
can also act as dehydrogenases.  In this case, the Fe(IV)-OH species is thought to abstract a 
hydrogen atom β to the substrate radical, instead of transfering the OH to the substrate 
radical.  Substrate specificity and regioselectivity in all of these reactions are determined by 
the surrounding protein scaffold.   The substrates can range in size from short linear alkanes 
up to large polycyclic aromatic compounds. 
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C.3.3. Less common P450 Catalyzed Reactions 
In addition to the common P450 catalyzed reactions briefly discussed above, members of 
the P450 superfamily are capable of a wide variety of other chemical transformations.  
important in the metabolism of drugs and xenobiotics.  It should be noted, however, that 
the biological significance of these reactions is not necessarily proven.  No protein 
engineering efforts have yet been undertaken to modify P450s involved in these reactions 
and thus, while they are interesting targets for future work, they are not discussed in this 
chapter.  The list of uncommon reactions is rather long: activities such as reduction, 
desaturation, oxidative ester cleavage, ring expansions, ring formations, aldehyde scissions, 
dehydration, ipso attack, one-electron oxidations, coupling reactions, rearrangements of 
fatty acids and prostaglandin hydroperoxides, isomeriziation and phospholipase D activity 
have been observed.  An extensive review discussing these various reactions and their 
proposed mechanisms was published recently [61]. 
 
D. Engineering Cytochromes P450 
D.1. Substrate Selectivity and Regioselectivity of Mammalian P450s 
Many of the mammalian cytochromes P450, especially those involved in metabolizing 
drugs and xenobiotics, exhibit broad substrate specificity, while the biosynthetically active 
P450s, such as the adrenal steroid hydroxylases, are rather specific.  Conversion of even a 
small fraction of mammalian P450 systems into useful synthetic catalysts, however, is 
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limited by several factors: the multi-component nature of most of these enzymes (they 
include an NADPH reductase component with or without a separate electron transfer 
component and a separate hydroxylase domain), the fact that most are membrane-bound, 
their limited stabilities, and their generally slow rates.  Many isoforms of mammalian 
P450s differ only in very few amino acids in the hydroxylase domain, while sharing the 
electron transfer systems.  Crystal structures of these membrane-bound P450s are not 
generally available. To date, only the structures of mutants of CYP2C5 [62-64], CYP2C8 
[65], CYP2C9 [66,67], CYP2B4 [68,69], and CYP3A4 [70,71] have been solved.   
Biosynthetically active P450s have been investigated using site-directed mutagenesis.  
These studies have helped unravel the structural basis of stereo- and regioselectivity of 
substrate hydroxylation in some mammalian isoforms [72-75], and have provided insight 
into the identity of substrate recognition sites in less related P450s [73,74,76-78]. 
Drug-metabolizing microsomal P450s have also been investigated using site-directed 
mutagenesis, capitalizing on the similarity of these enzymes among different species.  The 
results have been reviewed recently [79].  Most of the residues studied in these experiments 
are located in one of the so-called SRSs (substrate recognition sites), identified by Gotoh 
[80] on the basis of sequence comparison between the CYP2 family members and the 
structurally characterized bacterial P450cam (CYP101).  In some cases, chimeragenesis was 
applied to define regions of related P450s that are responsible for substrate specificity.  The 
results, which have been summarized in a recent review by Domanski and Halpert [79], 
have added considerably to our understanding of the role of specific residues in substrate 
binding and substrate specificity in these mammalian P450s. 
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The rational engineering of the substrate access channel of a protein for new substrates 
requires dynamic and structure-function information about the protein, information that is 
often missing.  An approach for obtaining proteins (especially poorly characterized ones) 
with new activities is to select them from libraries generated by random mutagenesis of key 
residues.  For example, Nakamura et al. [81] applied random mutagenesis to the substrate 
recognition sequences (SRS) of the indole-hydroxylating CYP2A6 and identified mutants 
that form primarily indigo from indole.     
It has become apparent that active site redesign of mammalian P450s to alter the 
hydroxylation regioselectivity of their natural substrates, or to accept new substrates is 
feasible.  Based on the increasing number of crystal structures and refined homology 
models, it is possible to study the affects of particular amino acids on substrate binding, or 
to engineer P450s with new activities, by identifying potentially important residues and 
performing mutagenesis experiments.   
 
D.2. Substrate Selectivity and Regioselectivity of Bacterial P450s 
Bacterial P450 systems generally exhibit higher catalytic rates than eukaryotic P450s and 
are easier to handle in the laboratory due to their solubility and high expressibility in 
heterologous hosts.  These properties also make bacterial P450s ideal targets for protein 
engineering.  Most work has focused on the two proteins P450cam (CYP101) and P450 BM-
3 (CYP102), and both have been engineered to accept a wide variety of substrates.  
P450cam, from Pseudomonas putida, requires the two additional electron transfer proteins 
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putidaredoxin, a ferredoxin of the [2Fe-2S] type, and putidaredoxin reductase, a FAD-
containing enzyme, for catalysis.  P450 BM-3 from Bacillus megaterium, is a single 
polypeptide chain, comprised of a heme domain and a FAD and FMN containing NADPH-
dependent reductase domain [82].  At hydroxylation rates on fatty acid substrates in the 
range of thousands min-1, P450 BM-3 has the highest known catalytic rate of any P450.  
These two proteins were the first two members of the P450 superfamily of which crystal 
structures became available [83,84], providing research groups with some insight into their 
mechanisms and ideas for their rational engineering.  Additional crystal structures of these 
enzymes bound to different substrates [85-89] and containing mutations [90-96] have 
become available and have contributed to this insight.  Most engineering work with these 
systems has focussed on altering the specificity and regioselectivity of hydroxylation 
reactions catalyzed by these proteins. 
 
D.2.1. P450cam
The first attempts at engineering a P450 were performed with P450cam which hydroxylates 
camphor at its 5-exo position.  Based on the three-dimensional structure of substrate-bound 
P450cam [97], active site substitutions T101M, T185F, and V247M were introduced to alter 
the stereochemistry and efficiency of ethylbenzene hydroxylation.   The reaction of the 
wild-type enzyme with this substrate produces one regioisomer, 1-phenylethanol, with only 
5% coupling of NADPH-consumption to product formation (i.e., 95% of reducing 
equivalents are nonproductively used to form hydrogen peroxide or water from dioxygen), 
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and a ratio of 73:27 for R- and S-alcohols, respectively.  The triple mutant hydroxylates 
ethylbenzene to give an R:S ratio of 87:13 and a coupling of reducing equivalents to 
product of 13% [98].  Various mutants of Y96 (Y96A, Y96G, Y96F), which hydrogen 
bonds to camphor, contain active sites with improved ability to oxidize aromatic 
compounds such as diphenylmethane, diphenylamine, 1,1-diphenylethylene, 
phenylcyclohexane, naphthalene and pyrene [99-103].  Moreover, the ability of P450cam to 
perform styrene oxidation using mutant Y87F was improved 25-fold, with a concomitant 
increase in coupling efficiency from 7% to 32% [104].  An additional mutation, V24L, 
further increased coupling efficiency to 60%, with substrate oxidation rates of 
approximately 100 min-1 [102].  Mutations at F87 and Y96 also greatly enhanced the 
monooxygenase activity of P450cam toward polycyclic aromatic hydrocarbons 
phenanthrene, fluoranthene, pyrene and benzo[α]pyrene [105], as well as for 
polychlorinated benzenes [106].  When the volume of the substrate binding pocket above 
the heme was decreased with mutant F87W, a 10-fold increase in activity with most of the 
polychlorinated substrates was observed.   The coupling rate was increased to >90% by the 
addition of F98W, although the NADH-dependent reaction decreased in those mutants 
[107].  In an effort to engineer P450cam for the selective oxidation of (+)-R-pinene, a 
structural relative to (+)-camphor, active-site mutants containing combinations of the 
Y96F, F87A, F87L, F87W, and V247L mutations were chosen based on the crystal 
structure.  The most active was the Y96F/V247L mutant, with a (+)-R-pinene oxidation 
rate of 270 min-1 [93].  French and coworkers improved P450cam catalyzed 2-
ethylhexanoic acid production from ethylhexanol.  The F87W and Y96W mutations 
improved regioselectivity, giving almost exclusively the desired product. The T185F 
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mutation improved coupling of NADH to product formation, and the L244A mutation 
altered the stereoselectivity of 2-ethylhexanoic acid production [108].  A definitive 
demonstration of the flexibility of the P450 platform was provided by Bell et al. with the 
engineering of P450cam to hydroxylate short-chain alkanes.  In this study, the volume of the 
active site above the heme was decreased by introducing bulky, hydrophobic residues, with 
the mutant F87W/Y96F/T101L/V247L showing butane oxidation rates of 750 min-1, and 
95% coupling to NADH oxidation [109].  The rate of propane hydroxylation in this study 
was 110 min-1 with 32% NADH coupling, but in a subsequent study using the mutant 
F87W/Y96F/T101L/V247L/L244M, this rate was increased to 170 min-1 with 66% NADH 
coupling [93]. 
 
D.2.2. P450 BM-3 
Cytochrome P450 BM-3 from Bacillus megaterium is a fast, water soluble, single-
component fatty acid hydroxylase readily expressed in laboratory strains of Escherichia 
coli, making it an ideal candidate for protein engineering.  In this P450, large structural 
changes are induced by substrate-binding.  A hydrophobic channel between the surface of 
the protein and the proximal side of the heme is evident in crystal structures of P450 BM-3 
(Figure 1.5).  In substrate free BM-3 [84], this channel is open while structures of BM-3 
complexed to palmitoleic acid [86] or N-palmitoylglycine [87] reveal a significant change 
upon substrate binding, involving closure of the active site channel.  The conformational 
changes correspond to a molecular switch, in which substrate binding converts the enzyme 
from an inactive form to a catalytically active one [87]. The hydrophobic residues in this 
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channel presumably contact the substrate during catalysis and comprise the majority of 
residues studied by site-directed mutagenesis.   
The propensity of wild-type P450 BM-3 to hydroxylate primarily fatty acids with chain 
lengths between C12 and C18 is reflected in the geometry of the active site. The fatty acid 
substrates are hydroxylated at the ω-1, ω-2 and ω-3 positions, but the regioselectivity is 
rather low.  The exact regioselectivity of the reaction is dependent on the substrate chain 
length [110].   
 
Figure 1.5. Crystal structure of P450 BM-3 (PDB access number 1JPZ [87]).   The heme is 
shown in red, while the palmitoylglycine substrate is shown in green.  The substrate is 
bound within a long, narrow channel that leads to the heme. 
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D.2.2.1. Substrate Specificity and Regioselectivity of P450 BM-3 
To extend the use of this fast and efficient enzyme for biotechnology applications, various 
groups have focused on engineering P450 BM-3 to accept and hydroxylate a variety of 
substrates (Table 1.3).  
In particular, active site residues that putatively contact the substrate during catalysis have 
been modified.  The active site residue F87, one of the first residues extensively studied by 
site directed mutagenesis, has been shown to affect both the substrate specificity and 
regioselectivity of fatty acid hydroxylation.  Engineering activity towards non-natural 
substrates, such as alkanes and arene compounds, usually involves these residues.  For 
example, a study to define the role of F87 in the substrate access channel of P450 BM-3 
was performed by Graham-Lorence et al. [119]  Replacement of F87 with valine converted 
the enzyme into a regio- and stereoselective arachidonic acid epoxygenase.  Mutants of this 
residue were used as the starting point for both the creation of new site-directed mutants 
with specificities towards other substrates, as well as the initiation of directed evolution 
experiments to evolve this P450 for biotechnological application (see below).  The mutant 
F87V/L188Q/A74G was designed by saturation mutagenesis of multiple sites that were 
chosen based on crystallographic data. This approach, termed “rational evolution,” was 
used with the assistance of a p-nitrophenol based screen described below. The mutant was 
shown to oxidize indole [114] and can also hydroxylate alkanes, cycloalkanes, arenes and 
heteroarenes [116].  This mutant was later shown to have hydroxylation activity on 
polycyclic, aromatic hydrocarbons such as naphthalene, fluorene, acenaphthene, 
acenaphthylene and 9-methylanthracene [120].  
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Table 1.3. Substrates of engineered P450s BM-3 
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However, coupling efficiencies for this mutant were very low – on the order of 5-15% 
[120].  Charmichael et al. [113] were also successful in obtaining activity towards 
polycyclic aromatic hydrocarbons using site-directed mutants of P450 BM-3.  Their mutant 
R47L/Y51F/A264G displayed the highest product formation rates when phenanthrene and 
fluoranthrene were used as substrates, while mutant R47L/Y51F/F87A/A264G was most 
active towards pyrene. This study also observed very low NADPH coupling efficiencies.  
Inspired by the diversity of activities supported by the P450 scaffold in nature, our 
laboratory has focused on engineering BM-3 to generate practical, P450-based oxidation 
catalysts.  In particular, we are interested in creating useful biocatalysts using directed 
evolution as the engineering strategy for the controlled oxidation of alkanes.  P450 BM-3 is 
particularly suited for directed evolution experiments since it is highly expressible in E. 
coli, soluble (i.e., not membrane bound), stable, fast (rates up to 3000 min-1), and self-
sufficient (i.e., the reductase, electron transfer, and hydroxylase components are included in 
a single protein).  In these experiments, a library of randomly mutated P450 BM-3 proteins 
is generated and screened for new or improved activities.  Mutants with improved activities 
are isolated and then used to generate new libraries.  This iterative cycle continues until the 
desired mutant or mutants is obtained [121,122].  Ideally, the screen used to identify these 
new mutants should contain a colorimetric aspect dependent either directly or indirectly 
upon formation of the desired products.  Alternatively, new mutants may be identified by 
increased NADPH consumption rates with a given substrate, which can be measured 
spectrophotometrically in a high-throughput manner using readily available plate readers.  
Using NADPH consumption rates as a screen is particularly useful for substrates which 
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cannot be examined colorimetrically, although care must be taken to ensure that NADPH 
oxidation is coupled to product formation.  The mutations accumulated over several rounds 
of directed evolution often appear in unpredictable places in the protein (i.e., not in the 
active site), illustrating the limitations to rational approaches to protein engineering.    
Schwaneberg et al. developed a product-based screen for detecting mutants with increased 
fatty acid hydroxylation activity using the “surrogate” substrates 8-p-nitrophenoxyoctanoic 
acid and 10-p-nitrophenoxydecanoic acid.  These substrates release the yellow compound 
p-nitrophenolate upon hydroxylation at their terminal carbon [123].  Saturation 
mutagenesis of several amino acids which had previously been shown to be important in 
defining the substrate and regioselectivity of the enzyme led to an increase in activity 
towards the surrogate substrates as well the corresponding fatty acids [124]. 
Using a modified version of the assay described above (8-p-nitrophenyl octane instead of 
the carboxylate), Farinas et al. were able to generate mutants that oxidized n-octane up to 
five times faster than the wild-type enzyme [125].  By additionally employing a cofactor 
dependent screen using short alkanes as substrates, the authors generated a mutant that 
readily oxidized not only octane at a higher initial rate than any known alkane hydroxylase, 
but also propane [118].  This enzyme was also more active towards its natural substrates. 
Interestingly, none of the eleven amino acid substitutions were homologous to the 
mutations Bell et al. introduced into P450cam [109] to achieve butane and propane 
oxidation.  While the enzyme exhibited high rates of substrate hydroxylation, it was not 
regioselective and produced a variety of subterminal alcohols. 
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The engineered BM-3 mutants described above were acquired either by altering individual 
amino acids in the protein, or by accumulating point mutations in directed evolution 
experiments.  An alternative method for obtaining P450s with new or altered properties is 
chimeragenesis, in which large portions of homologous P450s are swapped to form 
functional chimeras.  Recombination of homologous proteins generates variants in which 
every amino acid substitution has already proven to be successful in one of the parents.  
Recently, Voigt et al. [126] developed and Meyer et al. validated [127] a structure-based 
algorithm SCHEMA that identifies fragments of proteins that can be recombined to 
minimize disruptive interactions that would prevent protein folding.  Otey et al. [128] 
applied SCHEMA to design chimeras of P450 BM-3 and its homolog CYP102A2, sharing 
63% amino acid sequence identity.  Fourteen of the seventeen constructed hybrid proteins 
were able to fold correctly, as determined by CO difference spectra. Half of the chimeras 
had altered substrate specificities, while three mutants acquired activities towards a new 
substrate not hydroxylated by either parent.   
 
D.2.2.2. Electron Transfer in P450 BM-3 
P450 catalyzed monooxygenation reactions require two distinct electron transfer (ET) 
processes per substrate turnover.  The first electron is used to reduce the ferric heme iron.  
After binding of molecular oxygen to the reduced, ferrous heme iron, the second electron is 
transferred to activate the O=O bond.  ET between the heme and an external partner protein 
or domain is essential for the catalytic cycle, making its study a subject of extensive 
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research.  Most cytochromes P450 depend on interactions with partner proteins to receive 
electrons for oxygen activation and substrate conversion.  Class I proteins obtain electrons 
via a redoxin and an FAD-containing NAD(P)H-dependent reductase.  Class II proteins 
require only the FAD/FMN-containing NADPH-P450 reductase. Other classes, e.g., those  
using FMN as electron donor or a [4Fe-4S] protein have been identified in bacteria by 
genome analysis [129].  Only a few P450s do not require additional proteins for catalysis, 
e.g., class III P450s such as CYP5A1 and CYP74, which employ either endoperoxide or 
hydroperoxide substrates; CYP55A1 (P450nor, a class IV P450), which receives electrons 
directly from reduced pyridine nucleotides; and P450s such as P450 BM-3 with its heme-
containing hydroxylase domain and diflavin reductase domains fused into a single 
polypeptide chain. 
The catalytic mechanism of diflavin reductases, in particular of P450 BM-3, has been 
studied in detail.  Based on the observations that a) the degree of reductase reduction during 
catalysis does not exceed two electrons [130] b) a double semiquinone is formed [130] and 
c) the FMN cofactor serves as the heme reducing electron donor [130,131], the following 
mechanism of electron transfer from NADPH over FAD, FMN to the heme domain has 
been proposed [132]:  NADPH binds to the cofactor binding pocket of the diflavin 
reductase.  Next, hydride transfer from NADPH to FAD occurs, leading to a two-electron 
reduced hydroquinone form of FAD.  Electrons from FAD are transferred to FMN 
separately, to form the catalytically active semiquinone form of FMN that, in the final step, 
transfers electrons to the heme domain.  Reduction of the reductase by three electrons 
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inactivates the enzyme, and a four electron reduced state could not be obtained under 
aerobic conditions [130,133]. 
Electron transfer in P450 BM-3 is tightly regulated in multiple ways to ensure that electron 
transfer is coupled to substrate oxidation without wasting energy from NADPH and 
producing reactive oxygen species.  First, the redox potentials of the flavins (FAD and 
FMN) during catalysis [134] are significantly altered compared to those calculated from 
equilibrium potentiometric titrations [135].  It has been proposed that conformational 
changes as well as NADPH binding and NADPH oxidation influence the redox properties 
of the cofactors [132,136].  Secondly, preincubation of P450 BM-3 with NADPH without 
substrate leads to a catalytically inactive, three electron reduced state of the reductase 
domain [130,133].  Thirdly, substrate binding perturbs the spin-state equilibrium of the 
heme iron in favor of the high-spin form and also increases the heme iron reduction 
potential by approximately 130 mV [135].  These events trigger electron transfer to the 
substrate bound heme and start the catalytic cycle.  Later work pin-pointed the spin-shift, 
rather than the change in redox potential as the primary effector in activating electron 
transfer [95].  Substrate binding therefore acts as an enzyme activating switch.  
This beautifully regulated mechanism needs to be considered when engineering P450 BM-
3 for the hydroxylation of non-natural substrates.  Substrates other than the favored fatty 
acids that do not correctly fit into the active site thus adversely affect the fine-tuned 
electron transfer apparatus required for catalysis.  These electron-transfer difficulties are 
manifest as uncoupling of NADPH oxidation from substrate turnover, which can occur at 
various points of the electron transfer chain:  If electron transfer from FAD to FMN is 
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disturbed, electrons could be transferred to NADP+.  Dioxygen can potentially accept 
electrons from either FAD or FMN to produce superoxide or peroxide, depending on 
whether one- or two-electron reduction occurs (NADPH oxidase activity) [137].  In the 
active site, unproductive dissociation of reduced oxygen species can lead to the formation 
of superoxide, peroxide or water from the heme prior to reaction with substrate [53].  All 
this must be kept in mind when engineering a P450 for practical use, and monitoring of the 
coupling efficiency is a crucial aspect of any engineering approach.  
 
D.2.2.3. Peroxide Driven Catalysis 
Dependence on the expensive cofactor NADPH limits the common use of most P450s as 
oxidation catalysts.  An inefficient peroxide shunt pathway, in which oxygen pre-reduced 
by two electrons to a peroxide is used for catalysis in place of dioxygen and NADPH, 
exists in most P450s and allows them to function without the additional cofactor and 
electron transport proteins. Directed evolution was used to improve peroxide driven 
catalysis of P450cam and 102.  Cirino et al. characterized hydrogen peroxide driven catalysis 
with the heme domain of P450 BM-3 and its mutant F87A and found that mutation F87A 
significantly enhances peroxygenase activity towards medium-chain fatty acids while 
shifting regioselectivity away from the terminal position [138].  However, catalytic rates 
using hydrogen peroxide were still orders of magnitude slower than using NADPH as a 
cofactor.  Using directed evolution, a mutant P450 BM-3 heme domain was obtained that 
supports the H2O2-driven hydroxylation of fatty acids and epoxidation of styrene at 
catalytic rates and total turnover numbers improved by an order of magnitude relative to the 
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F87A mutant.  A significant decrease in thermostability of the enzyme, however, was 
observed [139].  None of the nine amino acid changes in this mutant (relative to wild-type 
P450 BM-3) were located in the substrate binding pocket.  In the first report on the 
thermostabilization of a P450, Salazar et al. were able to restore this loss in thermostability 
while maintaining its peroxygenase activity using directed evolution [140]. 
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Regio- and Enantioselective Alkane Hydroxylation with Engineered 
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A. Abstract 
Cytochrome P450 BM-3 from Bacillus megaterium was engineered using a combination of 
directed evolution and site-directed mutagenesis to hydroxylate linear alkanes regio- and 
enantioselectively using atmospheric dioxygen as an oxidant.  BM-3 variant 9-10A-A328V 
hydroxylates octane at the 2-position to form S-2-octanol (40% ee).  Another variant, 1-
12G, also hydroxylates alkanes larger than hexane primarily at the 2-position, but forms R-
2-alcohols (40-55% ee).   These biocatalysts are highly active (rates up to 400 min-1) and 
support thousands of product turnovers. The regio- and enantio-selectivities are retained in 
whole-cell biotransformations with Escherichia coli, in which the engineered P450s can be 
expressed at high levels and the cofactor is supplied endogenously.   
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B. Introduction  
Inspired by the diversity of activities supported by the P450 scaffold in nature, we have 
focused on engineering P450 BM-3 to generate practical P450-based oxidation catalysts.  
In particular, we are interested in creating useful biocatalysts for the controlled oxidation of 
alkanes.  Linear alkanes are difficult to hydroxylate: the alkane C-H bond is notoriously 
inert, due to its high (~97 kcal/mol) bond strength, making alkanes ideal solvents for use 
with very reactive oxidation catalysts [1].  Additionally, the activation energies for 
subsequent oxidations of an alcohol are similar to the energy required for the initial 
hydroxylation of the starting alkane, resulting in mixtures of alcohol, ketone/aldehyde, and 
carboxylic acid products in most alkane oxidation reactions [2].  The similarity of 
methylene C-H bond strengths in a linear alkane and the lack of functional groups that can 
serve to direct catalysis make selective hydroxylation of these compounds especially 
challenging.  Limited selective alkane hydroxylation has been reported for bulky 
cycloalkanes and aryl alkanes using biomimetic transition metal complexes as catalysts and 
peroxides as oxidants, but these complexes do not produce hydroxylated products in useful 
amounts (the catalysts support very few (<20) total turnovers) [3-6].  
Several biological systems are capable of dioxygen-supported alkane hydroxylation and, in 
some cases, even regioselective alkane hydroxylation.  For example, the particulate 
methane monooxygenase from Methylococcus capsulatus (Bath) can hydroxylate butane 
and pentane to yield primarily R-2-alcohols.  This enzyme does not accept larger alkanes.  
Soluble methane monooxygenase from the same organism hydroxylates several alkanes 
with little or no selectivity [7,8].  Neither enzyme is likely to serve as a practical 
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biocatalyst, due to their inability to be overexpressed in a suitable host organism and their 
rather low intrinsic activities.  Alkane hydroxylase B (AlkB) from Pseudomonas 
oleovorans hydroxylates octane selectively at the terminal (or ω) position, producing 1-
octanol.  This enzyme can be used in engineered whole cells to generate this product in 
two-phase bioconversions [9].  Some P450s (several members of the Cyp4 family, Cyp52, 
Cyp86, Cyp153) have also been reported to catalyze the hydroxylation of terminal methyl 
groups of fatty acids or n-alkanes [10-13].  Nonselective cytochrome P450 alkane 
hydroxylation systems include the site-directed mutants of P450cam of Wong and coworkers 
[14-16] and an engineered P450 BM-3 reported by our group [17,18].  Enantioselective 
(but not regioselective) hydroxylation of alkanes has been reported with whole-cell systems 
of soil bacteria genera such as Bacillus [19], Pseudomonas [20,21], and Rhodococcus 
[22,23], but the selectivity observed in these systems is most likely due to metabolism of 
specific isomers rather than the action of selective oxygenases.  
The natural substrates of cytochrome P450 BM-3 are medium-chain (C12 to C18) fatty 
acids, which are hydroxylated at their ω-1, ω-2, and ω-3 positions using atmospheric 
dioxygen and NADPH) [24] (the reader is referred to Chapter 1 for details).  In previous 
work, we used directed evolution to convert wild-type BM-3 into a fast, but non-selective, 
alkane hydroxylase called 139-3 [17,18].  A large increase in activity towards alkanes as 
small as propane was observed after five rounds of directed evolution experiments, which 
accumulated eleven amino acid substitutions in the heme domain.     
We have begun to further engineer P450 BM-3 for the hydroxylation of very small alkanes 
such as ethane and methane, activities never reported in a cytochrome P450, by applying a 
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combination of directed evolution and site-directed mutagenesis.  The mutants obtained 
from these experiments hydroxylate propane at faster rates and reach higher total turnover 
numbers than 139-3.  During the course of this work, we found that two of these mutants 
are highly regioselective and enantioselective towards longer alkanes.  One mutant forms 
R-2-alcohols from alkanes bigger than heptane, and the other forms S-2-octanol from 
octane.  The engineered P450 BM-3 enzymes described here are, to our knowledge, the 
only systems capable of direct, regio- and enantioselective hydroxylation of linear alkanes 
expressed in hosts suitable for large-scale biocatalytic processes. 
 
C. Results and Discussion  
C.1. Previous Work 
In previous work with this enzyme, five rounds of directed evolution starting with wild-
type cytochrome P450 BM-3 yielded the alkane hydroxylase 139-3[17,18].  In each round, 
a library of randomly-mutated BM-3 enzymes was screened for octane hydroxylation 
activity on the “surrogate” substrate p-nitrophenyl octyl ether.  Hydroxylation of this 
substrate at the carbon atom containing the p-nitrophenoxy moiety results in the formation 
of p-nitrophenolate, which was used for colorimetric identification of active mutants.  
Active mutants were then tested for octane hydroxylation activity, and the most active ones 
were used as parents for subsequent rounds of evolution.  In some cases, several active 
mutants were isolated from a single round of screening and recombined using DNA 
shuffling to obtain the parent for the next round.  In these and the evolution experiments 
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described in this chapter, random mutagenesis and recombination were applied only to the 
heme domain (residues 1-429, with 429 chosen for the convenience of introducing a SacI 
restriction site into the heme domain gene); the reductase domain was left untouched.  The 
complete BM-3 enzyme (modified heme domain attached to the unmodified reductase 
domain) was used in all the hydroxylation reactions described here.  
Of the eleven amino acid substitutions in the alkane hydroxylase 139-3 heme domain, only 
one  (V78A) occurs at a residue that contacts the fatty acid substrate in the (wild-type) 
enzyme [18].  The reader is referred to Appendix B, which summarizes the mutations.  The 
mechanisms by which the mutations contribute to the new activity are difficult to 
rationalize.  The rather broad distribution of 139-3’s hydroxylated alkane products (Table 
2.1, Figure 2.2), however, suggests that its active site is rather large and that its alkane 
substrates are “loosely” bound.  This is not surprising since the surrogate substrate used to 
identify these mutants is quite large relative to octane, the intended substrate.  The one 
active site substitution, in fact, replaces valine with a smaller, alanine side chain.  
P450 BM-3 mutant 139-3 shows significant activity on propane, even though small alkane 
substrates were not used to screen the mutant libraries in the directed evolution 
experiments.  We postulated that by continuously decreasing the size of the screening 
substrate, improvements in catalytic activity will eventually lead to activity towards even 
smaller alkanes.   
To improve the activity towards propane further, and perhaps even achieve activity towards 
ethane, we continued to apply iterative rounds of mutagenesis and screening, using propane 
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as a substrate.  The BM-3-catalyzed hydroxylation reaction results in the oxidation of one 
equivalent of NADPH for each equivalent of hydroxylated substrate.  Using a 96-well plate 
reader, the rate of NADPH oxidation in the presence of BM-3-containing cell lysate and 
substrate can be monitored spectrophotometrically at 340 nm to quickly identify mutants 
with high activity towards any given substrate.  Alternatively, the concentration of the 
oxidized form of NADPH, NADP+, can be measured spectrophotometrically in cell lysate 
[25].  It is possible that the reducing equivalents of NADPH become uncoupled to substrate 
oxidation, leading to false positives in a mutant library, but gas chromatographic analysis 
of reaction mixtures can confirm when an increased NADPH oxidation rate is accompanied 
by more or faster product formation.   
 
C.2. Alkane Hydroxylation Reactions 
To measure these alkane hydroxylation activities, ethanol solutions of liquid alkanes were 
added to buffer solutions containing the enzymes such that the total ethanol in the reaction 
mixture was one percent.  Several solvents, including ethanol, methanol, acetone, and 
dimethyl sulfoxide, were tested, and ethanol was shown to support the most product 
turnovers.  Reactions with liquid alkanes that contained no co-solvent produced no 
detectable products.   In the absence of substrate, NADPH has been reported to inactivate 
BM-3 by over-reducing the flavin cofactors in its reductase domain [26].  To avoid this 
problem, substrate was added to the enzyme first and incubated for a few seconds before 
NADPH was added.  Dioxygen was not added to the reactions, limiting the amount of 
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possible product formed to the 225-250 µM of oxygen present in air-saturated buffer.  The 
addition of excess dioxygen to the reactions by direct bubbling or rapid stirring did not 
increase and often decreased the total product turnover, possibly by denaturing the protein.  
Reaction mixtures for all BM-3 mutants containing 0.5-1.0 µM enzyme produced 225-250 
µM products.  We also noticed that total turnover numbers measured in systems containing 
less than ~50 nM protein were less than expected – i.e., 10 nM protein in a reaction gave 
much less than half the total turnovers of a 20 nM reaction.  At very low concentrations of 
BM-3, the FMN cofactor has been reported to diffuse out of the protein and inactivate it 
[27].  Given this fact and the dilution effects on total turnover we witnessed, a highly active 
mutant could be capable of even more turnovers than we can measure using this procedure. 
Reactions using propane did not contain co-solvent because of potential competition 
between the solvent and the small substrate.  These reactions were performed in propane-
saturated buffer under an atmosphere of propane and dioxygen (provided by a balloon 
filled with the two gases).  The addition of this atmosphere ensured that both gaseous 
substrates were saturated in the reaction solution, since a balloon of just propane or oxygen 
would dilute the concentration of the other gas.  Total turnovers determined with this 
system were not dependent on oxygen concentration in the balloon (data not shown), 
illustrating that only the original ~250 µM of dioxygen in the buffer was available to the 
reaction.  Additionally, we discovered that NADPH could neither be purchased nor easily 
purified in a form that contains less than 2-3% ethanol, which interferes with analysis of the 
reaction products.  For this reason, an NADPH-regeneration system was used for propane 
reactions [28].  
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C.3. Directed Evolution 
For the first round of directed evolution, a library of P450 BM-3 variants was generated by 
recombining mutant 139-3 with fifteen other mutants from the same generation that also 
exhibited increased activity towards p-nitrophenyl octyl ether and octane.  The shuffled 
gene library was transformed into E. coli DH5α competent cells, in which the enzymes 
were over-expressed.  Due to difficulties with obtaining high transformation efficiency, 
only 350 mutants were screened for activity.  Aliquots of the cell-free extracts from 
individual clones were transferred to 96-well plates, where NADPH consumption was 
monitored in the presence of propane.  Positive clones were grown up and their enzymes 
purified for comparative analysis using gas chromatography.  Mutant J (see Appendix B for 
mutations) was selected, based upon its increased rate of NADPH consumption in the 
presence of propane relative to 139-3.  This increased rate corresponded to an increase in 
total production of hydroxylated products with the substrates propane (800 turnovers) and 
octane (3,000 turnovers).  In comparison, 139-3 catalyzes 500 and 1000 turnovers for 
propane and octane, respectively. 
Error-prone PCR of the gene for P450 BM-3 mutant J, performed under conditions 
designed to yield 1-2 mutations on average per gene, generated the library for the second 
round of directed evolution.  Mutant 9-10A was selected from a library of approximately 
1,000 individual BM-3 variants for its increased NADPH consumption rate in the presence 
of propane; it was subsequently shown to support more turnovers of propane (1,100).  The 
properties of these mutants are detailed in Tables 2.1 and 2.2 and Figure 2.2 (see Appendix 
B for sequences and mutations).  Neither J nor 9-10A acquired active-site mutations, nor 
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did they show major changes in regioselectivity towards longer alkanes, compared to 139-
3.  Although these mutants supported more turnovers, their coupling efficiencies (see 
below) were not improved.  
Random mutagenesis of 9-10A generated the library for a third round of evolution.  To 
overcome the limitations of cofactor-dependent screens, this time, a second screen was 
applied to assess the amount of hydroxylation products generated by each mutant.  This 
screen uses the surrogate substrate dimethyl ether, which is similar to propane in size and 
C-H bond strength.  Upon hydroxylation, dimethyl ether is demethylated and forms 
formaldehyde, which can be detected in cell lysate with Purpald dye at concentrations as 




Figure 2.1. Dimethyl ether hydroxylation assay a) Hydroxylation of surrogate substrate 
dimethyl ether produces formaldehyde.  b)  Purpald reaction: Purpald reacts with 




Figure 2.2. Hydroxylation product distribution of BM-3 mutants.  Mutants 9-10A-A82L 
and 9-10A-A328V are abbreviated A82L and A328V, respectively.  The reaction 
conditions were: 4 mM alkane substrates, 25 to 100 nM BM-3 mutant, 1% (v/v) ethanol, 
500 µM NADPH, incubation at room temperature for 4 hours.  Mutants obtained by 
screening random mutagenesis libraries (139-3, J, 9-10A) show similar product 
distributions while mutants obtained by mutating active site residues (9-10A-A82L, 9-10A-
A328V, 1-12G) show significant shifts in regioselectivity.   Refer to Appendix B for 




Table 2.1. Product distributions [a] and % ee of selected products. 
Mutant product propane hexane % ee [c] heptane % ee [c] octane % ee [c] nonane % ee [c] decane % ee [c]
 1-alcohol 3 0  0  1  0  0  
 2-alcohol 97 14 14(S) 30 15(S) 61 58(S) 30 83(S) 15  
139-3 3-alcohol  86 39(S) 42 15(S) 20  50  37  
 4-alcohol    29  17  21  49  
 ketones [b]  <1  3  5  5  7  
 1-alcohol 4 0  1  1  0  2  
 2-alcohol 96 23 20(S) 29 12(S) 52 57(S) 29 67(S) 16  
J 3-alcohol  77 46(S) 42 11(S) 25  48  35  
 4-alcohol    28  22  23  48  
 ketones [b]  <1  2  5  5  5  
 1-alcohol 8 0  1  1  0  1  
 2-alcohol 92 6 14(S) 26 7(S) 53 50(S) 39 60(S) 16  
9-10A 3-alcohol  95 41(S) 41 8(S) 20  59  32  
 4-alcohol    33  26  3  51  
 ketones [b]  <1  3  5  5  6  
 1-alcohol 5 0  0  0  1  0  
 2-alcohol 95 35 39(S) 27 4(S) 22 10(S) 16 7(S) 21  
9-10A-A82L 3-alcohol  65 42(S) 46 30(S) 25 17(R) 16  19  
 4-alcohol    29  53  67  60  
 ketones [b]  <1  2  5  5  5  
 1-alcohol 10 6  14  10  3  1  
 2-alcohol 90 64 21(R) 62 15(R) 80 40(S) 76 0 79 5(S)
9-10A-
A328V 3-alcohol  30  17  8  19  17  
 4-alcohol    6  2  3  2  
 ketones [b]  <1  <1  <1  <1  <1  
 1-alcohol 11 9  5  5  3  1  
 2-alcohol 89 77 4 (R) 76 40(R) 82 39(R) 86 52(R) 86 55(R)
1-12G 3-alcohol  14  15  11  7  9  
 4-alcohol    3  3  5  4  
 ketones [b]  <1  <1  <1  <1  <1  
Reaction conditions were: 4 mM alkane substrates, 25 to 100 nM BM-3 mutant, 1% (v/v) 
ethanol, 500 µM NADPH, incubation at room temperature for 4 hours.  Refer to Appendix 
B for mutations in BM-3 variants 139-3, J, 9-10A 
[a]  Product distribution determined as ratio of a specific alcohol product to the total amount 
of all alcohol products (given in %).  Errors are at most ± 1%.   
[b] Product distribution for ketones was similar to alcohol product distribution.  The   
numbers reported here are the (%) total of all ketones relative to total products (alcohols + 
ketones).   
[c] Favored enantiomer is listed in parentheses. Errors are at most ± 5%. 
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139-3 Octane 2400 [b] 170 480 20 1000 1 
 Propane 190 [b] 50 12 6 500 1 
J Octane 3200 300 660 21 3000 3 
 Propane 910 300 30 3 800 1.6 
9-10A Octane 2820 220 540 19 3000 3 
 Propane 520 100 23 4 1100 2.2 
9-10A-
A82L Octane 1670 270 530 32 6000 6 
 Propane 390 200 54 14 2400 4.8 
9-10A-
A328V Octane 1900 720 50 3 2000 2 
 Propane 770 450 35 5 100 0.2 
1-12G Octane 1030 620 150 15 7500 7.5 
 Propane 660 640 160 24 6000 12 
[a] Initial NADPH consumption rates were measured over 15 seconds at 340 nm as nmol  
NADPH/min/nmol protein.  Octane reactions contained 100 nM  P450, 166 µM NADPH, 
and  4 mM octane in 1% ethanol and potassium phosphate buffer.  Propane reactions 
contained 200 nM P450, 166µM NADPH, and propane-saturated potassium phosphate 
buffer.  Background rates were measured under the same conditions, but without substrate.  
Errors are at most 10%..  
[b] The difference between these numbers and ones we reported [18] previously are due to 
the longer time period used to measure rates in this work (15 seconds compared to 2 
seconds). 
[c] Initial rates were measured by GC over 1 minute as nmol total products/min/nmol 
protein.  Octane reactions contained 100nM P450, 500 µM NADPH, and 4 mM octane in 
1% ethanol and potassium phosphate buffer.  Propane reactions contained 1 µM P450,  500 
µM NADPH, and propane-saturated potassium phosphate buffer.  Errors are at most 10%. 
[d] Coupling determined by ratio of product formation rate to NADPH consumption rate. 
[e] Total turnover numbers determined as nmol product/nmol enzyme. Octane reactions 
contained 10-25 nM P450, 500 µM NADPH, and 4 mM octane in 1% ethanol and 
potassium phosphate buffer.  Propane reactions contained 10-25 nM protein, potassium 
phosphate buffer saturated with propane, and an NADPH regeneration system containing 
100 µM NADP+, 2 U/mL isocitrate dehydrogenase, and 10 mM isocitrate. Errors are at 
most 10%. 
 [f] Fold improvement is based on total turnovers of hydroxylated products compared to 
139-3. 
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This third round, in which approximately 1,500 variants were screened, failed to produce a 
mutant with either increased NADPH oxidation in presence of propane, or more dimethyl 
ether hydroxylation products.  A possible explanation is that further increases in activity 
require amino acid substitutions not accessible by mutating only one base pair (single 
nucleotide changes to a codon typically access only about six of the nineteen possible 
amino acid substitutions).  Alternatively, two or more simultaneous, or coupled, genetic 
mutations might be necessary for further improvements.  Such events occur with very low 
probability and will not be found by screening only few thousand clones.  
 
C.4. Site-Directed Mutagenesis 
Wong et al. achieved hydroxylation activity towards butane and propane in the camphor 
hydroxylase cytochrome P450cam by reducing the size of the enzyme’s active site using 
structure guided site-directed mutagenesis [15].  We reasoned that decreasing the volume 
of the active site of 139-3 might serve to enhance its activity towards smaller substrates.  
Tightening up the active site might also confer regioselectivity towards longer alkanes – if 
the substrate is bound more tightly, fewer hydroxylation products should be possible.  We 
therefore turned to site-directed mutagenesis of residues in the active site for further 
improvements. 
Using a crystal structure of the heme domain of wild-type BM-3 containing a bound 





Figure 2.3. Positions of A328 and A82 in the active site of wild-type P450 BM-3.  The 
picture was made from the coordinates of the crystal structure 1JPZ in the Protein 
Database.  The substrate is palmitoyl glycine. 
 
Alanine 328 sits directly above the heme cofactor and is the residue closest to the proximal 
side of the heme iron.  Mutation of this residue to valine in the wild-type enzyme had been 
reported to affect substrate binding and turnover rates on fatty acids [31].  We substituted 
alanine 328 in 9-10A with the larger, hydrophobic valine and determined the activity of this 
mutant (termed 9-10A-A328V) towards several alkanes (Tables 2.1 and 2.2, Figure 2.2).  
Neither the propane hydroxylation activity nor the total propane turnovers improved 
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relative to its parent.  However, we observed a dramatic shift in the regioselectivity of 
hydroxylation on longer alkanes (Figure 2.2).  Wild-type and all mutants of BM-3 
generated in this laboratory by directed evolution hydroxylate longer alkanes such as 
heptane, octane, and nonane with roughly equivalent distributions of the 2-, 3-, and 4-
alcohols.   Mutant 9-10A-A328V, on the other hand, forms primarily (>80%) 2-alcohols 
from these substrates.  With octane, the resulting 2-alcohol is ~70% S-2-octanol (40% ee) 
(Table 2.1).  Other alkanes are not hydroxylated enantioselectively.  We rationalize that 
these changes in regioselectivity and enantioselectivity result from a reduction in possible 
binding geometries for these substrates in the active site.   
The alkane hydroxylation product distributions for 9-10A-A328V clearly show its 
selectivity for the alkane 2-position.  The fact that only 2-octanol is formed 
enantioselectively, but not 2-heptanol or 2-nonanol, suggests that a substrate-protein 
contact specific to the methyl group of octane furthest from the heme induces 
enantioselectivity towards this lone substrate.  The other non-regioselective mutants, 139-3, 
J, and 9-10A, also exhibit similar enantioselectivity towards octane; this contact must 
therefore function independently of residue 328.  It may be possible to engineer a mutant 
that is enantioselective for the S-2-position of other alkanes by changing other residues in 
the binding pocket (or outside) to mimic this contact. 
The second side chain we chose to alter is located near the active site that forms after the 
conformational change associated with substrate binding occurs.  In the crystal structure of 
BM-3 with bound palmitoyl glycine, alanine 82 is located within 3.5 Angstroms of the 
substrate ω-terminus [30].  We reasoned that changing this residue to a larger, hydrophobic 
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amino acid would decrease active site volume upon substrate binding.  BM-3 undergoes 
large conformational changes upon substrate binding and catalysis [32] which makes 
rational design an oftentimes fruitless approach.  We therefore chose to prepare a small 
library containing the four large, hydrophobic amino acids leucine, isoleucine, valine, and 
phenylalanine at position 82, and screened the library using dimethyl ether.  Mutant 9-10A-
A82L was identified as more active, and subsequent gas chromatographic analysis of the 
reaction mixtures revealed that this mutant supports more turnovers with propane (~2,400) 
than the 9-10A parent.  The rate of propane hydroxylation and its coupling efficiency with 
this mutant were also improved.  Hydroxylation of longer alkanes using this mutant 
occurred with a small shift in regioselectivity, in this case favoring the formation of 
primarily 3- and 4-alcohols (Table 2.1, Figure 2.2). 
 
C.5. Recombination 
To eliminate possible deleterious we had picked up in mutant 9-10A and to see whether the 
mutations A82L and A328V were beneficial in combination we shuffled the (heme 
domain) genes of J, 9-10A, 9-10A-A328V, and 9-10A-A82L using a modified DNA 
shuffling protocol [33].  The resulting small library (32 possible combinations) was then 
screened for activity on propane and dimethyl ether.  Mutant 1-12G was selected from this 
library.  Like mutant 9-10A-A328V, 1-12G hydroxylates alkanes at the 2-position (>80%).   
However, chiral GC analysis of the products revealed that 1-12G is as enantioselective as 
9-10A-A328V, generating R-2-alcohols (40-55% ee) of heptane, octane, nonane, and 
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decane (Tables 2.1 and 2.2, Figure 2.2).  Mutant 1-12G also supports thousands of 
turnovers on the substrates propane (6,000) and octane (7,500), resulting in approximately 
an order of magnitude improvement compared to 139-3.  Sequencing revealed that this 
mutant contains all of the mutations introduced into the recombination library – it is the 
double mutant A328V+A82L of 9-10A.   Addition of the A82L mutation to 9-10A-A328V 
has shifted the octane substrate in the active site such that the opposite enantiomer of its 2-
alcohol is now favored (Figure 2.4).   
 
 
Figure 2.4. GC/FID analysis of the (-)-menthyl carbonate diastereomers of the 2-octanol 
produced by BM-3 catalyzed alkane oxidation.  The S-2-octanol derivative elutes at 18.4 
minutes, the R-2-octanol derivative elutes at 18.6 minutes.  a) Reaction catalyzed by 9-
10A-A328V (40% ee),  b) Reaction catalyzed by 1-12G (40% ee).  The reaction conditions 
for the hydroxylation reactions were: 4 mM octane, 25 to 100 nM BM-3 mutant, 1% (v/v) 
ethanol, 500 µM NADPH, incubation at room temperature for 4 hours. 
 
Residue 82 was chosen for its proximity to the substrate ω-terminus, but it is not clear 
whether the larger leucine side chain “pushes” the substrate further up the active site or 
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blocks the channel such that the substrate is flipped relative to its position in the A328V 
mutant.  
In addition to its effect on selectivity, the A82L substitution, both with and without the 
A328V mutation, increases total turnover number and coupling to NADPH oxidation 
(Table 2.2).  It is possible that by increasing coupling efficiency this mutation protects the 
heme cofactor from degradation by reduced oxygen species such as peroxide and 
superoxide (see below), but further analysis is required to determine the cause.  The direct 
regio- and enantioselective hydroxylation activity towards linear alkanes exhibited by 
mutant 1-12G, with these rates (up to 400 min-1) and total turnover numbers (6,000-7,500), 
is unprecedented.   
 
C.6. Coupling of NADPH Reducing Equivalents to Product Formation 
Under oxygen limiting conditions, i.e., substrate and NADPH concentrations in large 
excess of the 225-250 µM dioxygen present in oxygen-saturated buffer, hydroxylation 
reactions catalyzed by the mutants in this work form 225-250 µM of products.  This upper 
limit to product formation suggests, as we have reported in our previous work [18], that 
substrate oxidation is tightly coupled to the consumption of dioxygen in these mutants.  In 
general with P450 systems, NADPH oxidation not coupled to the formation of product is 
assumed to be wasted on reducing heme-bound dioxygen to active oxygen species such as 
peroxide and superoxide (which may subsequently inactivate the enzyme) or to water.  If 
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oxygen reduction is the only mechanism for NADPH uncoupling, then our mutants should 
be fully coupled.   
When we compare the NADPH consumption rates of these mutants with their product 
formation rates, however, we discover that a large fraction of the NADPH oxidized is not 
used for product formation or uncoupled oxygen reduction.  Furthermore, the mutants 
oxidize NADPH even in absence of substrate (Table 2.2) at significantly higher rates than 
the wild-type enzyme, which has a relatively low background rate of about 8 min-1.   
Mutants generated by random mutagenesis have similar coupling efficiencies: 
approximately 20% for octane, and 5% for propane hydroxylation.  The A82L mutation 
increases coupling of NADPH oxidation to octane (32%) and propane hydroxylation (14%) 
while the coupling efficiency of 9-10A-A328V is significantly (3 and 5% for octane and 
propane, respectively).  Mutant 1-12G, with mutations A82L and A328V has an 
intermediate coupling efficiency for octane (15%), but shows the highest coupling 
efficiency of all mutants with propane (24%).   
The background NAPDH oxidation rates were measured under the same conditions but in  
the absence of substrate.  Because no octane turnovers could be detected in the absence of 
ethanol, NADPH oxidation rates were measured in the presence of 1% (v/v).  Ethanol does 
increase the background NADPH oxidation rate for most mutants, except for J and 1-12G.  
The background NADPH oxidation rates are similar for the mutants except for 9-10A-
A328V and 1-12G.  These mutants, however, exhibit very high background rates at 450 (9-
10A-A328V) and 640 min-1 (1-12G).  The NADPH consumption rate of 1-12G with 
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propane was only 20 min-1 faster than the background rate without substrate.  The higher 
propanol formation rate of 160 min-1suggests that propane hydroxylation with this mutant 
outcompetes the background NADPH consumption process.  Propane therefore induces 
electron transfer to the heme to initiate the catalytic cycle. 
As described in Chapter 1, electron transfer in wild-type P450 BM-3 is highly regulated:  
NADPH is oxidized only in the presence of substrate and tightly coupled to substrate 
oxidation.  The substrates we are employing differ substantially from fatty acids.  They lack 
the carboxylate moiety and are up to three times shorter than, for example, lauric acid.  In 
addition to uncoupling reactions in the active which can lead to the formation of 
superoxide, peroxide or water from the heme prior to reaction with substrate [34], several 
other uncoupling reactions have been described.  If electron transfer from FAD to FMN is 
disturbed, electrons could be transferred to NADP+.  Dioxygen can potentially accept 
electrons from either FAD or FMN to produce superoxide or peroxide, depending on 
whether one- or two-electron reduction occurs [35]. 
It has been proposed that the conformational changes upon substrate binding and during 
catalysis could be involved in the fine-tuning of the redox properties of the flavin 
cofactors [36].  NMR studies of the bacterial P450cam, for example, suggest that its 
electron donor, putidaredoxin, induces conformational changes to facilitate the 
oxygenation reaction [37].  It is likely that the mutations accumulated during random 
mutagenesis as well as the ones introduced by site-directed mutagenesis disturb the highly 
regulated electron transfer machinery of P450 BM-3.  Having ruled out reduction of 
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dioxygen as the predominant uncoupling reaction, we propose an alternative, possibly 
reduction of NADP+, as the most likely.    
We have noticed that when we screen for product formation using the dimethyl 
ether/purpald screen, the resulting mutants, 1-12G and 9-10A-A82L, are more coupled than 
mutants obtained by screening for NADPH consumption only and also support more total 
turnovers.  We therefore decided to further engineer P450 BM-3 to try and reduce any 
uncoupling reactions by performing additional rounds of mutagenesis and strictly relying 
on assays that are based on product formation.  This work is described in the following 
chapters.  
 
C.7. Whole-Cell Biotransformations 
Two major practical obstacles to implementing a biocatalytic process are the need for large 
amounts of purified protein and the expensive cofactors.  Lysates of E. coli (DH5α) 
containing overexpressed cytochrome P450 BM-3 mutants exhibit the same activity as 
purified protein (data not shown), but still require the addition of NADPH.  We have used 
an isocitrate dehydrogenase-based NADPH regenerating system [28] to perform reactions 
using both cell lysate and purified protein, with results indistinguishable from using 
NADPH alone (consistent with the fact that these reactions are generally oxygen limited - 
data not shown).  We were curious to see if we could use our E. coli system as a whole-cell 
catalyst, since the alkane substrates and alcohol products should be permeable to the cell 
membrane.  To test this, we prepared cultures of E. coli DH5α cells that overexpress the 9-
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10A-A328V and the 1-12G mutants.  Without optimizing the system, we prepared the cells 
and supplied them octane according to a procedure published by Witholt’s group that had 
used E. coli K27 expressing wild-type BM-3 and myristic acid as a substrate [38,39].  We 
used isopropyl-β-D-thiogalactopyranoside (IPTG) to induce expression.  Extraction of 
these whole-cell reaction mixtures with methylene chloride and analysis of the products 
revealed that both the regio- and enantioselectivity of the alkane hydroxylation products are 
preserved in the whole-cell system (Figure 2.5). 
 
 
Figure 2.5. GC/FID analysis of the octane hydroxylation product using 9-10A-A328V as 
a) purified protein and b) a whole-cell catalyst.  3-Octanol elutes at ~7.7 minutes, 2-octanol 
elutes at ~7.8 minutes, 1-octanol elutes at ~9.0 minutes. 
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Optimization of these reaction conditions, perhaps using a system analogous to the two-
phase system described by Witholt and coworkers for AlkB octane hydroxylation [9], 
could lead to cost-effective use of our E. coli cells for alkane hydroxylation.   
 
D. Conclusions  
Cytochrome P450 BM-3 is a highly “evolvable” catalyst: protein engineering by directed 
evolution and site-directed mutagenesis has generated variants with wide-ranging 
properties, including the ability to utilize different oxidants such as hydrogen peroxide for 
fatty acid hydroxylation [40,41], activity on nonnatural substrates [42-45] and in organic 
solvents [46], and greater thermostability [47].  The regio- and enantioselective alkane 
hydroxylation activities reported here further demonstrate the functional flexibility of the 
BM-3 scaffold.  We might (perhaps optimistically) regard BM-3 as a “one-enzyme-fits-all” 
oxidation catalyst. 
Regioselective alkane hydroxylation requires a catalyst that can discriminate between very 
similar methylene carbons.  In addition, there must be a mechanism to remove the 
hydroxylated substrate, to prevent overoxidation.  With the modifications presented in this 
work, the hydrophobic channel that serves as the active site of BM-3 provides the perfect 
environment for binding and oxidizing alkanes.  It should be possible to make further 
improvements in the enantioselectivity of the 9-10A-A328V and 1-12G biocatalysts, using 
directed evolution, as has been done for several other enzyme systems [48]. 
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The roles of P450 BM-3 active site residues in determining alkane hydroxylation activity 
and regioselectivity were investigated.  With the guidance of crystal structures of the 
substrate bound heme domain of wild-type BM-3, 11 active site residues in the substrate 
binding channel were identified that could potentially influence substrate binding. 
Saturation mutagenesis libraries at each of these positions were generated and activity 
towards octane and propane surrogate substrates was measured.  Furthermore, beneficial 
mutations were analyzed for their affects on the regioselectivity of octane hydroxylation.  
These data were used to identify key single active site changes important for discriminating 
between different-sized alkane substrates, generating specific hydroxylation products, 
and/or improving general alkane hydroxylation activity.  In addition, the data allowed us to 
select a limited number of active site mutations that were be recombined to generate a 




In this chapter, we further investigate the effects of substitutions in active site residues in 
P450 BM-3 on alkane hydroxylation activity.  Previous work has shown that this enzyme is 
an excellent hydroxylation catalyst that can be engineered to accept a large array of 
substrates while functioning under a variety of conditions [1].  In our laboratory, BM-3 was 
engineered by directed evolution to hydroxylate linear alkanes at so far unmatched rates 
[2,3].  Chapter 2 describes further engineering by directed evolution and site directed 
mutagenesis to achieve a regio- and enantioselective alkane hydroxylation catalyst, named 
1-12G.  Here, active site variants of BM-3 are described that extend the hydroxylation 
regioselectivities supported by this enzyme.   
P450 BM-3 consists of two distinct domains connected by a polypeptide linker: a 54 kDa 
heme domain in which substrate and oxygen are bound and activated and a 65 kDa 
reductase domain that transfers two electrons from NADPH via FAD and FMN cofactors 
to the heme domain.  Substrate selectivity and regioselectivity of hydroxylation should 
depend primarily upon the size and shape of the substrate binding channel.  The actual 
conformation of this channel is unclear, despite the availability of numerous crystal 
structures of substrate bound and unbound forms of the protein [4-7].  In the substrate 
bound structures, the substrate is located approximately 6 Å away from the heme iron, 
which is too far for catalysis to occur.  NMR studies suggest that a conformational change 
occurs prior to catalysis, moving the substrate by 6 Å into the correct position and 
orientation [8].   
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In addition, these structural changes upon substrate binding initiate electron transfer from 
NADPH into the heme by attenuating the redox potentials of the flavin and heme cofactors, 
and by shifting the spin-state of the heme-iron from low- to high-spin [9,10].  This 
intricately regulated electron transfer process may explain why the majority of mutations 
we accumulated in BM-3 during our directed evolution experiments are located outside of 
the active site [2,3,11].  In fact, out of the 14 heme domain mutations we found in our best 
alkane hydroxylase mutant obtained solely by directed evolution, mutant 9-10A, only one 
mutation, V78A, is located in the active site.   
Here, we further investigate how active site residues affect alkane hydroxylation activity 
and regioselectivity.  Using crystal structures of the heme domain of wild-type BM-3 with 
bound substrates [5,6], we identified 11 residues in the substrate binding channel, located 
directly above the heme cofactor, that might influence substrate binding.  We generated 
saturation mutagenesis libraries at each of these positions and screened the libraries for 
activity towards octane and propane surrogate substrates before examining the effects of 
specific mutations on alkane hydroxylation activity.  These data allowed us to identify key 
single active site changes in 9-10A that are important for discriminating between different-
sized alkane substrates, generating specific hydroxylation products, and/or improving 
general alkane hydroxylation activity.  In addition, the data allowed us to select a limited 
number of active site mutations that were recombined to generate a reasonably sized library 




C.1. Screening for Alkane Hydroxylation Activity 
Several problems must be solved simultaneously to identify mutants from a library with 
high, regioselective hydroxylation activity towards alkanes.  The desired alcohol products 
are colorless and are formed at concentrations too low to detect by their in situ chemical 
conversion to dye-sensitive compounds such as aldehydes and ketones.  Screening libraries 
by spectroscopically monitoring NADPH consumption rates in the presence of the alkane 
often selects for mutants with NADPH oxidation rates highly uncoupled to product 
formation.  In the past, we overcame these problems with the use of surrogate substrates 
that mimic our desired substrates, yet yield species when hydroxylated that are easily 
detected either directly or with the addition of a dye.  For example, the screen for the high-
throughput identification of mutant BM-3 enzymes with activity towards propane was 
described in Chapter 2 and uses dimethyl ether (DME) as a propane surrogate substrate 
[11].  Upon hydroxylation, it decomposes into methanol and dye-sensitive formaldehyde.  
For the work described in this chapter, we additionally use hexyl methyl ether (HME) as a 
surrogate for octane.  It shares most of the physical properties of octane, including 
solubility in buffer, size, shape, and strength of its C-H bonds.  When HME is hydroxylated 
at its methoxy carbon, it also produces an equivalent of formaldehyde which is visually 
detected at concentrations as low as 10 µM with the dye Purpald [12] (Figure 3.1).  
Hexanal, the aldehyde product formed when the α-carbon of the hexyl group is 
hydroxylated, is practically unreactive towards Purpald at the concentrations we encounter 
in our screens.  Formaldehyde is approximately 42 times more sensitive to Purpald than 
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hexanal (Figure 3.2).  This disproportionate response makes HME, in contrast to the 
symmetric ether DME, a regio-selective screen for terminal alkane hydroxylation.   
Figure 3.1. Alkylmethyl ether assays.  a) Hydroxylation of the propane surrogate dimethyl 
ether produces formaldehyde which can easily be detected using the dye Purpald.  b) Hexyl 
methyl ether can be used as an octane surrogate.  The outcome of the screen, formation of 
formaldehyde and detection via Purpald, remains the same.  c) A typical screening plate 
with P450-containing cell lysate, which, upon hydroxylation of the methoxy group of DME 
or HME and addition of Purpald, forms a purple color.  Each well represents a different 






















Figure 3.2. Standard curves for formaldehyde (■) and hexanal (♦) using Purpald.  The 
assay was performed in a 96-well microtiter plate and the final volume was 250 µL per 
well.  The absorbance was measured using a Spectramax Plus microtiter plate reader 
(Molecular Devices, Sunnyvale, CA) and is therefore not normalized to a pathlength of 
1cm.  The sensitivity for formaldehyde is approximately 42 times greater than for 
hexanal.  
 
The screen is an endpoint assay because Purpald needs to be solubilized in 2 M sodium 
hydroxide solution.  We incubated the DME and HME reaction mixtures for 15 min before 
adding the Purpald solutions.  Beneficial mutations therefore support more turnovers within 
this time and/or are more coupled to NADPH oxidation.  Using both of these screens to 
characterize a library of mutants reveals important information about the active mutants: 
mutants that are selective for one substrate over the other can be immediately identified 





C.2. Construction of Active Site Saturation Mutagenesis Libraries of 9-10A 
We used the BM-3 heme domain crystal structures with bound substrates palmitoleic acid 
[5] and N-palmitoyl glycine [6], to identify 11 residues with side chains that are within 5 Å 
of the terminal eight carbons of the alkyl chains of the bound substrates.  These were A74, 
L75, V78, F81, A82, F87, T88, T260, I263, A264, and A328 (Figure 3.3).  Six of these 
positions (74, 78, 82, 87, 264, and 328) have been identified by our laboratory and other 
research groups as important residues for altering the activity of BM-3.  For example, 
changes to F87 have long been known to affect the distributions of hydroxylated fatty acid 
products in wild-type BM-3 [13-16] and selectivity towards non-natural substrates [17].  In 
order to utilize peroxides in place of dioxygen and NADPH to drive hydroxylation by the 
peroxide shunt pathway,  F87 must be altered to a small hydrophobic residue such as 
alanine or leucine [16,18].  Residues 74, 87, and 264 have been altered in combination with 
other mutations to increase the activity of wild-type BM-3 towards a variety of substrates 
including octane and polyaromatic compounds [19-23].  Mutation of A328 to valine in the 
wild-type enzyme has been reported to affect substrate binding and turnover rates on fatty 
acids [24].  The only active site mutation acquired during our directed evolution 
experiments to engineer BM-3 for alkane hydroxylation was V78A.  Mutant 1-12G, which 
has the two additional mutations, A82L and A328V, exhibits an increase in alkane 
hydroxylation activity and regio- and enantiopurity of products (see Chapter 2).   
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Figure 3.3. The active site of cytochrome P450 BM-3 showing the 11 active site residues 
in contact with the last eight carbon atoms of the bound fatty acid substrates from  a)  the 
crystal structure 1FAG (from the Protein Data Bank) containing the substrate palmitoleic 
acid [5] and  b) the crystal structure 1JPZ containing N-palmitoyl glycine [6]. 
 
We used mutant 9-10A as the parent for generating the active site libraries because it was 
the most active laboratory evolved BM-3 alkane hydroxylase in which no active site 
residues had been intentionally altered.  Additionally, as shown in Chapter 2, we already 
knew that active site changes to 9-10A can lead to dramatic improvements in alkane 
hydroxylation activity.  We generated saturation mutagenesis libraries at each of these 11 
active site positions in 9-10A and screened 174 mutants of each library for increased 
activity towards DME and HME.  We also performed high throughput protein folding 
assays on each of these libraries to determine how active site mutations affect the integrity 
of the protein.  Mutants that were correctly folded and retained at least some activity were 
isolated and eight individual colonies of each mutant were rescreened.  
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C.3. Active Site Saturation Mutagenesis Library Folding Data 
Carbon monoxide difference spectroscopy was used to monitor incorporation of the heme 
cofactor.  This technique can be performed in 96-well plates, enabling us to estimate the 
fraction of folded variants in a saturation mutagenesis library [25] (refer to Chapter 8 for 
experimental details).  The reduced ferrous heme-CO complex with a Soret band near 
450 nm is indicative of heme incorporation and thus a correctly-folded P450 [26].  P450 
active site variants with a significant peak at 450 nm (> 5% of the control protein) were 
considered correctly folded, while variants showing no peaks in their CO difference 
spectra and were deemed unfolded.  Depending on the residue mutated, the fraction of 
folded proteins ranged from 52% to 100% (Figure 3.4).  This value takes into account 






















Figure 3.4. Fraction f of folded proteins in the 11 saturation mutagenesis libraries.  Stop 
codons are encoded by 3/64 (4.7%) possible codons, leading to truncated proteins.  
Therefore, the fraction of folded proteins was adjusted by the adding to f the fraction f* = 
0.049 (F/N) of proteins that would be folded if they were not encoded by a stop codon.  N 
is the total number of proteins screened; F is the number of folded proteins.  Error bars 
are the standard error of two separate 96-well plates. 
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Several positions can accept almost any amino acid in place of the one present in the 
wild-type protein.  Only a few residues, such as T88, are not mutable to this extent.  The 
average fraction of folded protein is 0.81, which seems high given that the active site of 
P450 BM-3 is located in the core of the protein.  It has been observed that mutations 
within the core of a protein are more disruptive on average than mutations of solvent 
exposed residues [27].  Core residues are coupled to a higher degree to other residues 
than are solvent exposed residues, thereby decreasing their site entropy and tolerance for 
mutation [28].  It can also be argued, however, that active site residues are often optimized 
for function, and not for stability.  This “stability-function” hypothesis predicts that 
mutations in the active site are not destabilizing but generally decrease the catalytic activity 
[29].  This possibility was addressed by analyzing the libraries for function. 
 
 
C.4. Active Site Saturation Mutagenesis Library Screening Data 
The saturation libraries were screened with DME and HME, and the activity of each 
mutant towards these substrates was compared to that of 9-10A.  Only mutants with 
improved activity towards either substrate were selected for further analysis and 
incorporation into an active site recombination library.  However, taken as a whole, the 
screening results from each library revealed the importance of the corresponding active site 
position with respect to alkane hydroxylation activity.  Figure 3.5 shows the screening 

















Figure 3.5. DME activity profile for the V78 saturation mutagenesis library.  The activity 
of each of the 174 library members was normalized to the average 9-10A activity and is 
plotted in descending order (♦).  The activities of 16 parental clones cultured in the same 
96-well plate under the same conditions are shown (◊) to illustrate the variability of the 
assay.  The coefficient of variance (CV) for this particular plate was 8%.  Overall, the CV 
of the screen was 13%.  Enzymes with more than 20 % of 9-10A’s activity were deemed 
active for further analysis.  Please refer to Chapter 8 for experimental details, and to 
Appendix C for activity profiles of the other saturation mutagenesis libraries. 
 
The libraries were analyzed based on the fraction of active members of all folded members 
using a conservative cutoff level of 20% of 9-10A’s activity.  These data illustrate, which 
of the amino acids can be mutated without losing activity towards the screening substrate 
































Figure 3.6. Fraction of folded mutants that remain active towards DME and HME in the 
saturation mutagenesis libraries at each of the 11 positions.  Error bars are based on the 
standard deviation of two separate 96-well plates. 
 
The positions A74, F81, T260 and A82 accept any amino acid substitution compatible with 
correct folding without losing hydroxylation activity.  At positions 75, 78, 87, 88, 260, 263 
and 328, 60 to 90% of the folded mutants remain active.  Only at position 264, the fraction 
of active mutants drops to 20%.  This position is somewhat sensitive to mutation in terms 
of activity on HME and DME.   
The fraction of functional proteins for a given position can be estimated using the 
neutrality of a random mutation (ν) [30].  ν has been calculated previously for other 
proteins and ranged from 0.38 to 0.56 [31].  However, some proteins, such as lac 
repressor, 3-methyladenine DNA glycosylase, and T4 lysozyme, seem to be more tolerant 
towards random mutations, with ν values of 0.65, 0.66, and 0.84, respectively [32-34].  
Variations in neutrality of different proteins are likely to depend on the size, expression 
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level, or level of conservation of the protein, making a meaningful comparison of ν 
between proteins difficult.  Random mutagenesis studies that target the catalytic centers 
of proteins have been performed on a limited number of enzymes.  These studies indicate 
that tolerance for mutations is generally limited, with ν ranging from 0.19 and 0.56 [33], 
thus supporting the “stability-function” hypothesis described above.   
For the eleven BM-3 residues studied here, the average ν is 0.70.  The degree of 
substitutability of the BM-3 active site is high compared to other proteins.  One 
explanation could be that the active site residues targeted for mutagenesis are important 
for binding and orienting substrate, but do not participate in the catalytic mechanism, 
which is primarily governed by the cysteine-ligated heme.  In any case, the observed 
tolerance to mutation within the active site makes BM-3 highly evolvable.  In addition to 
its other favorable properties, such as high activity, solubility and expressibility, this trait 
makes BM-3 a good target for engineering approaches.  
 
C.5. Improved Mutants Selected from Saturation Mutagenesis Libraries 
Based on the beneficial mutations we picked from each library (Table 3.1), we grouped the 
amino acid positions into four categories:  a) amino acid positions at which no mutant 
showed a change in DME and HME activity, b) positions at which improvements in 
activity towards the smaller substrate DME were found, c) positions at which 
improvements in activity towards the larger substrate HME were found, and d) positions at 
which no improved mutants could be identified but having many with decreased activity 
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towards DME and HME.  In Chapter 2, we had observed that mutating active site residues 
putatively in contact with bound substrates induce changes to the distributions of 
hydroxylated products.  We therefore performed octane hydroxylation reactions with E. 
coli cell lysate of each mutant in a library with increased activity towards DME or HME, 
and grouped the mutants within each library according to their distributions of formed 
octanols (Table 3.2).  In all cases, each group of mutants with similar product distributions 
proved to be the same after sequencing. 
Only one of the 11 saturation mutagenesis libraries, the library for position 74, showed no 
change among its full length (i.e., corrected for stop codons introduced during the library 
construction) members in either DME or HME activity relative to 9-10A.  Ten mutants 
were randomly selected from the library and their product distributions with octane 
determined.  All 10 mutants exhibited a product distribution similar to unmodified 9-10A.  
In the crystal structures of BM-3 with a bound fatty acid substrate, the alanine 74 side chain 
is at least 6.3 Å from the last eight carbon atoms of the substrate which are most likely in 
the same position as a bound octane molecule in the active site, but this residue should 
contact carbon atoms of a longer alkane.  In decane reactions with the 10 selected mutants, 
however, no difference in their product distribution was found.  Three of these mutants 
were randomly chosen for sequencing and found to be A74T, A74H, and A74P.  Their 
similar activities on DME and HME and their similar regioselectivities suggest that the 
octane hydroxylation rates are not affected either.   
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Table 3.1. Activities of single active site mutants towards the screening substrates DME 
and HME. 
mutation ` DME[b] HME[b] DME/HME
9-10A 1.00 1.00 1.00 
L75I [c] 0.74 1.00 0.7 
L75W 0.49 1.43 0.3 
A78T 1.37 0.95 1.4 
A78F 1.64 0.40 4.1 
A78S [c] 0.87 0.95 0.9 
A82T 1.32 0.88 1.5 
A82S 1.07 1.06 1.0 
A82F 2.27 0.53 4.3 
A82I 1.70 0.56 3.0 
A82C 1.08 0.38 2.8 
A82G 1.23 0.81 1.5 
F87I 0.94 2.42 0.4 
F87V 0.98 1.43 0.7 
F87L 0.96 1.58 0.6 
T88C 0.31 1.16 0.3 
T260L 1.20 0.73 1.6 
T260S 0.48 1.57 0.3 
T260N 1.11 0.48 2.3 
A328F 1.50 1.71 0.9 
A328M 1.30 1.65 0.8 
A328L 1.42 1.62 0.9 
[a] Mutations are in variant 9-10A (with amino acid mutations R47C, V78A, K94I, P142S, 
T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V). 
[b] Terminal hydroxylation activity of dimethyl ether and hexyl methyl ether are reported 
relative to 9-10A. 
[c] Mutations L75I and A78S exhibited increased HME activity compared to 9-10A in the 
initial screen but were found to be only as active as 9-10A in the rescreen. 
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Table 3.2. Regioselectivities, rate of product formation and total turnover numbers of 
octane hydroxylation reactions catalyzed by variants of BM-3 containing single active site 
mutations[a]. 
Mutation [b] 1-ol [%] 2-ol [%]  3-ol [%] 4-ol [%] Others [c] rate [d] ttn [e]
9-10A 0 51 21 27 1 540 3000 
L75I 3 42 18 17 20 210 4500 
L75W 3 46 18 24 9 200 4000 
A78T 4 22 27 45 2 500 4000 
A78F 4 37 17 31 11 380 3000 
A78S 5 48 18 20 9 260 2500 
A82T 5 23 25 44 3 340 2700 
A82S 6 40 19 26 9 300 2600 
A82F 4 26 20 48 2 140 3000 
A82I 4 11 21 59 5 600 3500 
A82C 5 26 26 42 1 200 3000 
A82G 7 52 17 23 1 360 2000 
F87I 8 70 6 3 13 60 2600 
F87V 5 52 13 4 26 240 3600 
F87L 7 55 22 12 4 60 2300 
T88C 4 51 21 22 2 460 4000 
T260L 7 67 11 10 5 260 2500 
T260S 6 39 26 29 0 160 3000 
T260N 6 29 23 42 0 300 2500 
A328F 6 88 4 0 2 40 2800 
A328M 24 71 0 0 5 10 700 
A328L 13 87 0 0 0 20 1000 
[a] Reactions were carried out using cell lysate instead of purified protein.
[b] Mutations are in variant 9-10A (with amino acid mutations R47C, V78A, K94I, P142S, 
T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, L353V). 
[c] These are overoxidation products (ketones and aldehydes) with similar product 
distribution as the alcohols. 
[d] Measured as nmol octanol/nmol P450/minute. 
[e] Measured as nmol octanol/nmol P450 produced in 4 hour reaction. 
 
Three of the 11 saturation mutagenesis libraries contained mutants with improved activity 
towards DME, determined by the ratio of each mutant’s DME and HME activities relative 
to the comparable activities in 9-10A.  In the crystal structures we used to identify active 
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site residues, the wild-type amino acids at these positions, 78, 82, and 260, contact the three 
terminal carbon atoms of the fatty acid substrate which are located directly above the heme 
cofactor where propane must bind for activation.  The mutant 910A-A78F has a relative 
DME activity 4 times greater than its relative HME activity, suggesting it has an increased 
preference for the small alkane propane over octane.  As expected from our previous work, 
changes at position 82, especially the mutations A82C, A82T, A82I, and A82F, increased 
the preference of 9-10A for the smaller substrate.   At position 260, the mutations T260N 
and T260L increased the DME activity of 9-10A over the corresponding HME activity.  
The octanol product distributions of all of these mutants tend to favor the formation of 4-
octanol, suggesting that the “back” end of DME is hydroxylated by these mutants (Figure 
3.7) 
 
Figure 3.7. a) Active site positions 78, 82 and 260, at which mutations with increased 
activity towards DME relative to HME were identified.  Select gas chromatograph traces of 
octane hydroxylation products catalyzed by mutants b) A78T, c) A82I.  
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Five of the 11 saturation mutagenesis libraries contained mutants with improved activity 
towards HME without a comparable change in DME activity.   In the crystal structure, 
these five residues, L75, F87, T88, T260, and A328, contact the eight carbons of the bound 
substrate where octane probably binds during catalysis.  The beneficial mutations at these 
positions, L75W, L75I, F87L, F87I, F87V, T88C, T260S, A328L, A328F, and A328M, 
primarily consist of large neutral side chains that alter the shape of the binding pocket 
above the heme and in the channel where the non-hydroxylated end of octane lies.   The 
octanol product distributions of these mutants are primarily shifted towards the terminal 
position since they were selected based on their activity in an HME screen that favors this 
type of hydroxylation (Figure 3.8)   
 
 
Figure 3.8. a) Active site residues with increased activity towards HME relative to DME.  
Select gas chromatograph traces of octane hydroxylation products catalyzed by mutants b) 
L75I, c) F87I, d) T88C, e) A328F. 
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Finally, three of the 11 libraries, for positions 81, 263, and 264, contained no 9-10A 
mutants with improved DME or HME activity.  But not all of the mutants were active, as 
seen with position 74.  These results suggest that the wild-type residue at these positions is 
optimal for alkane hydroxylation and that the position is sensitive to mutation.  
 
C.6. Recombination of Active Site Mutations 
Active site mutations that increased the activity towards at least one of the screening 
substrates, as well as the wild-type residues were recombined to form a large library 
containing all possible combinations of these mutations.  The mutation L75I which was not 
found to increase activity was selected for its change in regioselectivity and added to the 
library to increase its diversity.  The mutations A82L and A328V were added to the library 
because of their beneficial effects described in Chapter 2.  Mutation A82V was added due 
to constraints in designing the degenerate primer used to construct the library. 
Many of the mutations are too close to each other to be recombined using methods such as 
DNA shuffling [35].  Therefore, the library was constructed in stages using designed 
oligonucleotide primers containing the mutations (see Chapter 8 for details).  The libraries 
were screened using 1-12G as a control because we were interested in finding mutants with 
improved activities relative to our best alkane hydroxylase mutant to date.  Mutants from 
the partial and the final recombination libraries exhibiting improved DME or HME activity 
relative to 1-12G were selected for further characterization.   
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The first recombination library screened contained all possible combinations of the 
mutations A78, T78, F78, S78, A82, T82, S82, F82, I82, C82, G82, L82, V82, T260, 
N260, and L260.  Approximately 350 members of this small (81 possible combinations) 
library were screened with DME, and random members were sequenced to verify that it 
had been constructed properly.  The next library combined the mutations F87, I87, V87, 
L87, T88, C88, A328, L328, F328, V328, and M328 with the mutations in the first library.  
Approximately 9,000 members of this library (3,240 possible combinations) were screened 
with DME and HME, and 13 mutants were isolated based on their improved activity 
towards either substrate relative to the 1-12G control.  The mutations L75, I75, and W75 
were then introduced into these 13 mutants to form a small library of 39 possible 
combinations, of which 174 members were also screened with DME and HME to produce 
3 new mutants.  
 
C.7. Characterization of Active Site Mutants 
The octane hydroxylation activities were determined for the 24 single active site mutants 
selected from the 11 saturation mutagenesis libraries (Table 3.1).  Octane and propane 
hydroxylation activities were determined for the 16 recombined mutants.  These data are 
presented in the following Chapters. 
In some cases, increased DME response in the screen was associated with increased total 
turnovers on octane when the regioselectivity of the mutant favored the formation of 3- and 
4-octanols.  Alternatively, mutants with high activity towards HME in the screen generally 
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produced more total turnovers on octane than the positive 9-10A controls, especially when 
the product distributions of the mutants favored the formation of 1- and 2-octanols. 
All of the selected single active site mutants of 9-10A exhibit similar levels of product 
formation relative to 9-10A, but none of the mutants have levels higher than our best 
mutant to date, 1-12G.  The rates of product formation with octane are, for the most part, 
similar in magnitude to the rates of 9-10A and 1-12G on these substrates.  The major 
differences among these mutants reside in their varying distributions of octanol regio-
isomers, reflecting the role of their active site changes in perturbing the conformation of the 
bound substrate during catalysis.   
 
D. Discussion 
Our work is focused on obtaining mutants of cytochrome P450 BM-3 that can convert 
target alkanes into alcohols at high rates and total turnover numbers (ttn).  The BM-3 
catalytic mechanism is complex.  Substrate binding, efficient electron transfer through the 
protein in response to the new substrate, coupling of the transferred electrons to the heme 
cofactor during catalysis, and product release must be accomplished if multiple turnovers 
on new substrates are to occur.  A mutant performing well at these tasks should support 
more catalytic turnovers than a mutant deficient in one or more of these areas.  For this 
reason, we use ttn in our screens as our primary indicator of improved activity towards a 
new substrate.  Our DME and HME screens identify mutants that hydroxylate ever larger 
amount of these substrates within a reasonable amount of time (i.e., 15 minutes), and an 
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improved mutant in this work is defined by its relative increase in ttn on the screening and 
desired substrates.  
We have used directed evolution to obtain variants of BM-3 with improved alkane 
hydroxylation activity.  Starting with wild-type BM-3, we randomly mutated the heme 
domain of the enzyme, and then screened libraries of these mutants for increased activity 
towards alkanes [2,3,11].  After 7 rounds of evolution we accumulated 13 mutations in the 
BM-3 heme domain to generate mutant 9-10A.  Only one of these mutations, V78A, was 
located in the active site.  The removal of the V78A mutation from 9-10A retains the high 
rates and total turnover numbers of 9-10A towards alkanes but returns its altered product 
regioselectivity to wild-type’s product distribution.  When additional active site changes 
were made to 9-10A with the intention of improving binding of small substrates, the 
enzyme became a much more effective catalyst [11].  Comparable active site changes in 
wild-type BM-3 do not lead to the large increases in alkane hydroxylase activity we see in 
our evolved mutants (data not shown).  
Although we have determined that the non-active site mutations in 9-10A are responsible 
for its high activity towards alkanes, the active site mutation V78A does alter the 
distribution of product regioisomers (9-10A produces 51% 2-, 21% 3- and 27% 4-octanol 
from octane while 9-10A-V78A produces 27% 2-, 34% 3- and 39% 4-octanol), suggesting 
that this residue interacts with the substrates during catalysis.  We have also shown that the 
right combination of additional active site mutations to 9-10A can result in higher activities 
towards alkanes and also impart new regio- and enantioselective activities [11].  For 
example, BM-3 mutant 9-10A-A328V converts octane into 80% R-2-octanol, and mutant 
 100
9-10A-A82L-A328V (also named 1-12G), hydroxylates alkanes with two-fold higher ttn 
than any of our previous mutants and converts octane into 82% S-2-octanol.   
Ideally, we would like to look at the effects of all possible combinations of active site 
mutations on 9-10A, but the 2011 possible mutants cannot be screened.  Therefore, to create 
a more practically sized active site library with a high probability of containing active 
mutants, we first screened saturation mutagenesis libraries at each of 11 active site 
positions.  Using crystal structures of BM-3 to identify active site residues to test is not 
without difficulties, however.  First, the active site is formed with a large conformational 
change during substrate binding.  Structures of BM-3 without bound substrate show these 
same active site residues in different positions relative to the heme [4,7].  The conformation 
with bound small alkane substrates is unknown.  Secondly, in the BM-3 structures with 
bound substrate, the ferric heme cofactor is too far from the substrate to represent the actual 
conformation of the active site during catalysis.  It is not clear whether or not the substrate 
shifts relative to the active site residues they contact or the heme shifts to meet the substrate 
in their crystallographic conformations upon reduction of the heme before its activation by 
dioxygen [8].  The fact that no amino acid substitution at position 74 affects the 
regioselectivity of octane hydroxylation suggests that octane is bound to 9-10A in a similar 
position as the comparable portion of bound fatty acid substrates in the crystal structures.   
We obtained 24 mutants with single active site mutations in 9-10A that increase the 
productivity of 9-10A on either DME or HME and then used these mutations to construct a 
multiple active site library.  In addition to its role as a filter for finding active site mutations 
for the recombination library, screening these 11 saturation mutagenesis libraries provides 
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information on how particular active site residues influence a specific catalytic activity.   
For example, we examined a library of all possible mutations at position 74, which is 
within 5 Å of the ω-9 position of the fatty acid substrate but much farther from the terminal 
eight carbon atoms.  This residue could be changed to any other amino acid in 9-10A 
without altering the enzyme’s activity towards the screening substrates or regioselectivity 
towards octane.  This suggests that the residue, even when replaced with a larger side 
chain, does not contact octane during catalysis and confirms our assumptions that octane is 
bound in the active site similarly to the alkyl tail of the fatty acid substrates.  Screening data 
from the other saturation mutagenesis libraries further confirm our assumptions about 
alkane binding in the active site.  The residues that can be changed to increase DME 
activity, A78, A82, and T260, all contact the terminal three carbon atoms of the bound fatty 
acid substrate in the crystal structures.  Mutant 9-10A-V78F, which has one of the highest 
ratios of DME activity relative to HME activity, appears to attenuate the binding of larger 
substrates like HME and octane while promoting the binding and hydroxylation of small 
substrates by partially blocking the active site with a large aromatic side chain.   At the 
other 8 positions, few or no residues are found that increase DME activity, suggesting that 
these other positions do not form part of the DME binding site in BM-3.  Alternatively, 6 of 
the 11 chosen active site residues, L75, A82, F87, T88, T260, and A328, could be modified 
to increase HME activity relative to DME activity.  In the crystal structures these five 
residues contact most of the terminal eight carbon atoms of the fatty acid substrates.  The 
remaining positions, F81, I263, and A264, are most effective with the wild-type amino acid 
in 9-10A.  
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The single active site mutants used to construct the recombination library were chosen for 
their response to the DME and HME screens.  Their activities towards octane were 
determined separately.  None of the 24 single active site mutations in 9-10A supported 
more total turnovers on any of our target substrates than 1-12G, although the mutants 
oftentimes out-performed 9-10A.  The major effect of these active site mutations in 9-10A 
is on octanol product distribution.  Because screening on HME identifies mutants selective 
for the terminal position of the substrate, mutants with an overall increase in 1- and 2-
octanol production were generally selected with this screen over mutants that favor 3- and 
4-octanol production.  Alternatively, mutants selected based on DME activity tended to 
favor the formation of 3- and 4-octanol.   
Octane is challenging to hydroxylate selectively because it contains no functional groups to 
facilitate binding of the substrate in a single conformation while it reacts with the active 
heme iron-oxo species.  Each of these mutants, however, possesses a modified active site 
that binds octane differently to produce the varied regioselectivities reported here.  These 
binding differences can be expected to be even more pronounced with complex substrates 
with functional groups and three dimensional structures that favor single binding 
conformation and can result in the very clean formation of a single hydroxylation product 
with these substrates.  Data supporting this hypothesis are provided in Chapter 5.  
As we have demonstrated with mutant 1-12G, multiple active site changes to 9-10A can 
increase the ttn of alkane hydroxylation.  To find new 9-10A mutants with beneficial 
multiple active site mutations, we created a library containing all possible combinations of 
the 24 single active site mutants described above and screened the library with DME and 
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HME to find mutants more active than 1-12G on either substrate.  As described in the next 
chapter, out of 9,700 possible recombination mutants, 16 were isolated and their activities 
towards propane and octane were determined.   
The combination of random mutagenesis and active site residue mutagenesis is a powerful 
approach for engineering new activities for P450 BM-3.  The iterative process of 
generating libraries of variants containing mutations throughout the protein and screening 
them for improved variants generally accumulates non-active site mutations because most 
of the residues in an enzyme are not in the active site, statistically biasing the experiment to 
find mutations at these positions.  In our work with cytochrome P450 BM-3, we have 
shown that active site engineering primarily affects substrate binding, resulting in changes 
in hydroxylation regioselectivity and substrate specificity that would be difficult to obtain 
by random mutagenesis.  Both approaches were necessary to obtain the improved mutants 
described throughout this thesis.  Libraries consisting of mostly non-active site mutations 
were initially created to increase the activity towards alkanes in general, and active site 
libraries to tighten the substrate specificity and regioselectivity 
Selective alkane hydroxylation is difficult due to the lack of functional groups in alkanes to 
direct catalysis and the fact that their overoxidation to ketones and acids is as energetically 
favored as their hydroxylation.  Many chemical catalysts have been used to hydroxylate 
various types of alkanes under relatively mild conditions using both hydrogen peroxide and 
dioxygen [36], but the regioselective hydroxylation of medium chain linear alkanes at 
positions other than the terminal one has not been reported with any of these systems.  In 
contrast to most chemical catalysts, P450 BM-3 has been evolved in our laboratory to 
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convert alkanes to alcohols at higher rates and ttn under mild conditions.  Additionally, as 
we have demonstrated in this work, we can modify the active site of these evolved enzymes 
to obtain mutants that support the conversion of linear alkanes with distinct 
regioselectivities. 
 105
E. References  
1. Miles, C. S., Ost, T. W. B., Noble, M. A., Munro, A. W. & Chapman, S. K. (2000). 
Protein engineering of cytochromes P-450. Biochim. Biophys. Acta 1543, 383-
407. 
2. Farinas, E. T., Schwaneberg, U., Glieder, A. & Arnold, F. H. (2001). Directed 
evolution of a cytochrome P450 monooxygenase for alkane oxidation. Adv. 
Synth. Catal. 343, 601-606. 
3. Glieder, A., Farinas, E. T. & Arnold, F. H. (2002). Laboratory evolution of a 
soluble, self-sufficient, highly active alkane hydroxylase. Nat. Biotechnol. 20, 
1135-1139. 
4. Ravichandran, K. G., Bodupalli, S. S., Hasemann, C. A., Peterson, J. A. & 
Deisenhofer, J. (1993). Crystal structure of hemoprotein domain of P450BM-3, 
a prototype for microsomal P450's. Science 261, 731-736. 
5. Li, H. & Poulos, T. L. (1997). The structure of the cytochrome P450BM-3 haem 
domain complexed with the fatty acid substrate, palmitoleic acid. Nat. Struct. 
Biol. 4, 140-146. 
6. Haines, D. C., Tomchick, D. R., Machius, M. & Peterson, J. A. (2001). Pivotal role 
of water in the mechanism of P450BM-3. Biochemistry 40, 13456-13465. 
7. Sevrioukova, I. F., Li, H., Zhang, H., Peterson, J. A. & Poulos, T. L. (1999). 
Structure of a cytochrome P450-redox partner electron-transfer complex. 
Proc. Natl. Acad. Sci. 96, 1863-1868. 
8. Modi, S., Sutcliffe, M. J., Primrose, W. U., Lian, L. Y. & Roberts, G. C. K. (1996). 
The catalytic mechanism of cytochrome P450 BM3 involves a 6 Angstrom 
movement of the bound substrate on reduction. Nat. Struct. Biol. 3, 414-417. 
9. Daff, S. N., Chapman, S. K., Turner, K. L., Holt, R. A., Govindaraj, S., Poulos, T. 
L. & Munro, A. W. (1997). Redox control of the catalytic cycle of 
flavocytochrome P-450 BM3. Biochemistry 36, 13816-13823. 
10. Ost, T. W. B., Clark, J., Mowat, C. G., Miles, C. S., Walkinshaw, M. D., Reid, G. 
A., Chapman, S. K. & Daff, S. (2003). Oxygen activation and electron transfer 
in flavocytochrome P450BM3. J. Am. Chem. Soc. 125, 15010-15020. 
11. Peters, M. W., Meinhold, P. & Arnold, F. H. (2003). Regio- and enantioselective 
alkane hydroxylation with engineered cytochromes P450 BM-3. J. Am. Chem. 
Soc. 125, 13442 -13450. 
 106
12. Hopps, H. B. (2000). Purpald: a reagent that turns aldehydes purple. 
Aldrichimica Acta 33, 28-30. 
13. Graham-Lorence, S., Truan, G. L., Peterson, J. A., Falck, J. R., Wei, S., Helvig, C. 
& Capdevila, J. H. (1997). An active site substitution, F87V, converts 
cytochrome P450 BM-3 into a regio- and stereoselective (14S, 15R)-
arachidonic acid epoxygenase. J. Biol. Chem. 272, 1127-1135. 
14. Oliver, C. F., Modi, S., Sutcliffe, M. J., Primrose, W. U. & Roberts, G. C. K. 
(1997). A single mutation in cytochrome P450 BM3 changes substrate 
orientation in a catalytic intermediate and the regiospecificity of 
hydroxylation. Biochemistry 36, 1567-1572. 
15. Li, H. Y. & Poulos, T. L. (1999). Fatty acid metabolism, conformational change, 
and electron transfer in cytochrome P-450(BM-3). Biochim. Biophys. Acta 1441, 
141-149. 
16. Cirino, P. C. & Arnold, F. H. (2002). Regioselectivity and activity of cytochrome 
P450BM-3 and mutant F87A in reactions driven by hydrogen peroxide. Adv. 
Synth. Catal. 344, 932-937. 
17. Li, Q. S., Ogawa, J., Schmid, R. D. & Shimizu, S. (2001). Residues size at 
position 87 of cytochrome P450 BM-3 determines its stereoselectivity in 
propylbenzene and 3-chlorostyrene oxidation. FEBS Lett. 508. 
18. Li, Q. S., Ogawa, J. & Shimizu, S. (2001). Critical role of the residue size at 
position 87 in H2O2-dependent substrate hydroxylation activity and H2O2 
inactivation of cytochrome P450BM-3. Biochem. Biophys. Res. Commun. 280, 
1258-1261. 
19. Li, Q. S., Schwaneberg, U., Fischer, M., Schmitt, J., Pleiss, J., Lutz-Wahl, S. & 
Schmid, R. D. (2001). Rational evolution of a medium chain-specific 
cytochrome P-450 BM-3 variant. Biochim. Biophys. Acta 1545. 
20. Li, Q. S., Ogawa, J., Schmid, R. D. & Shimizu, S. (2001). Engineering 
cytochrome P450 BM-3 for oxidation of polycyclic aromatic hydrocarbons. 
Appl. Environ. Mirobiol. 67, 5735-5739. 
21. Cowart, L. A., Falck, J. R. & Capdevila, J. H. (2001). Structural determinants of 
active site binding affinity and metabolism by cytochrome P450BM-3. Arch. 
Biochem. Biophys. 387, 117-124. 
22. Li, Q. S., Schwaneberg, U., Fischer, P. & Schmid, R. D. (2000). Directecd 
evolution of the fatty-acid hydroxylase P-450 BM3 into an indole-
hydroxylating catalyst. Chem. Eur. J. 6, 1531-1536. 
 107
23. Appel, D., Lutz-Wahl, S., Fischer, P., Schwaneberg, U. & Schmid, R. D. (2001). A 
P450 BM-3 mutant hydroxylates alkanes, cycloalkanes, arenes and 
heteroarenes. J. Biotechnol. 88, 167-171. 
24. Peterson, J. A., Hedge, A., Graham, S. & Mullin, D. (2002). Sixth International 
Symposium on Cytochrome P450 Biodiversity, University of California, Los 
Angeles. 
25. Otey, C. (2003). High-throughput carbon monoxide binding assay for 
cytochrome P450. In Screening and Selection for Directed Enzyme Evolution 
(Arnold, F. H. & Georgiou, G., eds.), Vol. 230. Humana Press, Inc., Totowa, NJ. 
26. Omura, T. & Sato, R. (1964). The carbon monoxide-binding pigment of liver 
microsomes. I. Evidence for its hemoprotein nature. J. Biol. Chem. 239, 2370-
2378. 
27. Reidhaar-Olson, J. F. & Sauer, R. T. (1988). Combinatorial cassette mutagenesis 
as a probe of the informational content of protein sequences. Science 241, 53-
57. 
28. Voigt, C. A., Mayo, S. L., Arnold, F. H. & Wang, Z. G. (2001). Computational 
method to reduce the search space for directed protein evolution. Proc. Natl. 
Acad. Sci. 98, 3778-3783. 
29. Shoichet, B. K., Baase, W. A., Kuroki, R. & Matthews, B. W. (1995). A 
relationship between protein stability and protein function. Proc. Natl. Acad. 
Sci. 92, 452-456. 
30. Bloom, J. D., Silberg, J. J., Wilke, C. O., Drummond, D. A., Adami, C. & Arnold, 
F. H. (2005). Thermodynamic prediction of protein neutrality. Proc. Natl. Acad. 
Sci. 102, 606-611. 
31. Bloom, J. D., Meyer, M. M., Meinhold, P., Otey, C. R., Macmillan, D. & Arnold, F. 
H. (2005). Evolving strategies for enzyme engineering. Curr. Opin. Struct. Biol. 
accepted. 
32. Markiewicz, P., Kleina, L. G., Cruz, C., Ehret, S. & Miller, J. H. (1994). Genetic 
studies of the lac repressor. XIV. Analysis of 4000 altered Escherichia coli lac 
repressors reveals essential and non-essential residues, as well as "spacers" 
which do not require a specific sequence. J. Mol. Biol. 240, 421-433. 
33. Guo, H. H., CHoe, J. & Loeb, L. A. (2004). Protein tolerance to random amino 
acid chagne. Proc. Natl. Acad. Sci. 101, 9205-9210. 
 108
34. Rennell, D., Bouvier, S. E., Hardy, L. W. & Poteete, A. R. (1991). Systematic 
mutation of bacteriophage T4 lysozyme. J. Mol. Biol. 222, 67-88. 
35. Stemmer, W. P. C. (1994). DNA shuffling by random fragmentation and 
reassembly: in vitro recombination for molecular evolution. Proc. Natl. Acad. 
Sci. USA 91, 10747-10751. 
36. Arakawa, H.et al. (2001). Catalysis research of relevance to carbon 
management: progress, challenges, and opportunities. Chem. Rev. 101, 953-996. 
 
 109 
C h a p t e r  4  




Saturation mutagenesis of selected active site residues followed by recombination of 
beneficial mutations generated a library of approximately 9,000 BM-3 variants that 
catalyze the hydroxylation of of linear alkanes with varying regioselectivity.  By applying 
a high-throughput screening assays that detects terminal hydroxylation activity, we were 
able to identify a variant that hydroxylates octane at its terminal position with 50% 






Biocatalysis provides a useful alternative to classic chemical synthesis due to the inherent 
specificity of enzymes [1] and directed evolution has proven a powerful methodology to 
tailor biocatalysts for specific applications [2,3].  Oftentimes, the substrate specificity of 
an enzyme needs to be altered to enable conversion of a new substrate.  A more difficult 
task is to engineer regio- and enantioselectivity.  Enantioselective catalysts that accept 
only a single enantiomer or regioisomer of a substrate have been created using directed 
evolution [2].  Engineered enzymes that regio- and enantioselectively functionalize 
achiral compounds, however, are rarely reported.  In particular, the regio- and 
enantioselective hydroxylation of saturated hydrocarbons remains a problem in chemical 
synthesis [4]  and would lead to improved utilization of petrochemicals and natural gas 
and provide valuable synthons for the pharmaceutical industry.   
Progress has been made with synthetic catalysts, but remains hindered by the problems of 
overoxidation, and lack of regioselectivity and enantioselectivity [5]. Indeed, without 
restricted access of the substrate molecule to the catalytic center, the regioselectivity of 
hydroxylation is typically governed by the relative bond dissociation energies; i.e., 
tertiary and secondary carbon atoms are favored over primary carbon atoms.  
Cytochromes P450 catalyze the hydroxylation of non-activated carbon atoms on a wide 
variety of substrates using a single reactive iron-oxo species chelated by a porphyrin.  
Model studies with metalloporphyrins show that the regioselectivity of n-alkane 
hydroxylation is determined by the relative bond dissociation energies.  Therefore, 
hydroxylation of the internal methylene groups is highly favored [6] and significant 
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terminal hydroxylation activity is only observed upon sterically restricting substrate 
access [7].   
P450 BM-3 hydroxylates fatty acid substrates at subterminal (ω-1, ω-2, and ω-3) 
positions at approximately equal amounts (the exact regioselectivity varies with the chain 
length of the substrate).  Various groups have engineered this enzyme to alter the 
substrate specificity [8-12] as well as regioselectivity [13-15].  However, a BM-3 variant 
with terminal hydroxylation activity has not been engineered (Variant F87A has been 
reported to support ω-hydroxylation of lauric acid [16].  Contradicting results obtained in 
our and other laboratories, however, show that this mutation actually broadens the 
regioselectivity and shifts hydroxylation away from the terminal position [17,18]).    
In Chapter 2 of this thesis we describe how the regioselectivity of BM-3-catalyzed alkane 
hydroxylation could be altered by targeting important active site residues for mutation.  
Saturation mutagenesis of eleven active site residues that are in close contact to the 
substrate is described in Chapter 3.  Mutations that increased activity towards dimethyl 
ether (DME) or hexyl methyl ether (HME) Beneficial mutations were recombined, 
generating a library of approximately 9,000 BM-3 variants.  Each of these mutants 
contains a characteristic active site and catalyzes the hydroxylation of linear alkanes with 
varying regioselectivity.  This chapter discusses the regioselectivity of octane 
hydroxylation of improved mutants, one of which hydroxylates octane at its terminal 
position with 50% selectivity.   
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C. Results and Discussion 
C.1. Properties of Improved Mutants and Correlation with the Screening Data 
As described in Chapter 3, we identified 11 active site residues that are in close proximity 
to bound fatty acid substrates in crystal structures of BM-3 [19,20].  To create a 
practically-sized library of variants with combinations of active site mutations, we first 
screened saturation mutagenesis libraries at each of 11 active site positions to identify a 
small pool of single active site mutants.  Beneficial mutations were then recombined into 
a multiple active site library.  After screening the saturation mutagenesis libraries, we 
obtained 24 mutants with single active site mutations in 9-10A that increase the 
productivity of 9-10A on either DME or HME (see Table 3.1 in Chapter 3) and then 
recombined these mutations to construct a multiple active site library. 
Because we were interested in finding mutants with improved activity relative to our best 
alkane hydroxylase mutant to date, mutant 1-12G [15] was used as a control in the 
screening procedure that used HME and DME as surrogate substrates.  The library 
contains approximately 9,000 P450 BM-3 variants, each of which contains a 
characteristic active site.  Most mutants (> 64 %) in this library were active towards HME 
while only 39% where active towards DME.  A total of 16 mutants with improved 
activity towards DME or HME relative to 1-12G (Table 4.1) were selected for 
purification and further characterization.   
Octane was used as a model substrate for alkane hydroxylation, and rates of product 
formation, total turnover numbers, and regioselectivities were determined (Table 4.2).  
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Table 4.1. Mutations[a] in active site variants and activity towards the screening 
substrates DME and HME. 
 
 A75 A78 A82 F87 A328 DME[b] HME[b]
9-10A      0.5 0.6 
1-12G   L  V 1.0 1.0 
77-9H  T G  L 0.9 1.5 
1-7D I F G  L 1.3 1.5 
68-8F  F G  L 1.9 1.2 
49-9B   G V L 0.4 2.1 
35-7F  F S  L 1.8 1.5 
1-5G I F S  L 1.4 1.4 
13-7C  T   L 1.4 1.1 
49-1A  T G V L 0.3 2.0 
2-4B I T   L 1.2 1.7 
12-10C   G V V 0.7 1.9 
11-8E    V L 0.6 2.0 
41-5B  F G  V 1.6 0.9 
29-3E  F G  F 1.5 0.5 
7-11D   F  V 1.5 0.8 
29-10E   F  F 1.6 0.7 
53-5H  F S  F 1.4 0.7 
[a] mutations are relative to 9-10A which contains amino acid substitutions R47C, V78A 
K94I, P142S, T175I, A184V, F205C, S226R, H236Q, E252G, R255S, A290V, and 
L353V. 
[b] terminal hydroxylation activity of dimethyl ether and hexyl methyl ether are reported 















Table 4.2. Product distribution[a], rates and total turnover numbers of octane 
hydroxylation reactions catalyzed by variants of BM-3 containing active site mutations. 
 
 4-ol [%] 3-ol [%] 2-ol [%] 1-ol [%] ttn[b] rate
[c] 
[min-1] 
9-10A 27 21 51 0 3000 540 
A82L 53 25 18 0 6000 540 
A328V 0 8 91 0 2000 50 
1-12G 4 11 79 3 7500 150 
77-9H 0 3 45 52 1300 160 
1-7D 1 6 55 38  1300 220 
68-8F 2 8 58 31 1400 180 
49-9B 0 2 76 20 3800 310 
35-7F 1 6 74 18 2000 200 
1-5G 1 7 74 17  2200 380  
13-7C 1 8 74 17 2600 310 
49-1A 0 2 81 15 3700 350 
2-4B 1 8 76 14  3900  320 
12-10C 1 6 77 12 3100 240 
11-8E 0 2 87 8 5700 550 
41-5B 5 15 68 7 1800 370 
29-3E 3 10 79 6 3200 160 
7-11D 2 13 78 6 2200 150 
29-10E 1 8 84 5 3200 140 
53-5H 1 5 87 3 7400 660 
 [a] Product distribution determined as ratio of a specific alcohol product to the total 
amount of alcohol products (given in %).  Errors are at most 3%.  The formation of 
ketones was also observed but is less than 10% of the total amount of product.   
[b] Initial rates of product formation were measured by GC over 60 s as nmol total 
products/min/nmol protein.  The reactions contained P450 (100 nM), NADPH (500 µM), 
and octane (4 mM) in ethanol (1%) and potassium phosphate buffer (0.1 M, pH 8.0).  
Errors are at most 10% 
[c] Total turnover numbers determined as nmol product/nmol protein.  The reactions 
contained P450 (25 nM), NADPH (500 µM), and octane (4 mM) in ethanol (1%) and 





In general, mutants with high total turnover of HME in the screen generally produced 
more 1-octanol than compared to 1-12G.  The regioslectivity alone does not necessarily 
correlate with HME activity.  However, the total amount of 1-octanol formed (percent of 
1-octanol multiplied by ttn) correlates with the amount of HME converted (Figure 4.1). 
For example, mutant 77-9H is not improved relative to 1-12G when considering rates and 
total turnovers on octane, but this mutant converts octane to 52% 1-octanol, and is highly 
active towards HME in the screen.  The deviation from the linear trendline in Figure 4.1 
could be due partly to the fact that during the screening no account is taken for varying 
protein concentration in the lysate.  The proportion of 1-octanol in the product mixture 
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Figure 4.1. The amount of 1-octanol formed during an octane hydroxylation reaction 
correlates well with the screening data (HME activity). 
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C.2. Regioselectivity of Mutant 77-9H on n-Alkanes and Fatty Acids 
Mutant 77-9H, the variant with the highest proportion of terminal hydroxylation activity, 
was characterized in greater detail.  Alkanes of varying chain length (C6 to C10) were 
used as substrates and the products were analyzed using gas chromatography with 
authentic standards.  Unexpectedly, only octane is hydroxylated primarily at its terminal 
position.  Alkanes shorter or longer than octane are primarily hydroxylated at the 2-
position (Table 4.3 / Figure 4.2).   
Table 4.3. Product distributions[a] of 77-9H-catalyzed alkane hydroxylation reactions. 
 
Substrate 1-ol [%] 2-ol [%] 3-ol [%] 4-ol [%] 5-ol [%] 
hexane 11.4 83.8 4.9   
heptane 21.3 74.3 4.2 0.2  
octane 51.8 45.1 2.8 0.3  
nonane 9.7 88.1 1.5 0.7 0.0 
decane 5.5 91.8 2.0 0.7 0.0 
[a] Product distribution determined as ratio of a specific alcohol product to the total 
amount of alcohol products (given in %).  Errors are at most 3%.  The formation of 


























Figure 4.2. Regioselectivity of 77-9H-catalyzed alkane hydroxylation. 
The active site of 77-9H is therefore not highly restricted in proximity of the activated 
oxygen to prevent subterminal hydroxylation.  The specificity for the terminal methyl 
group of octane probably arises due to specific interactions of active site residues with 
certain octane methylene groups and/or the opposite methyl group.  The surrogate 
substrate hexyl methyl ether, which was used for screening of terminal hydroxylation 
activity, has the same chain length as octane.  The mutations that enable terminal 
hydroxylation of this substrate likely act in a similar fashion when octane is the substrate 
but not when the length of the substrate is altered.   
The wild-type enzyme hydroxylates lauric and palmitic acid primarily at subterminal 
positions.  Lauric acid is primarily (48 %) hydroxylated at the ω-1 position, and palmitic 
acid is primarily (48 %) hydroxylated at the ω-2 position [21].  Mutant 77-9H follows the 
same trend (Table 4.4).   
Table 4.4. Product distributions[a] of 77-9H-catalyzed fatty acid hydroxylation reactions. 
 
Substrate ω [%] ω-1 [%] ω-2 [%] ω-3 [%] 
lauric acid 7.5 52.1 2.8 37.5 
palmitic acid 8.9 5.2 83.0 3.0 
[a] Product distribution determined as ratio of a specific hydroxylation product to the total 
amount of hydroxylation products (given in %).  Errors are at most 3%.   
 
We have only altered residues that contact the terminal eight carbons of the substrate 
based on the crystal structure with bound palmitoylglycine [20]. Interactions of amino 
acid residues outside of this region with the fatty acid substrates have not been altered.  
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We therefore might expect changes in regioselectivity to be less drastic than with alkane 
substrates. 
P450 BM-3 Mutant F87A has been reported to support ω-hydroxylation of lauric acid 
[16]. Contradicting results obtained in our laboratory [17] and by others [18] show that 
this mutation actually broadens the regioselectivity and shifts hydroxylation away from 
the terminal position.  To address this controversy, we engineered the F87A substitution 
into wild-type and 9-10A and analyzed the alkane and fatty acid hydroxylation product 
regioisomers.  The data for lauric acid hydroxylation with the wt F87A mutant are in 
agreement with our previous report [17]. Neither variant supports terminal hydroxylation 
activity on alkanes (Table 4.5)  or on fatty acids (Table 4.6). 
 
Table 4.5. Product distributions[a] of wt F87A- and 9-10A F87A-catalyzed alkane 
hydroxylation reactions. 
 
Mutant Substrate 1-ol [%] 2-ol [%] 3-ol [%] 4-ol [%] 5-ol [%] 
 hexane 0 54 46   
 heptane 0 36 61 3  
wt F87A octane 0 14 43 44  
 nonane 0 7 20 2 72 
 decane 0 10 9 0 81 
 hexane 0 42 57   
 heptane 2 62 34 3  
9-10A F87A octane 1 55 37 7  
 nonane 0 24 46 5 25 
 decane 0 14 23 1 62 
[a] Product distribution determined as ratio of a specific alcohol product to the total 
amount of alcohol products (given in %).  Errors are at most 3%.  The formation of 




Table 4.6. Product distributions[a] of wt F87A- and 9-10A F87A-catalyzed fatty acid 
hydroxylation. 
 















Wt F87A lauric acid 0 5 9 39 20 27 0 0 
 palmitic acid 0 11 36 18 22 13 0 0 
9-10A 
F87A lauric acid 0 5 6 28 14 47 0 0 
 palmitic acid 0 0 1 1 2 8 20 68 
[a] Product distribution determined as ratio of a specific alcohol product to the total 
amount of alcohol products (given in %).  Errors are at most 3% for WT F87A and 6% 
for 9-10A F87A.  
 
The highly desirable terminal hydroxylation of linear alkanes has been achieved using 
synthetic catalysts with varying degrees of success.  To our best knowledge, the highest 
selectivity for terminal hydroxylation of linear alkanes using chemical catalysts was 
achieved using molecular-sieve catalysts.  With these, n-alkanes, such as octane, can be 
oxidized primarily (65% of all products) at the terminal methyl group, yielding octanoic 
acid, octanal and n-octanol [22].  In comparison, the enzymes used by several 
microorganisms for the utilization of linear alkanes as a source of carbon and energy [23] 
hydroxylate n-alkanes exclusively at their terminal position [24].  Some P450s (several 
members of the Cyp4 family, Cyp52, Cyp86, Cyp153) catalyze the hydroxylation of 
terminal methyl groups of fatty acids or n-alkanes [25-28].  These enzymes must 
therefore override the inherent specificity of the catalytic species for the methylene 
groups by restricting substrate access to the heme iron so that only the terminal methyl 
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carbon is positioned correctly above the heme-iron.  However, the known P450s with 
terminal hydroxylation activity are membrane bound and have a multi-component nature, 
making them difficult to manipulate or produce in large quantities.  Additionally, none of 
these proteins has its crystal structure solved.  The work presented in this chapter opens 
up the prospect of converting the fast and easily expressible P450 BM-3 into a terminal 
alkane hydroxylase.  
 
C.3. Total Turnover Numbers, Rates and Coupling Efficiency 
Total turnover numbers (ttn) and rates of product formation were measured for the 
different alkanes (Table 4.7).  To determine ttn, the enzymes were diluted to a 
concentration at which the P450 is neither oxygen-limited nor inactivated due to dialysis 
of the flavins, a likely inactivation mechanism at low P450 concentrations [29].  The total 
turnover number was found to be substrate dependent and generally increases with the 
alkane chain length.  The observed decrease in ttn for decane hydroxylation might be an 
artefact of the limited solubility of decane in the reaction buffer (calculated as ~ 0.4 mM 
in water with 2% ethanol [30]) and not an inherent property of the enzyme itself.  Rates 









Table 4.7. Total turnover, product formation rates, NADPH oxidation rates, and coupling 
efficiency of 77-9H-catalyzed alkane hydroxylations. 
 











hexane 1800 ± 130  251 ± 29 1560 ± 60  16.1 ± 2.0 
heptane 1730 ± 110 112 ± 9 1630 ± 20 6.9 ± 0.6 
octane 3040 ± 150 236 ± 24 1630 ± 30 14.5 ± 1.7 
nonane 4240 ± 680 742 ± 30 1150  ± 100 65.6 ± 9.3 
decane 2831 ± 225 318 ± 47 940 ± 50 33.4 ± 7.2 
[a] Total turnover numbers determined as nmol product/nmol protein.  The reactions 
contained P450 (25 nM), an NADPH regeneration system (166 µM NADP+, 6.6 U/mL 
isocitrate dehydrogenase, 41.6 mM isocitrate) and octane (4 mM) in ethanol (2 %) and 
potassium phosphate buffer (0.1 M, pH 8.0). 
 [b] Rates of product formation were measured by GC over 20 s as nmol total 
products/min/nmol protein.  The reactions contained P450 (200 nM), NADPH (500 µM) 
and octane (2 mM) in ethanol (2%) and potassium phosphate buffer (0.1 M, pH 8.0). 
[c] Rates of NAPPH oxidation were measured over 20 s at 340 nm as nmol 
NADPH/min/nmol protein.  The reactions contained P450 (200 nM), NADPH (160 µM), 
and octane (2 mM) in ethanol (2 %) and potassium phosphate buffer (0.1 M, pH 8.0).  
The background NADPH oxidation rate (without substrate) rate was 220/min.  
[d] Coupling efficiency is the ratio of product formation rate to NADPH oxidation rate.   
 
Wildtype P450 BM-3 tightly regulates electron transfer from the cofactor (NADPH) to 
the heme when fatty acids are the substrates.  In absence of substrate, a weakly-bound 
water molecule acts as the the sixth, axial ligand.  Substrate replaces this water molecule, 
resulting in a shift in spin-state of the heme iron to the high-spin form and an increase (~ 
140 mV) in heme iron reduction potential, inducing reduction of the ferric [31,32]. 
However, with mutant BM-3 enzymes and nonnatural substrates, NADPH consumption 
is not necessarily coupled to the formation of product, but instead reduces heme-bound 
dioxygen to water or the reactive oxygen species peroxide and superoxide [29].  To 
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determine the coupling efficiency of mutant 77-9H, rates of NAPDH oxidation upon 
addition of the alkane substrates were measured and compared to product formation rates 
(Table 4.6).  It was found that rates of product formation correlate well with coupling 
efficiency; i.e.,  the more the reaction is coupled to NADPH oxidation, the higher the rate 
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Figure 4.3. The coupling efficiency ((product formation rate) / (NADPH oxidation rate)) 
correlates with the product formation rate.    
 
We had anticipated that the oxidation of the disfavored terminal methyl group of octane 
might lead to a decrease in the rate of product formation.  However, here we show that 
the rate of product formation is correlated to coupling efficiency.  Interestingly, the 





We have created a library of approximately 9,000 different P450 active site mutants.  
Members of this library were screened for terminal alkane hydroxylation activity.  And to 
our best knowledge, this is the first report of an engineered P450 BM-3 exhibiting this 
activity.  Wild-type P450 BM-3 hydroxylates its preferred substrates, medium-chain fatty 
acids (C12 to C18), at subterminal positions.  The terminal carbon is not hydroxylated 
[33]. Similarly, reports of engineered, bacterial alkane hydroxylating P450s do not 
describe terminal hydroxylation activity [8,34].  The first law of directed evolution - “you 
get what you screen for” [35] - was once again proven true.  Mutant 77-9H preferentially 
hydroxylates the terminal carbon of octane which has approximately the same chain 
length as the screening substrate hexyl methyl ether.  Alkanes larger or smaller are 
hydroxylated at this position to a much lesser degree.  We anticipate that by screening 
with methyl ether derivatives of alkanes of various chain lengths it will be possible to 
generate a terminal hydroxylase mutant with an even higher proportion of terminal 
hydroxylation.  Additionally, the screen can be adapted for the regioselective 
hydroxylation of more complex substrates by using methyl ether derivatives of them as 
surrogate substrates.  In such an approach, the same library of active site mutants should 
yield promising results.  We also anticipate that a variety of substrates can be 
hydroxylated regioselectively by at least one of the variants. Indeed, as described in 
Chapter 5, mutations in the active site can yield variants that hydroxylate complex 
substrates such as 2-cyclopentylbenzoxazole with high regio- and enantioselectivity, 
yielding potentially valuable intermediates for chemical synthesis [36]. 
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A. Abstract 
Two discrete strategies for improving the preparative outcome of enzymatic 
hydroyxlation reactions are protein and substrate engineering.  The carboxylic acid 
moiety of cyclopentanecarboxylic acid, which is not converted by P450 BM-3 or variants 
thereof, was protected with benzoxazole.  This modified substrate, 2-
cyclopentanebenzoxazole was regio- and enantioselectively, using cytochrome P450 BM-
3 mutants engineered for regio- and enantioselective hydroxylation of linear alkanes.  
The reaction proceeds at rates of up to 230 min-1, with high ttn of up to 9,200 and an ee of 





As described in Chapter 1, cytochrome P450 BM-3 has been engineered to accept 
nonnatural substrates with enhanced regioselectivity, enantioselectivity, catalytic rates and 
total turnover.  Mutations in the active site, for example, enable the enzyme to hydroxylate 
alicyclic, heterocyclic, aromatic and even polyaromatic compounds [1-4].  As described in 
Chapter 2, linear alkanes can be hydroxylated by mutants engineered for this purpose.  And 
as shown in Chapter 3, engineering of the active site enabled us to adjust the 
regioselectivity of linear alkane hydroxylation.  This poses the possibility that other 
compounds might also be hydroxylated regio-and enantioselectively, if they were to be 
accepted as substrates.   
If a given compound is not accepted as a substrate, it can still be engineered to improve its 
reactivity in a biotransformation, as in the docking/protecting (d/p) group concept for 
biotransformations [5,6].  Similar to the common practice of using protective groups in 
organic chemistry, a (d/p) group is introduced into an enzyme substrate before the 
biotransformation is performed, and finally the d/p group is removed.  The aims of this 
concept are to improve the predictability of the hydroxylation position, prevent undesired 
side reactions, and aid substrate detection, and product recovery.  This approach has been 
successfully applied to carboxylic acids, ketones, aldehydes, and alcohols [6].  Overall, 
this approach improves the applicability of bioconversions in chemical synthesis, especially 
for preparing chiral molecules.  In this chapter, we show that protein engineering in 
combination with substrate engineering improves the synthetic outcome of a 
biohydroxylation.   
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A method for direct biohydroxylation of cyclic carboxylic acids to produce preparatively 
valuable starting materials, such as carboxylic acid 1 to compound 4 (Figure 5.1), would be 












4 3  
Figure 5.1. The conversion of carboxylic acid 1 to product 4 employing the 
docking/protecting group concept. 
 
Carbovir (Figure 5.2), for example, is a carboxylic nucleoside potentially active against 
human HIV [7].  (R,R)-4 would be a potentially useful precursor to this much needed 
medication.  Unfortunately, finding microorganisms containing monooxygenase systems 
capable of hydroxylating substances such as 1 has proven difficult, especially when a 
specific product stereoselectivity is required.  In addition, these simple carboxylic acids are 
troublesome to purify from complex fermentation/biotransformation mixtures due to their 








Figure 5.2. Structure of carbovir 
 
The d/p group concept was found to circumvent these problems, at least in part.  
Carboxylic acid 1 has been chemically modified to give model compound 2-
cyclopentylbenzoxazole 2 (Figure 5.1).  The resulting substrate is easy to manipulate as 
well as amenable to biohydroxylation with whole cell systems such as Cunninghamella 
blakesleeana DSM 1906 [8-10].  Protecting group removal provides end product 4.  
Regardless of the microorganisms and fermentation conditions used, however, only a single 
diastereoisomer, (S,S)-4, could be obtained with synthetically useful diastereoselectivities 
[8-10].  Side products were also formed during this transformation because the 
microorganisms used catalyzed further, undesired transformations, such as oxidation.  
Consequently, we tested P450 BM-3 mutants engineered for regio- and enantioselective 





C. Results and Discussion 
C.1. Whole-Cell Biotransformations 
Our collaborators in Austria performed initial whole-cell biotransformations using E. coli 
DH5α cells transformed with plasmids carrying the genes of 13 different P450 mutants (see 
Appendix D for experimental details).  The mutants included in this set of experiments 
were created in previous studies [11,12] as well as in the experiments described in Chapter 
2.  Results for the wild-type and three of these mutants are listed in Table 5.1 (mutations 
are listed in Appendix B).  All of the mutants tested in this set of experiments contain the 
same active site, with the exception of 9-10A-A328V and 1-12G.  The enantioselectivies 
obtained using the remaining ten mutants were therefore unexpectedly similar to 139-3.   
 















BM-3 variant Main  Isomer 3 ee de 
wild-type S, S 1.5% 87% 
139-3 S, S 79% 87% 
B S, S 82% 87% 
1-12G R, R 89% 87% 
 
Refer to Appendix D for experimental details 
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Biohydroxylation using the wild-type enzyme in E. coli gave very low enantioselectivity 
(1.5%, S,S) and high diastereoselectivity (87%).  Mutant 139-3 also afforded (S,S)-3, but 
in high ee (79%) and de (96%).  Mutant B gave comparable selectivities to 139-3.  In 
dramatic contrast, mutant 1-12G was found to produce the highly sought (R,R)-3 in high 
selectivities (89% ee, 94% de).  The yields of 3 were modest, ranging from 0.4% to 15%.  
Total turnover numbers of the enzymes are reported in below (Table 5.3) and are 
sufficient to expect higher yields.  For example, a reasonable estimate of the BM-3 
concentration in a culture is 50 mg/L (0.42 µM).  Thus, 10,000 turnovers would produce 
4.2 mM of product.  Here, only 0.012 to 0.45 mM of product are produced from 3 mM 
substrate.  To improve the yields of these whole cell biotransformations it is therefore 
necessary to optimize the reaction conditions and/or the host organism.  Sufficient 
aeration of the growth medium, for example, is necessary to support the central 
metabolism of the host organism so that it can supply enough cofactors for the desired 
monooxygenation reaction.  Metabolic engineering aimed at increasing the intracellular 
NADPH concentration of non-growing E. coli cells has successfully been applied in a 
whole-cell monooxygenase reaction to significantly enhance the product yield [13].  
 
C.2. Characterization of Purified Enzymes 
Upon obtaining these promising results, we decided to purify the enzymes from the four 
strains listed in Table 5.1 for in vitro enzymatic bioconversions.  Results are summarized in 
Table 5.2.   
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Table 5.2. Biohydroxylation of 2 with purified enzymes. 
BM-3 variant %  3 [a] Main Isomer ee de 
wild-type 20.0 R, R 25.3 n.d.[b]
139-3 85.9 S, S 84.5 93.6 
B 89.6 S, S 87.9 96.4 
1-12G 97.6 R, R 87.7 95.3 
Refer to Chapter 8 for experimental details.  
[a] Proportion of 3 with respect to total products as determined with HPLC.  
[b] wt protein did not yield sufficient product to accurately determine de of 3. 
 
Within experimental error, employing the purified enzymes produced results comparable to 
those in whole cell reactions.  However, pure wild-type BM-3 produced two new results: 3 
slightly favored in the (R,R) configuration and an unknown compound, tentatively 
identified as a product hydroxylated in the 2 position of the cyclopentane ring, as the major 
product (~80%). 
Total turnover numbers (ttn) and rates of formation of 3 were measured (Table 5.3).  To 
determine ttn, the enzymes were diluted to a concentration at which the P450 is neither 
oxygen-limited nor inactivated due to dialysis of the flavins, a likely inactivation 
mechanism at low P450 concentrations [14].  The three mutant enzymes catalyze the 
reaction at approximately the same rate, which is two orders of magnitude greater than that 
of wild-type.  The total turnover number varies, however.  Mutant B catalyzes about an 




Table 5.3. Rates and total turnover numbers (ttn) of P450 BM-3 catalyzed hydroxylation 
reactions. 
BM-3 variant ttn [a] Rate [b]
Wt 1260 ± 130 2.6 ± 0.3 
139-3 3970 ± 1080 231 ± 19 
B 9200 ± 2040 215 ± 4 
1-12G 6840 ± 1970 213 ± 14 
Refer to Chapter 8 for experimental details.   
[a] ttn is reported as nmol 3 per nmol protein.  The protein is inactivated after 12 hours of 
incubation.   
[b] Rates (nmol 3 per nmol protein per min) were determined by measuring formation of 3 
over one minute. 
 
The P450 BM-3 mutants examined in this work have at least 9 amino acid substitutions, 
including at least one active site mutation (A78V) (see Appendix B for details).  With 
linear alkanes such as octane, these mutations increase the regioselectivity of subterminal 
hydroxylation [12,15].  Mutant 1-12G has the highest regioselectivity with linear alkanes 
[15] and also exhibits the highest regioselectivity with substrate 2 (97.6%).  Although the 
mutants were engineered for the hydroxylation of short, linear alkanes, and not for 
substrates such as compound 2, ee´s and de´s of almost 90% were obtained.  The fact that 
1-12G produces the (R,R) diastereomer of 3 is notable.  This enzyme had previously been 
shown to catalyze the hydroxylation of octane primarily to R-2-octanol (39% ee), while all 
the other mutants produce mainly S-2-octanol (up to 58% ee) [15].  In addition to the active 
site mutation V78A, 1-12G contains mutations A82L and A328V.  Only in this particular 
combination do these mutations generate R-2-octanol from octane and R,R-3 from 2.   
Consequently, this mutant favors a different binding conformation of the prochiral 
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molecule 2 in which the pentyl ring is flipped by 180° relative to the conformation in all the 
other mutants.   
Wild-type P450 BM-3 and the most promising mutants thereof (139-3, B and L) were 
found to be inactive towards cyclopentanecarboxylic acid 1.  Employing substrate 
engineered, achiral 2, however, enabled the biohydroxylation, and two out of the four 
possible isomers of 3 were prepared in high stereoselectivities.  This result endorses the use 
of substrate engineering to broaden the range of compounds accepted by P450 enzymes.  It 
also further demonstrates the functional flexibility of P450 BM-3 and supports the notion 
that the P450 BM-3 can be regarded as a “one-enzyme-fits-all” oxidation catalyst [15].   
We proposed that total turnover numbers, and stereoselectivities can be further improved 
by directly screening BM-3 mutant libraries with substrate 2.  This, however, would require 
a high-throughput screening system for the detection of regio- and enantioselective 
hydroxylation of this compound.  Currently, only high-throughput gas chromatography 
would be suitable for this task, as colorimetric hydroxylation assays can typically not 
distinguish between different regioisomers and diastereomers.   
The success in applying enzymes engineered for the selective hydroxylation of linear 
alkanes for compound 2, prompted us to investigate the use of the 16 active site variants 
from the recombination library described in Chapter 4.  Preliminary data are presented in 
Table 5.4.   
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[a] %  3 [b] Main Isomer ee de 
wild-type 1260 20.0 R, R 25.3 n.d. [c]
139-3 4000 85.9 S, S 84.5 93.6 
1-12G 7000 97.6 R, R 87.7 95.3 
77-9H 11,000 99.7 R, R 1.4 97.9 
1-7D 6,000 99.7 S, S 71.4 98.3 
68-8F 12,000 99.8 S, S 81.9 99.5 
49-9B 4,000 92.9 S, S 44.0 61.1 
35-7F 7,500 99.7 S, S 68.8 97.5 
1-5G 7,500 99.8 S, S 68.6 98.4 
13-7C 10,000 99.7 R, R 63.3 96.3 
49-1A 4,000 91.0 R, R 0..2 49.2 
2-4B 9,000 99.7 R, R 70.0 91.8 
12-10C 4,000 53.4 S, S 82.3 65.9 
11-8E 5,500 88.5 S, S 29.4 42.9 
41-5B 4,000 99.6 S, S 87.3 95.3 
29-3E 6,000 99.7 S, S 60.3 99.2 
7-11D 7,500 99.7 S, S 60.8 98.9 
29-10E 9,500 99.5 S, S 32.8 98.6 
53-5H 5,000 99.1 S, S 55.8 97.6 
Refer to Chapter 8 for experimental details.   
[a] ttn is reported as nmol 3 per nmol protein.  The error is 20% at most.  The protein is 
inactivated after 12 hours of incubation.   
[b] Proportion of 3 with respect to total products as determined with HPLC.   
[c] wt protein did not yield sufficient product to accurately determine de of 3. 
 
All mutants presented in this table have a propensity to hydroxylate the terminal or 
subterminal carbon of octane. They also tend to hydroxylate 2 at the 3-position of the 
cyclopentane ring.  The regioselectivity on octane can therefore be used as a starting point 
for identifying mutants that might be useful for the hydroxylation of 2 to form 3.  The 
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enantiomeric and diastereomeric excess (ee and de, respectively), however, varies 
dramatically from mutant to mutant and is not predictable.  While other variants could be 
identified that produce R,R-3, 1-12G remains the most enantioselective mutant.  Variants 
with low de produce significant amounts of R,S-3 or S,R-3; products which had not been 
observed previously at these high concentrations.   
All of these variants presented in Table 5.4 support thousands of catalytic turnovers.  
Therefore, with a screen for enantioselectivity in hand, they can be used as starting points 
for the generation of enantioselective hydroxylation catalysts, which could enable new 
applications of biohydroxylation in organic synthesis. 
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C h a p t e r  6  


















During the work described in Chapter 2, it became clear that mutations in the active site of 
P450 BM-3 are key to engineering the P450 to bind and position new substrates.  In 
Chapter 3, extensive analysis of 11 active site residues is presented. While the results of 
this work provided information about the amenability of the active site to mutations and the 
effects of these mutations on regioselectivity of substrate hydroxylation, the ultimate goal 
of this work was to engineer an active site capable of binding and oxidizing the smallest 
alkanes, ethane and methane. No P450 or porphyrin-based catalyst has been shown to 
oxidize ethane and methane, which are known substrates only for methane 
monooxygenases [1] and, in the case of ethane, some of their homologs from alkane-
assimilating microorganisms [2]. This chapter describes the direct oxidation of ethane to 
ethanol using dioxygen, catalyzed by one of the active site variants. Mutant 53-5H was 
found to be the most active propane hydroxylase, and additionally catalyzes the selective 
conversion of ethane to ethanol without overoxidation to acetaldehyde or acetic acid. Upon 
performing one further round of random mutagenesis, this time targeting the reductase 
domain of the enzyme, a mutant with improved productivity was identified. Achieving 
P450-catalyzed oxidation of ethane is a key step in the pathway to P450-catalyzed methane 




Most natural gas sources remain untapped as energy and chemical feedstocks, due to the 
difficulty of transporting the gas to facilities that can either use it as a fuel or convert the 
methane and ethane components into useful compounds. A catalyst for the selective 
oxidation of gaseous alkanes under mild conditions into easily transported alcohols could 
allow economical exploitation of both local, small natural gas resources and vast, remote 
reserves. Although catalytic alkane hydroxylation has been reported by many groups [3], 
selective conversion of ethane and methane mainly to their corresponding alcohols has yet 
to be demonstrated [4].  For example, limited (i.e., < 500 total turnovers) catalytic ethane 
oxidation is supported by a variety of transition metal catalysts, but these systems produce 
mixtures containing significant amounts of acetaldehyde and acetic acid in addition to 
ethanol [5-11].  Harsh oxidants such as hydrogen peroxide or sulfuric acid are usually 
required, although catalytic systems using dioxygen have also been reported [9-11].  The 
ideal catalyst should convert ethane to ethanol with high selectivity and productivity, be 
easily prepared from relatively common, nontoxic materials, function at ambient 
temperature and pressure, use dioxygen from the air as the oxidant, and produce little or no 
hazardous waste. 
Biological systems have evolved efficient and productive metalloenzymes that convert 
alkanes into alcohols using dioxygen from the air. Methane monooxygenases (MMO) 
catalyze the conversion of methane to methanol, thereby enabling methanotrophic bacteria 
to use methane as a source of carbon and energy [1].  Microorganisms that grow on larger 
gaseous alkanes (ethane, propane, butane)  have also been reported [2] and putatively use 
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similar enzymes for the first, alkane oxidation step [12,13]. The relatively well-studied 
MMOs have long been a source of inspiration for designers of chemical catalysts [14].  
Unfortunately, these structurally complex enzymes have never been functionally expressed 
in a heterologous organism suitable for bioconversion and process optimization, and 
therefore have proven to be of little practical use themselves for production of alcohols. 
We previously used laboratory evolution techniques to convert P450 BM-3 into a 
hydroxylation catalyst for small alkanes [15-17]. One of the reasons this P450 was chosen 
is that all of the machinery required for catalysis--the hydroxylase domain and reductase 
domain--is included on a single polypeptide chain [18], unlike MMOs and most other P450 
enzymes. Although they support analogous oxygen insertion reactions on a wide variety of 
larger substrates, none of the thousand-plus members of the P450 enzyme superfamily are 
known to catalyze the oxidation of ethane or methane.  
Communication between the heme and reductase domains of BM-3 is substrate-dependent 
and fine-tuned to transfer a pair of electrons from an NADPH cofactor through two 
reductase-bound flavins, and subsequently shuttle the electrons, one at a time, into the 
hydroxylase domain during catalysis [19].  Engineering the protein for activity on a new 
substrate, such as ethane, must conserve this regulated communication, and thus poses 
significant technical challenges. The engineered enzyme must bind ethane, a substrate 
considerably smaller than a fatty acid, directly above the heme in the active site of the 
hydroxylase domain. This substrate binding event must initiate electron transfer from the 
reductase domain to the heme domain during catalysis. Once electron transfer occurs, the 
active iron-oxo species must be capable of breaking the high energy C-H bond in ethane 
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(101.1 kcal mol-1  vs. 95-99 kcal mol-1 for the secondary C-H bonds of the fatty acid 
substrates [20] of wild-type BM-3). Finally, the singly-hydroxylated product must be 
released from the active site before further oxidation can occur.  
Crystal structures of BM-3 heme domain with and without substrate are available [21-23]; 
a structure of the reductase domain, however, is not.  Furthermore, large conformational 
changes in both domains during catalysis [24] make it difficult to identify amino acid 
substitutions which can address all these issues.  Therefore, an ‘evolutionary’ strategy in 
which mutations are accumulated in multiple generations of random mutagenesis and 
screening [25] is likely the most efficient way to engineer an ethane hydroxylase. The 
approach has been to use directed evolution methods to adapt the enzyme to exhibit higher 
turnover on smaller and smaller alkanes (Figure 6.1), since high productivity is indicative 




Figure 6.1. Reduction of substrate size and increase in C-H bond dissociation energy 
achieved by directed evolution. Directed evolution was used to convert wild-type P450 
BM-3 stepwise from a fatty acid hydroxylase into an enzyme capable of activating the 
higher-energy C-H bond of ethane. The figure shows the substrate range of wild-type P450 




C. Results and Discussion 
In the first generations, we increased the activity of BM-3 towards octane using iterations 
of random mutagenesis of the heme domain (residues 1-429) and screening based on the 
hydroxylation of the (octane surrogate) substrate p-nitrophenyl octyl ether. The resulting 
mutant, 139-3, contained 11 amino acid substitutions distributed throughout the 
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hydroxylase domain and exhibited good activity on octane [16]. It had also acquired a 
small but appreciable activity on propane, producing 2-propanol and a very small (less than 
3%) amount of 1-propanol. As described in Chapter 2, the propane-hydroxylating activity 
of this mutant was subsequently increased by introducing random mutations in the heme 
domain.  The resulting libraries were screened for activity towards the substrate dimethyl 
ether, a propane surrogate. Mutant 9-10A obtained in this way was much more active 
towards propane than 139-3 and produced significantly more 1-propanol (8 %) [17].  The 
increase in 1-propanol was particularly interesting because the propane terminal C-H bond 
energy (100.4 kcal/mol) is similar to the C-H bond energy of ethane (101.1 kcal/mol) [20].  
Propane hydroxylation activity was further increased by introducing two active site 
mutations (A82L, A328V) into 9-10A, resulting in mutant 1-12G (described in Chapter 2).  
Upon saturating buffer containing this mutant with ethane, the ferric heme iron of this 
enzyme shows a characteristic, substrate-dependent shift from the low-spin to the high-spin 






















Figure 6.2. UV/VIS Spectra of P450 BM-3 mutant 1-12G (3 µM in 0.1 M potassium 
phosphate buffer, pH 8.0) in its unbound, low-spin configuration (solid line), and in its 
high-spin configuration in ethane-saturated buffer (approximately 2 mM ethane) (dashed 
line). 
 
However, despite numerous reactions under various conditions, no ethanol concentrations 
significantly above background were achieved with this mutant.  To obtain an ethane-
hydroxylating P450, we continued to engineer mutant 9-10A. This variant was chosen 
over the more active variant 1-12G as the basis for targeting mutations to the active site 
because none of its active site residues had previously been modified.  To create a 
practically-sized library of variants with combinations of active site mutations, we first 
screened saturation mutagenesis libraries at each of 11 active site positions to identify a 
small pool of single active site mutants (see Chapter 3).  Beneficial mutations, most of 
which were not accessible by the previously applied random mutagenesis due to the 
conservative nature of the genetic code, were then recombined into a multiple active site 
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library.  This library contained approximately 9,000 P450 BM-3 variants, each of which 
contains a characteristic active site.  A total of 16 mutants with improved activity towards 
DME or HME relative to 1-12G (Table 4.1) were selected for purification and further 
characterization.   
In Chapter 4, we discussed these mutants in regards to their regioselectivity of octane 
hydroxylation.  For the work described in this chapter, we picked the mutant with the 
highest propane hydroxylation activity among the mutants: mutant 53-5H catalyzes 
thousands of turnovers of propane to propanol at a rate of 370 min-1 (Table 6.1). 
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Table 6.1. Propane hydroxylation activities of wild-type and mutant cytochromes P450 
BM-3. 
BM-3 variant ttn [a] rate [b]
9-10A 1100 23 
77-9H 1 1500 37 
68-8F 1 2000 59 
13-7C 1 3300 48 
49-9B 1 890 37 
35-7F 1 960 31 
49-1A 1 500 15 
23-11B 1 500 15 
12-10C 1 1600 53 
41-5B 1 850 66 
11-8E 1 1900 120 
7-11D 1 4200 120 
29-3E 1 3200 160 
29-10E 1 3000 180 
53-5H 1 5000 370 
 [a] Total turnover number (ttn) was measured using GC after completion of the reaction and 
is reported as (nmol product)/(nmol protein). Errors are at most 10%.  Reactions conditions 
were: purified protein (25 nM) in potassium phosphate buffer (0.1 M, pH 8.0, saturated 
with propane and dioxygen), NADPH regeneration system (0.1mM NADP+, 10 U/mL 
isocitrate dehydrogenase, 25 mM isocitrate). The vial was pressurized with 20 psi of 
propane and stirred at 25°C for 4 hours  
[b] Initial rates of propanol and octanol formation were measured over 1 min by GC and are 
reported as (nmol product)/(min/nmol protein). Errors are at most 15%.  Reactions 
conditions were: purified protein (100 nM) in potassium phosphate buffer (0.1 M, pH 8.0, 
saturated with propane and dioxygen), NADPH (0.5 mM).  The reactions were performed 
at 25oC.  
 
Notably, mutant 53-5H also hydroxylates ethane to generate ethanol. 53-5H contains three 
active-site mutations, A78F, A82S, and A328F, all of which replace alanine with a larger 
side chain, thus presumably reducing the volume of the active site and positioning small 
alkane substrates above the heme during catalysis. In addition to its activity towards ethane, 
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53-5H exhibits the highest regioselectivity (89% 2-octanol) and enantioselectivity (65% S-
2-octanol) towards octane encountered in any BM-3 variant (Table 6.2), further evidence of 
tighter substrate binding in the engineered active site.  
 
Table 6.2. Alkane hydroxylation activities of wild-type and mutant cytochromes P450 
BM-3. 
   ethane propane octane [a]
BM-3 
variant 






rate [b] ttn [c] rate [d] ttn [c] rate [d] ttn [c] % 2-octanol % ee 
[e]
Wild-type 
BM-3 --- --- --- --- --- --- 30 150 17 n.d. 
[f]










0.4 250 210 6000 420 8000 89 65 (S) 
[a] Octane reactions were performed in presence of 1% ethanol.  
[b] Rates of ethanol formation were measured over 30 min using gas chromatography (GC) 
coupled to an electron capture detector (ECD), and are reported as (nmol 
ethanol)/(min/nmol enzyme). Errors are at most 10%.  
[c] Total turnover number (ttn) was measured using GC after completion of the reaction and 
is reported as (nmol product)/(nmol protein). Errors are at most 10%.   
[d] Initial rates of propanol and octanol formation were measured over 1 min by GC and are 
reported as (nmol product)/(min/nmol protein). Errors are at most 15%.   
[e] ee of 2-octanol (main product) was measured by GC; the favored enantiomer is listed in 
parenthesis.  [f] Wild-type P450 BM-3 primarily produces 3- and 4-octanol. The yields of 2-
octanol were not sufficient for the determination of ee for wt BM-3. 
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Ethane hydroxylation by 53-5H was measured after 12-hour incubations of the enzyme in 
ethane-saturated buffer containing an ethanol-free NADPH regeneration system 
(commercial NADPH contains 2-3% ethanol). At less than 1 min-1, the rate of ethanol 
formation is low. The reaction is also highly uncoupled to NADPH oxidation in the 
presence of ethane, which proceeds at a rate of 660 min-1 (Table 6.3). 
 
Table 6.3. Rates of NADPH oxidation by ethane hydroxylation catalysts 53-5H and 35-
E11. 
 53-5H 35-E11 









no substrate 540  390  
Ethane 660 0.06  [c] 520 0.08 [c]
Propane 930 40 800 26 
Octane 820 80 660 64 
[a] Errors are at most 5%.  [b] Coupling efficiency is estimated from product formation rate / 
NADPH oxidation rate in presence of substrate.  [c] NADPH oxidation rates cannot be 
measured on the same time scale as ethanol formation rates. 
 
Nonetheless, 53-5H consistently produces at least 50 equivalents of ethanol, independent of 




Figure 6.3. Final ethanol concentrations in 53-5H and 35-E11 catalyzed reactions.  The 
reactions (5 mL) were carried out under the following conditions: To 100- 500 nM purified 
protein in 0.1 M potassium phosphate buffer (pH 8.0) saturated with ethane and dioxygen, 
300 µL NADPH regeneration system (1.66 mM NADP+, 167 U/mL isocitrate 
dehydrogenase, 416 mM isocitrate) was added to initiate the reaction.  The vial was 
pressurized with 20 psi of ethane and stirred at 25°C for 12 hours.  Conversion of ethane to 
ethanol using 200 nM protein corresponds to 50 and 250 turnovers per enzyme active site 
of 53-5H and 35-E11, respectively. Halving or doubling the enzyme concentration yielded 
approximately correspondingly lower or higher product concentrations, respectively. 
Control reactions, either without ethane or with inactivated protein, did not contain ethanol 
concentrations above the background level of 1 µM (1.2 ± 0.1 µM for the control reaction 
without ethane, or 0.8 ± 0.1 µM for the control reaction with inactivated P450 in which 
sulfuric acid is added before initiation of the reaction.  See Chapter 8 for details). Error bars 





Figure 6.4. Gas chromatograms of ethanol reaction mixtures using variant 53-5H as the 
catalyst. Prior to analysis, ethanol was derivatized to form ethyl nitrite for detection via an 
electron capture detector (ECD).  
 
We tested for overoxidation of ethanol by supplying ethanol as a substrate and monitoring 
ethanol depletion by gas chromatography, and monitoring the production of acetaldehyde 
and acetic acid by 13C NMR using 13C-labeled ethanol. No (i.e., less than 10%, the 
detection limit of these experiments) overoxidation products were detected in these 






Figure 6.5. 13C NMR spectrum (Varian Mercury 300 MHz) of singly 13C-labeled ethanol 
incubated with 53-5H and NADPH regeneration system in 0.1M potassium phosphate 
buffer, pH 8.0, with 10% deuterium oxide added.  No 13C-labeled carbonyl peaks due to 
overoxidation of ethanol are detected. 
 
In general, the hydrophobic active sites in P450s assist in the release of singly-hydroxylated 
products, and we have witnessed very little (typically less than 5%) overoxidation of longer 
and more hydrophobic alcohols in any BM-3 mutants. In addition, as shown in Chapter 2 
(Table 2.1), there exists a trend that alkane-hydroxylating mutants overoxidize longer-chain 
alkanes, such as decane, to a higher extent (≤ 7%) than shorter ones such as hexane (≤ 1%) 
[17]. Mutant 53-5H also catalyzes the rapid (660 min-1) and efficient (80% coupled) 
conversion of octane primarily to 2-octanol in the presence of 1% ethanol, demonstrating 
that ethanol does not inhibit the catalyst (Tables 6.2 and 6.3). These results demonstrate 
that the 101.1 kcal/mol C-H bond dissociation energy of ethane does not pose a 
fundamental barrier to a cytochrome P450, as a P450-based biocatalyst can cleanly convert 
ethane into ethanol without undesired side reactions. 
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We performed a further round of directed evolution to increase the ethane activity of 53-
5H, this time targeting mutations to the reductase domain, including the polypeptide 
linker that connects it to the heme domain. In previous, unpublished work in our 
laboratory, the amino acid substitution E464G in the linker region had been implicated in 
increasing total turnover in selected BM-3 mutants, presumably by facilitating 
communication between the highly mutated hydroxylase domain and the as-yet 
unmodified reductase domain. Alone, this mutation does not enhance the production of 
ethanol by 53-5H, but further improvement was found upon screening a library of 53-5H 
containing this mutation and random mutations in the reductase domain for high activity 
towards dimethyl ether accompanied by reduced NADPH consumption rates in the 
absence of substrate. The resulting mutant 35-E11 contains all 15 of the hydroxylase 
domain substitutions found in 53-5H, the linker mutation E464G, and a new mutation, 
leading to the substitution I710T, located in the reductase domain. Compared to 53-5H, 
mutant 35-E11 exhibits a fivefold increase in total turnover of ethane to ethanol (total 
turnover number (ttn) = 250, Table 6.2). In a typical reaction with ethane, 200 nM of 
mutant 35-E11 produces over 50 µM of ethanol (Figure 6.2). The rate of product 
formation by 35-E11 equals that of 53-5H, while the NADPH consumption rate in the 
presence of ethane has decreased to ~520 min-1 (Table 6.3). The increased productivity 
likely reflects a prolonged catalyst lifetime, achieved by reducing non-productive 
cofactor oxidation, which inactivates the protein by forming various reactive species. 
Amino acid residue I710 is located, by comparison to the crystal structure of  the 
homologous rat P450 reductase [26], near the FAD cofactor. Increased coupling 
efficiency has also been demonstrated in the past: For propane, NADPH oxidation in 
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mutant 139-3, a predecessor of 1-12G is only 9 % coupled to product formation. In 
contrast, the coupling efficiency of 53-5H catalyzed propane hydroxylation is 40 %. 
Wild-type P450 BM-3 tightly regulates electron transfer from the NADPH binding 
reductase domain (containing FAD and FMN) to the heme in the attached heme domain. 
Substrate binding to the heme iron results in displacement of a weakly-bound water 
molecule that acts as the sixth axial ligand of the substrate-free heme iron. This results in 
an increase (~ 140 mV) in heme iron reduction potential and a shift in spin-state 
equilibrium to the high-spin form, inducing reduction of the ferric heme iron by the 
reductase domain [19,27].  In addition, when substrate is not bound, the reductase domain 
of P450 BM-3 is slowly inactivated by the accumulation of three reducing equivalents in 
the flavins of the reductase. In the presence of NADPH, substrate binding is therefore 
necessary to maintain enzyme activity.  Mutants 53-5H and 35-E11 in their substrate-free 
form are low-spin (Figure 6.5). Ethane, however, does not induce the characteristic spin-














Figure 6.6. Absorption spectrum of 53-5H (3 µM in 0.1 M potassium phosphate buffer, 
pH 8.0).  The ferric heme iron is in low-spin form. A shift low- (Amax at 418 nm) to high-
spin (Amax at 390 nm) ferric iron upon addition of ethane could not be detected. Addition 
of octane did not induce an increase at 390 nm. The spectrum of 35-E11 is identical. 
Earlier mutants, e.g., 9-10A exhibit a significant spin shift upon incubation with good 
substrates, such as octane.   
Interestingly, even propane and octane, which can be hydroxylated at high rates and total 
turnover numbers, do not induce the spin-shift observed for 1-12G with the same 
substrates. The presence of ethane in the reaction buffer, however, induces NADPH 
oxidation (Table 6.3). The difference in background rate without substrate and with 
ethane is ca. 220 and 140 min-1 for 53-5H and 35-E11, respectively, indicating that 
ethane is bound in the active site of the enzyme. In comparison, propane induces a 
NADPH oxidation rate of around 400 min-1 for both enzymes (Table 6.3).  
The strategy of adapting P450 BM-3 to ever smaller substrates appears to have been 
successful. The wild-type enzyme is inactive on propane. Evolving it to become an 
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octane hydroxylase, however, generated a small amount of activity towards propane. 
Similarly, increasing the newly acquired propane activity produced measurable activity 
towards ethane. Although the activity is still low for practical purposes, we have shown 
that continual improvements can be achieved, and we anticipate that further directed 
evolution will generate a biocatalyst with similar productivity to what we have obtained 
with propane (6,000 turnovers). It is also possible that high activity towards ethane will 
be accompanied by the emergent ability to convert methane to methanol. Thus this 
enzyme may provide the foundation for a novel biocatalytic route to methanol production 
from methane.  
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A. Random vs. Targeted Mutagenesis 
Directed evolution involving random mutagenesis of the full gene has proven to be a useful 
tool for engineering proteins.  When improving characteristics such as rate, thermostability, 
or pH-dependence, directed evolution may be superior to rational design since the 
mechanisms for such changes are frequently not well enough understood for rational 
engineering to be successful.  Changing the substrate specificity or regioselectivity of an 
enzyme, however, might require mutations within the active site and it became apparent 
during this work that this was true for P450 BM-3.  Mutations within the active site of BM-
3 are only rarely to be found by random mutagenesis of the full protein since only a few 
residues are mutated and chances are greater for these residues to be on the surface rather 
than in the core of the protein where the active site typically is located.  Additionally, single 
nucleotide changes to a codon typically access only about six of the nineteen possible 
amino acid substitutions.  We therefore chose to take advantage of structural and 
mutational data available for P450 BM-3 to target mutagenesis to specific active site 
residues. 
 
B. Single vs. Multiple, Simultaneous Substitutions 
The number of amino acid residues that can be randomized simultaneously depends on 
the strategy for finding improved mutants – screening or selection.  If, for example, four 
amino acid residues are mutated simultaneously, the complete  library consists of 160,000 
possible variants.  This is usually beyond the upper limit for high-throughput screening 
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systems.  With limited resources, and an assay that requires single colonies to be grown 
in each well of a 96-well plate, screening of 10,000 variants already becomes a very 
demanding and time-intensive process.  We identified 11 active site residues that are in 
close proximity to bound fatty acid substrates in crystal structures of BM-3 [1,2].  Ideally, 
we would like to look at the effects of all possible combinations of mutations at these 
sites, but screening 2011 possible mutants is impossible.  To create a more manageable 
active site library with a high probability of containing active mutants, we first screened 
saturation mutagenesis libraries at each of 11 active site positions to identify a small pool 
of single active site mutants and then recombined beneficial mutations into a multiple 
active site library containing approximately 9,000 variants.   
The reason for recombining only beneficial mutations was to create a reasonably sized 
library highly enriched in active variants.  In doing so, we made two assumptions: a) 
mutations that are beneficial separately will also be beneficial in combination with others, 
and b) improved mutants are more likely to be identified by recombining beneficial 
mutations than neutral or deleterious ones.   
Both assumptions are problematic, because they leave out the possibility for synergistic 
effects.  Recent engineering studies of various enzymes have targeted several active site 
residues for mutagenesis simultaneously.  In combination with powerful screening or 
selection systems, this approach was successful in identifying improved variants (reviewed 
in [3]).  The best mutants discovered by targeted mutagenesis almost always contain 
multiple mutations.  These mutations are often beneficial as single mutations, but evidence 
is accumulating that at least some of them are beneficial only in combination [4].  A 
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possible reason for these synergistic effects is that multiple active site mutations can cause 
significant structural changes in the active site, as has been noted for tRNA synthetases [5].  
In this case, targeted mutagenesis strategies that simultaneously mutate multiple residues 
offer an approach to uncover coupled mutations that cannot be found with random 
mutagenesis or saturation mutagenesis of single residues.  Given the limits of our screening 
system, however, we felt this strategy was reasonable and the most manageable.   
 
C. Alternative Strategies 
The number of active site residues of P450 BM-3 that putatively interact with the substrate 
is large. To take advantage of beneficial effects of combinations of this large number of 
mutations in the future, a selection system will become necessary.  In absence of such a 
system, other alternatives can be sought to access coupled mutations that are not 
necessarily beneficial on their own. 
One approach that has been successfully implemented is to perform saturation mutagenesis 
of a first amino acid, then isolate the best mutant, then perform saturation mutagenesis of a 
second mutant and so on.  This way, in contrast to our approach, mutations can be 
uncovered that are coupled to the previously randomized amino acid.  However, there is no 
rationale for choosing the sequence of amino acids to be mutated, and the number of 
possible pathways quickly becomes as intractable just as when several mutations are 
randomized simultaneously.  A similar approach is to target a limited number of amino 
acids for randomization, say three, of which all possible combinations, in this case 8000, 
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can be screened for improved activity.  The selected, best mutant can then be subjected to 
the same procedure again.  
A third approach is to use random oligonucleotide mutagenesis to generate diversity by 
incorporating random mutations, encoded on a synthetic oligonucleotide, into the active 
site region of the gene.  The number of mutations in individual enzymes within the 
population can be controlled by varying the length of the target sequence and the degree of 
randomization during synthesis of the oligonucleotides. The advantages of this more 
defined approach are that all possible amino acid mutations and also coupled mutations can 
be found. We tried this approach during the engineering of P450 BM-3 for alkane 
hydroxylation.  The oligonucleotide primer was randomized at the nucleotide codons 
encoding seven active site residues to yield an average mutation rate of approximately two 
per gene. At this mutation rate the library size is approximately 7,800 and is still 
manageable. The library was screened as described in the foregoing chapters but no 
improved mutants could be identified.  The problem, however, was not the method itself 
(which has proven to be successful in many studies [6-8]), but unwanted errors on the 
oligonucleotide.  
 
D. Selection Systems for Identifying P450 Alkane Hydroxylases  
By using a selection system capable of identifying the most active variant out of a large 
pool (e.g., millions) of mutants, the number of mutants containing simultaneous mutations 
can be enhanced.  We have accumulated and established in this laboratory several 
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engineered bacterial strains that grow on n-alcohols.  Clark and coworkers engineered E. 
coli strains that can grow on small-chain alcohols [9,10].  Although it has not been 
demonstrated that these strains could grow on gaseous alkanes, it is likely that expression 
of an active P450 monooxygenase will enable them to use gaseous alkanes as the sole 
carbon source.  Witholt and co-workers have developed E. coli and Pseudomonas putida 
strains that grow on medium-chain primary alcohols.  These  strains have been used by the 
Witholt laboratory to identify homologs of the multicomponent alkane monooxygenase 
alkB [11].  By incorporating a P450 monooxygenase that can efficiently convert n-alkanes 
into primary alcohols in these bacterial strains, we will enable them to grow on a variety of 
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All chemicals, including liquid alkanes and product standards were purchased from Sigma-
Aldrich (St. Louis, MO).  Solvents (hexanes, chloroform, methylene chloride) were 
purchased from EMD (Gibbstown, NJ) or Mallinckrodt (Paris, KY). Ethanol was 
purchased from AAPER (Shelbyville, KY).  Ethane (99.95% or 99.99%), propane (99.5 
%), and dimethyl ether (99.8%)) were purchased from Special Gas Services (Warren, NJ). 
Methane (99.0%) and ethane of higher purity (99.99%) was purchased from Sigma-Aldrich 
but as this did not change the outcome of the experiments it was not routinely used. Hexyl 
methyl ether was purchased from TCI America (Portland, OR).  NADP+ for experiments 
described in Chapter 2 was purchased from Sigma-Aldrich.  For experiments described in 
all other chapters, NADP+ was purchased from BioCatalytics, Inc. (Pasadena, CA), as was 
NADPH.  Restriction enzymes (BamHI, SacI, EcoR1) were purchased from Roche 
(Indianapolis, IN) or New England Biolabs (Beverly, MA), Taq DNA polymerase from 
Roche (Indianapolis, IN), Pfu turbo DNA polymerase from Stratagene (La Jolla, CA), and 
T4 DNA ligase from Invitrogen (Carlsbad, CA). isopropyl β-D-1-thiogalactopyranoside 
(IPTG) was from MP Biomedicals, Inc. (Aurora, OH). Protease inhibitors phenyl methyl 
sulfonyl fluoride (PMSF), pepstatin, and leupeptin were purchased from Gibco BRL 
(Gaithersburg, MD), Roche (Indianapolis, IN), and USB (Cleveland, OH) respectively.   
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B. Expression of P450 BM-3 (Chapters 2-6) 
The P450 BM-3 gene or mutants thereof, which include a silent mutation to introduce a 
SacI site 130 bp upstream of the end of the heme domain, were cloned behind the double 
tac promoter of the expression vector pCWori (pBM3_WT18-6, see Appendix B for 
details). E. coli DH5α, transformed with these plasmids, was used for expression of P450 
BM-3 on a 500 mL scale, as well as for expression in 96-well plates. For protein 
production, supplemented terrific broth (TB) medium (500 mL, 100 µg/mL ampicillin, 50 
µg/mL thiamine) was inoculated with an overnight culture (1 mL) and incubated at 30°C 
and 250 rpm shaking.  After 12 hours of incubation, the rotation speed was lowered to 200 
rpm, δ-aminolevulinic acid hydrochloride (δ-ALA; 0.5 mM) was added, and expression 
was induced by addition of isopropyl β-D-1-thiogalactopyranoside (IPTG; 1 mM). Cells 
were harvested by centrifugation 20 to 24 hours after induction.   Yields varied from day to 
day and depending on the mutant being expressed from about 10 to 100 mg/L. 
 
C. Purification of P450 BM-3 
C.1. Single-Step Purification of P450 BM-3 (Chapters 2-6) 
All purification steps were performed on ice or at 4oC.  The cell pellet was resuspended 
with Tris-HCl buffer (20 mL, 25 mM, pH 7.9, 100 µM PMSF) and lysed by sonication (2 x 
1 min, output control 7, duty cycle 60%; Sonicator, Heat Systems – Ultrasonic, Inc.). The 
lysate was then centrifuged at 75,000 x g for 45 min and further cleared by filtration using a 
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Steriflip 22 µm filter (Millipore, Billerica, MA). The enzyme was purified essentially as 
described [1] by ion exchange chromatography using an Äkta Explorer FPLC System 
(Pharmacia Biotech) and Toyopearl® SuperQ-650M column packing. The P450 containing 
fractions were collected and concentrated using a Centriprep YM-30 centrifugal filtration 
device. The protein solution was then buffer-exchanged with potassium phosphate buffer 
(100 mM, pH 8.0) using a PD-10 Desalting column (Amersham Pharmacia Biotech).  
P450 enzyme concentrations were quantified by CO-binding difference spectra of the 
reduced heme as described [2], using an extinction coefficient of 91 mM-1cm-1 for the 450 
nm minus 490 nm peak. P450 total expression yields were estimated from CO-binding 
difference spectra of the clarified lysates. Protein solutions were stored at -80°C. 
 
C.2. Four-Step Purification of P450 BM-3 
To obtain highly pure protein preparations for ethane reactions described in Chapter 6, the 
protein was purified in four steps according to published procedures [3,4].  No difference in 
background ethanol concentration, or productivity and rate of alkane hydroxylation was 
observed using these preparations. Therefore, for all practical purposes, the purification 
system described above was employed. 
All purification steps were performed on ice or at 4oC.  The cell pellet was thawed and 
resuspended in 20 mL of buffer A (50 mM KPi, pH 7.4, 2 mM DTT, 0.1 mM EDTA, 0.1 
mM PMSF).  Protease inhibitors, pepstatin and leupeptin at 1µg/mL each were added to the 
lysis buffer. The cells were lysed by sonication (2 min, output control 7, duty cycle 60%, 
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Sonicator, Heat Systems – Ultrasonic, Inc.). The lysate was centrifuged at 75,000 x g for 45 
minutes at 4°C and the red-colored supernatant was further cleared through a 0.22 µm filter 
(Millipore, Billerica, MA) 
A HiPrep 16/10 Q FF anion exchange column (Amersham, Piscataway, NJ) was 
equilibrated with at least one column volume of buffer A. After the cell extract was loaded, 
the column was washed with 3 volumes of 0.2 M KCl in buffer A at a flow rate of 4 
mL/min. A gradient of 0.2 – 0.5M KCl in buffer A was used to elute the protein.  
Next, a 2’5’-ADP-Sepharose affinity column (1-5 x 10 cm) (Amersham, Piscataway, NJ) 
was equilibrated with approximately 40 mL of buffer B (0.1 M KPi, pH 7.4, 0.5 mM DTT). 
The pooled red fractions from the previous step were applied directly, without prior 
concentration, and the column was washed with an additional 60 to 80 mL of buffer B and 
50 mL buffer C (0.5 M KPi, pH 7.4, 0.5 mM DTT). The protein was eluted with 15 mM 
NADP+ in buffer C. The red eluent was collected and concentrated to approximately 0.7 
mL using a Centriprep YM-30 concentrator (Millipore, Billerica, MA). 
A HiPrep 16/60 Sephacryl S-200 HR column (Amersham, Piscataway, NJ) was 
equilibrated with 2 column volumes of buffer D (0.1 M KPi, pH 7.4, 1 mM DTT, 0.1 mM 
EDTA, 0.1 mM PMSF) before loading the concentrated protein. The protein was eluted at 
a flow rate of 0.2 mL/min; pure fractions were collected and once again concentrated to 
approximately 1 mL using a Centriprep YM-30 concentrator.  
To remove NADP+ and trace amounts of ethanol, the protein was dialyzed against 3.5 L of 
0.1 M KPi, pH 8.0 using 12-14 kDa MWCO dialysis tubing. The protein was determined to 
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be homogeneous on a protein gel, and the protein concentration was determined in 
triplicate by CO-difference spectroscopy [2]. Protein solutions were stored at -80°C. 
 
D. Library Generation of P450 BM-3 Mutants and Site Directed Mutagenesis 
D.1. Recombination of P450 BM-3 Variants (Chapter 2) 
The first generation of mutants was created by StEP recombination of mutant 139-3 [5] 
with fifteen other mutants from the same generation, according to published procedures [6]. 
Mutant J was isolated from a library of ~350 mutants, based on its increased NADPH 
depletion rate using propane as a substrate (see section E.2 for details).  
 
D.2. Random Mutagenesis of P450 BM-3 (Chapter 2) 
Libraries for the second (~1,000 mutants) and third (~1,500 mutants) generations were 
created by error-prone PCR using the Genemorph kit (Stratagene, La Jolla, CA) according 
to the manufacturer’s protocol, using approximately 50 ng of plasmid DNA as template and 
primers BamHI-forw (5’-GGAAACAGGATCCATCGATGC-3’) and SacI-rev (5’-
GTGAAGGAATACCGCCAAGC-3’).  Mutant 9-10A was isolated from this library based 




D.3. Site-Directed/Saturation Mutagenesis (Chapter 2) 
Base mutations were introduced into mutant 9-10A by PCR overlap extension mutagenesis 
[7]. Position A82 was mutated to L, I, V and F using mutagenic primers  
A82forw (5’-GGAGACGGGTTATTTACAAGC-3’) and 
A82rev (5’-GCTTGTAAATAACCCGTCTCCAANAAAATCACG-3’). 
Position A328 was mutated to V using mutagenic primers 
A328Vforw (5’-GCTTATGGCCAACTGTTCCTGC-3’) and 
A328Vrev (5’-GCAGGAACAGTTGGCCATAAGC-3’). 
For each mutation, two separate PCRs were performed, each using a perfectly 
complementary primer (BamHI-forw (5’-GGAAACAGGATCCATCGATGC-3’) and 
SacI-rev (5’-GTGAAGGAATACCGCCAAGC-3’)) at the end of the sequence and a 
mutagenic primer. The resulting two overlapping fragments that contain the base 
substitution were then annealed in a second PCR, and the complete mutated gene 
amplified.  
 
D.4. Recombination of P450 BM-3 Variants (Chapter 2) 
The fifth generation of mutants was created by recombination of mutants 139-3, J, 9-10A, 
9-10A-A82L and 9-10A-A328V (see Appendix B for mutations) using a modification of 
Stemmer’s DNA shuffling protocol [8]. Mutant 1-12G was identified as the most active 
enzyme towards the surrogate screening substrate dimethyl ether (see section E.3 for 
details).  
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D.5. Random Mutagenesis of Variant 1-12G (Chapter 3) 
The random library of 1-12G was created by error-prone PCR using four different 
concentrations of MnCl2  (0, 50, 100, and 150 µM) to induce mutations, Taq DNA 
polymerase (Roche), approximately 50 ng of plasmid DNA as template,  and primers 
BamHI-forw (5’-GGAAACAGGATCCATCGATGC-3’) and 
SacI-rev (5’-GTGAAGGAATACCGCCAAGC-3’). 
The amplified gene (with mutations) was then cut with BamHI and SacI restriction 
enzymes and ligated with T4 DNA ligase into pBM3_WT18-6, previously cut with BamHI 
and SacI to remove the wild-type gene. The ligation mixtures were then transformed into E. 
coli DH5α cells that had previously been made electro-competent.  The transformed cells 
were plated onto Luria-Bertani (LB) agar plates to form single colonies for picking.  For 
each Mn2+ concentration, a small library of 88 mutants in a 96-well plate (8 wells 
containing parent 1-12G) was picked and screened for activity towards dimethyl ether and 
hexyl methyl ether as described below (section E.3). The library prepared with a Mn2+ 
concentration of 100 µM yielded ~40-50% of the mutants with no activity in the screen. 
Subsequently, 1500 members of this library were screened for activity towards dimethyl 
ether and hexyl methyl ether.  
 
D.6. Construction of Saturation Mutagenesis Libraries (Chapter 3) 
Mutations were introduced into mutant 9-10A by PCR overlap extension mutagenesis 
using Pfu turbo DNA polymerase [7]. The following amino acids were chosen for 
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saturation mutagenesis: A74, L75, A78, F81, A82, F87, T88, T260, L263, I264 and A328.  
The primers for each saturation library contained all possible combinations of bases, NNN 
(N = A, T, G, or C), at the codon for a particular residue (in bold).  The primers in the 












The reverse primers for each of these libraries complement their corresponding forward 
primers.  For each mutation, two separate PCRs were performed, each using a perfectly 
complementary primer, BamHI-forw (5’-GGAAACAGGATCCATCGATGC-3’) and 
SacI-rev (5’-GTGAAGGAATACCGCCAAGC-3’), at the end of the sequence and a 
mutagenic primer. The resulting two overlapping fragments that contain the mutations were 
then annealed during a second PCR to amplify the complete mutated gene.  The full gene 
was then cut with BamHI and SacI restriction enzymes and ligated with T4 ligase 
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(Invitrogen) into pBM3_WT18-6, previously cut with BamHI and SacI to remove the wild-
type gene. The ligation mixtures were subsequently transformed into E. coli DH5α cells 
that had previously been made electro-competent. The cells were then plated onto Luria-
Bertani  (LB) agar plates to form single colonies for picking.  
 
D.7. Construction of Recombination Libraries (Chapters 3 and 4) 
Beneficial mutations that were found by screening the saturation mutagenesis libraries (L75 
(W), A78 (T, F), A82 (T, S, F, I, C, G), F87 (I, V, L), T88 (C), T260 (N, L), A328 (L, F, 
M)) were recombined in a combinatorial fashion. Saturation libraries of amino acid 
positions A74, F81, L263 and I264 did not yield improved mutants, thus only beneficial 
mutations at the remaining seven sites were recombined.  The mutation L75I which was 
not found to increase activity was selected for its change in regioselectivity and added to 
the library to increase its diversity.  The mutations A82L and A328V were added to the 
library because of their beneficial effects described in Chapter 2.  Mutation A82V was 
added due to constraints in designing the degenerate primer used to construct the library. 
Mutations were added sequentially using overlap extension PCR with degenerate primers 
(see above) or a mixture of primers (mutation sites in the primers are in bold letters; the 
reverse primers for each of these libraries complement their corresponding forward 
primers).   
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Mutations at amino acid position 78 and 82 were introduced into 9-10A using primers:  
78A/T 82A/T/S/F/I/C/G/L/V for* (5’-
GCTTAAATTCRCGCGTGATTTTDBCGGAGACG-3’),  
78F 82A/T/S/F/I/C/G/L/V for (5’-GCTTAAATTCTTTCGTGATTTTDBCGGAGACG-
3’). 
Next, mutations at position 260 were introduced using primers: 
260Tfor* (5’-CAAATTATTACATTCTTAATTGCGGGAC-3’),  
260Nfor (5’-CAAATTATTAACTTCTTAATTGCGGGAC-3’),  
260Lfor (5’-CAAATTATTCTTTTCTTAATTGCGGGAC-3’). 
Next, mutations at position 87 and 88 were introduced using primers:  
87F/I/V/L 88Tfor* (5’-GAGACGGGTTANTYACAAGCTGGAC-3’), 
87F/I/V/L 88Cfor (5’-GAGACGGGTTANTYTGTAGCTGGAC-3’). 
Next, mutations at position 328 were introduced using primers: 
328Afor* (5’-CCAACTGCTCCTGCGTTTTCC-3’), 
328L/F/Vfor (5’-CCAACTBTTCCTGCGTTTTCC-3’), 
328Mfor (5’-CCAACTATGCCTGCGTTTTCC -3’). 




Mutants selected for improved activity towards HME were found only at amino acid 
positions 75, 78, 82, 87 and 328.  We are confident, however, that the all mutations were 
recombined.  While building the library, we screened and sequenced ten improved 
members of a partial library containing mutations at positions 78, 82 and 260 to verify 
that the library had been constructed properly.  All possible amino acids at position 75 
and 260, and four out of eight amino acids at postion 78 were found.    
 
D.8. Construction of the Reductase Library (Chapter 6) 
The mutation E464G was found by directed evolution of another BM-3 variant not reported 
in this work (Katsu Takahashi, unpublished). A random mutant library of the reductase 
portion of the BM-3 gene containing this mutation (1285 to 3147 bp) was PCR-amplified 
using primers SacI-for (5’-GACTTTGAAGATCATACAAACTACGAGCTCG-3’) and 
EcoRI-rev (5’-AGATCTGCTCATGTTTGACAGCTTATCATCGATGAATTC-3’) in the 
presence of 100 µM MnCl2. The amplified DNA was restriction digested using SacI and 
EcoRI and then ligated with T4 DNA ligase into the pCWori plasmid containing the gene 
for 53-5H with its reductase portion removed with SacI and EcoRI. A library containing 




D.9. Construction of F87A Variants of Wild-Type P450 BM-3 and Variant 9-10A 
(Chapter 5) 
The F87A mutations was introduced into wild-type P450 BM-3 and mutant 9-10A[9] by 
PCR overlap extension mutagenesis as described above.  The mutagenic primers were 
F87Afor (5’-GAGACGGGTTAGCAACAAGCTGGAC-3’) and 
F87Arev (5’-GTCCAGCTTGTTGCTAACCCGTCTC-3’) 
 
E. High-Throughput Screening of P450 BM-3 Mutant Libraries 
E.1. Preparation of Cell Lysates for High-Throughput Screening (Chapters 2-4, 6) 
Single colonies were picked and inoculated by hand or using a Qpix colony picking robot 
(Genetix, Beaverton, OR) into 1-mL deep-well plates containing Luria-Bertani (LB) 
medium (350 µL, supplemented with 100 mg/mL ampicillin), except for a row of eight 
wells in which single colonies of the best parent from the previous library were picked for 
reference and a single control well with no cells added. The plates were incubated at 30°C, 
250 rpm, and 80% relative humidity in a Kühner ISF-1-W incubator shaker (Kühner, 
Birsfeden, Switzerland). After 24 hours, clones from this preculture were inoculated using 
a 96-pin replicator (V&P Scientific, San Diego, CA) into 2-mL deep-well plates containing 
TB medium (400 µL, supplemented with 100mg/mL ampicillin, 10 µM IPTG and 0.5 mM 
δ-ALA).  The cultures were grown at 30°C, 250 rpm, and 80% relative humidity for 
another 24 hours. Cells were then pelleted and stored frozen at -20°C until they were 
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resuspended in phosphate buffer (500 µL, 0.1 M, pH 8.0, containing 0.5 mg/mL lysozyme, 
2 Units/mL DNaseI, and 10 mM MgCl2). After 60 min at 37°C, the lysates were 
centrifuged in Allegra 25R Centrifuge (Beckman Coulter, Fullerton, CA) and the 
supernatant was diluted for activity measurements in 96-well microtiter plates. 
 
E.2. High-Throughput Protein Folding Assay (Chapter 3) 
Carbon monoxide difference spectroscopy yields a spectral peak at approximately 450 nm 
when comparing bound and unbound forms [2].  This difference demonstrates the presence 
of a correctly-folded cytochrome P450.  Binding of carbon monoxide in the presence of a 
biologically inactive form of a cytochrome P450 yields a spectral peak at 420 nm [10].  
Thus CO binding effectively assays for the presence of a correctly-folded cytochrome 
P450, an incorrectly-folded P420, or a lack of either.  The assay has been modified for 
high-throughput in microtiter plates [11].   
Into each well of a 96-well microtiter plate, 40 µL of a sodium hydrosulfite solution (300 
mM) and then 160 µL of P450-containing cell lysate were added.  A baseline spectrum was 
taken before placing the plate into a chamber.  The chamber was evacuated and 
subsequently filled with carbon monoxide.  The plate was incubated for approximately 10 
minutes before removing it to record the difference spectrum from 400-500 nm using a 
Spectramax Plus microtiter plate reader (Molecular Devices, Sunnyvale, CA). 
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E.3. High-Throughput NADPH Consumption Assay (Chapters 2 and 6) 
The recombination library (see D.1.) and first mutant library (see D.2.) were screened in 
96-well plates for NADPH depletion in presence of propane. To 30 µL of E. coli 
supernatant, 170 µL of phosphate buffer (0.1 M, pH 8.0) saturated with propane was added.  
The reaction was initiated by addition of 50 µL NADPH (0.8 mM), and NAPDH oxidation 
was monitored at 340 nm for five minutes using a Spectramax Plus microtiter plate reader 
(Molecular Devices, Sunnyvale, CA).  The next library (see D.2.), in which no improved 
mutants found were found, was additionally screened for NADP+ formation in presence of 
propane as the substrate, as described [12,13]. In brief, residual NADPH was destroyed 
with acid after an appropriate amount of time, followed by conversion of NADP+ to a 
highly fluorescent alkali product at high pH, which was then measured fluorometrically.  
Mutants were selected from these libraries based upon increased NADPH consumption. 
The medium from LB plates for each selected mutant was then streaked onto LB-agar 
plates and allowed to grow overnight at 37°C. Single colonies of each mutant were picked 
into rows of eight, one row per mutant, into 1-mL 96-well plates containing LB and a row 
of parent. These plates were processed and screened as described above.  The activity of 
each mutant was determined by the ratio of the average NADPH oxidation rate of each row 





E.4. High-Throughput Product-Formation Assays (Chapters 2-4 ,6) 
For direct measurement of product formation, screens based on the demethylation of 
dimethyl ether (DME) and/or hexyl methyl ether (HME) were used for the later generation 
libraries (D.3. to D.9.).  
For the DME screen, 120 µL of phosphate buffer (0.1 M, pH 8.0) saturated with DME was 
added to 30 µL of E. coli supernatant. For the HME screen, 120 µL of phosphate buffer 
(0.1 M, pH 8.0), followed by 2 µL of 400mM HME in ethanol were added to 30 µL of E. 
coli supernatant. After 1 min of incubation at room temperature, NADPH (50 µL, 0.8 mM) 
was added to the diluted lysate and substrate. 50 µL of purpald solution (168 mM in 2 M 
NaOH) was added 15 min after initiating the reaction to form a purple product with the 
formaldehyde that was generated upon demethylation of the substrate. The purple color 
was read approximately 15 min later at 550 nm using a Spectramax Plus microtiter plate 
reader (Molecular Devices, Sunnyvale, CA).  Mutants were selected from these libraries 
based upon an increase in their absorbance at 550 nM relative to the average of the 
absorbance of the eight parent wells. The medium from LB plates for each selected mutant 
was then streaked onto LB-agar plates and allowed to grow overnight at 37°C.  Single 
colonies of each mutant were picked into rows of eight, one row per mutant, into 1-mL 96-
well plates containing LB and a row of parent. These plates were processed and screened as 
described above.  The activity of each mutant was determined by the ratio of the average 
absorbance at 550 nm of each row of mutants to the average absorbance at 550 nm of the 
parent row. 
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F. Determination of NADPH Consumption Rates (Chapters 2-4, 6) 
The enzymes were purified and quantified as described above. Initial rates of NADPH 
consumption were measured at 25°C in 1 cm pathlength cuvettes using a BioSpec-1601 
UV/VIS spectrophotometer (Shimadzu, Columbia, MD) or a Cary 100 UV/VIS 
spectrophotometer (Varian, Walnut Creek, CA). For the liquid alkanes, substrate stock 
solutions in ethanol (10 µL) were added to the protein solution (100 to 200 nM final 
concentration) in potassium phosphate buffer (0.1 M, pH 8.0) and incubated for 2 min. The 
reaction was initiated by addition of 200 µL NADPH (0.8 mM), and the decrease in 
absorption at 340 nm was monitored.  Rates using gaseous alkane substrates (methane, 
ethane, and propane) were measured using 200 nM protein, substrate saturated potassium 
phosphate buffer (0.1 M, pH 8.0), and the same amount of NADPH.  In addition, NADPH 
depletion rates in absence of substrate were measured for each enzyme. Rates were 
determined at least in triplicate. 
 
G. Alkane Hydroxylation Reactions 
G.1. Linear Alkanes (C5 to C10) (Chapters 2-4, 6) 
To measure alkane hydroxylation activities, ethanol solutions of liquid alkanes (hexane to 
decane) were added to buffer solutions containing the enzymes such that the total ethanol in 
the reaction mixture was one percent (v/v). Several solvents, including ethanol, methanol, 
acetone, and dimethyl sulfoxide, were tested, and ethanol was shown to support the most 
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product turnovers. Reactions with liquid alkanes that contained no co-solvent produced no 
detectable products. In the absence of substrate, NADPH has been reported to inactivate 
BM-3 by over-reducing the flavin cofactors in its reductase domain [14]. To avoid this 
problem, substrate was added to the enzyme first and incubated for a few seconds before 
NADPH was added. Dioxygen was not added to the reactions, limiting the amount of 
possible product formed to the 225-250 µM of oxygen present in air-saturated buffer.  The 
addition of excess dioxygen to the reactions by direct bubbling or rapid stirring did not 
increase and often decreased the total product turnover, possibly by denaturing the protein.   
Reaction mixtures for all BM-3 mutants containing 0.5-1.0 µM enzyme produced 225-250 
µM products.  We also noticed that total turnover numbers measured in systems containing 
less than ~25 nM protein were less than expected – i.e., 10 nM protein in a reaction gave 
much less than half the total turnovers of a 20 nM reaction.  At very low concentrations of 
BM-3, the FMN cofactor has been reported to diffuse out of the protein and inactivate it 
[15]. Given this fact and the dilution effects on total turnover we witnessed, later mutants 
that efficiently hydroxylate linear alkanes might be capable of even more turnovers than 
reported. 
To determine total turnover numbers and regioselectivity (i.e., the product regioisomers a 
given enzyme produces) product distributions, reactions with the liquid alkanes hexane, 
heptane, octane, nonane, and decane were performed in closed 20 mL scintillation vials and 
stirred at low speed using magnetic stirring bars. In a typical 3.0 mL reaction, purified 
protein was added to potassium phosphate buffer (0.1 M, pH 8.0) such that the total 
enzyme concentration equaled 25 to 100 nM.  30 µL of substrate solution (400 mM in 
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ethanol) was added to this solution to give 4 mM total substrate and 1% ethanol. For the 
experiments described in Chapter 4, 60 µL of substrate solution (200 mM in ethanol) was 
added to this solution to give 4 mM total substrate and 2% ethanol. After a few seconds, 
300 µL of NADPH (5 mM in 0.1 M potassium phosphate buffer, pH 8.0) or 300 µL of a 
NADPH-regeneration system (300 µL, 1.66 mM NADP+, 66 U/mL isocitrate 
dehydrogenase, 416 mM isocitrate) was added to the reaction and the vial was capped.  
After 4 or 12 hours of stirring (the enzymes are inactive after 4 hours) at room temperature, 
a 1.5 mL aliquot of the reaction was removed from the vial and quenched with 300 µL of 
chloroform in a 2 mL microcentrifuge tube.  An internal standard containing 15 µL of 10 
mM 1-hexanol was added to the tube.  The tube was vortexed and then centrifuged at 
10,000 g for 2 minutes in a microcentrifuge.  The chloroform layer was removed with a 
pipet and analyzed by gas chromatography. Control reactions without substrate revealed no 
detectable background levels of these specific products. All reactions were performed in 
triplicate. 
To analyze the formation of overoxidation products as described in Chapter 6, the 
reactions were performed under similar conditions as described above.  The reactions 
were carried out in potassium phosphate buffer (0.1 M, pH 8.0, 3 mL), containing 
purified protein (200 nM), substrate (octane, nonane, or decane, 50 µM) or the 1-alcohol 
(1-octanol, 1-nonanol 1-decanol (4 mM)).  After 1 min, NADPH (500µM) was added to 
the reaction before the vial was capped and pressurized with dioxygen (20 psi).  At the 
end of the reaction, an aliquot (1500 µL) was removed from the vial. All reactions were 
carried out in triplicate. 
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For the determination of product formation rates (measured at 21oC), the reactions (5 mL) 
were performed similarly, except for the use of more enzyme (200 nM) and NADPH 
(500 µM) instead of a regeneration system. Additionally, the vials were not pressurized 
with dioxygen.  Aliquots of the reaction (1400 µL) were removed at 20, 40 and 60 s. In 
all cases, the aliquots were quenched with CHCl3 (300 µL) and HCl (6 M, 100 µL) in a 2 
mL microcentrifuge tube.  An internal standard containing 1-hexanol (14 µL, 10 mM) for 
octane, nonane and decane reactions or 1-octanol (14 µL, 10 mM) for hexane and 
heptane reactions was added to the tube.  The tube was vortexed and then centrifuged at 
10,000 g for 2 minutes in a microcentrifuge.  The chloroform layer was removed with a 
pipet and analyzed by gas chromatography to determine product concentrations.  Control 
reactions performed by repeating these steps without the addition of substrate revealed no 
detectable background levels of these specific products.  All reactions were carried out in 
triplicate. 
 
G.2. Chiral Analysis of Alkane Reactions (Chapters 2 and 6) 
Chiral analysis of liquid alkane hydroxylation products was performed with a slight 
modification of an existing method [16], starting with extracting  9 mL alkane reactions 
(using the reaction conditions above) with 2 mL CH2Cl2 in a 15 mL centrifuge tube.  After 
centrifugation at 2800 g for 15 minutes, the organic layer was removed with a pipet and 
dried over a small amount of anhydrous MgSO4.  The MgSO4 was removed by filtration, 
and 1 µL of pyridine and 2.5 µL (-)-menthyl chloroformate was added.  After an hour, 1 
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mL of deionized water was added to the reaction.  After vortexing and letting the layers 
separate, the organic phase was removed with a pipet and dried with anhydrous MgSO4.  
The drying agent was again removed with a pipet filter and the remaining solution analyzed 
by gas chromatography.  Control reactions were performed by repeating these steps without 
the addition of substrate and revealed no background levels of these specific products. All 
reactions were performed in triplicate. 
 
G.3. Propane Hydroxylation Reactions (Chapters 2-4, 6) 
Reactions using propane did not contain co-solvent because of potential competition 
between the solvent and the small substrate.  These reactions were performed in propane-
saturated buffer under an atmosphere of propane and dioxygen (provided by a balloon 
filled with the two gases).  The addition of this atmosphere ensured that both gaseous 
substrates were saturated in the reaction solution, since a balloon of just propane or oxygen 
would dilute the concentration of the other gas.  Total turnovers determined with this 
system were not dependent on oxygen concentration in the balloon (data not shown), 
illustrating that only the original ~250 µM of dioxygen in the buffer was available to the 
reaction.  Additionally, we discovered that NADPH could neither be purchased nor easily 
purified in a form that contains less than 2-3% ethanol, which interferes with analysis of the 
reaction products.  For this reason, an NADPH-regeneration system was used for propane 
reactions [17]. 
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Propane hydroxylation reactions were performed in 20 mL scintillation vials.  In a typical 
reaction, enzyme (either purified or in cell lysate) was added to 4.7 mL of propane-
saturated 0.1 M potassium phosphate buffer pH 8.0 to a final concentration of 50-100 nM.   
To this mixture, 300 µL of NADPH-regeneration system (1.66 mM NADP+, 167 U/mL 
isocitrate dehydrogenase, 416 mM isocitrate) was quickly added.  The flask was topped 
with a balloon filled with equal amounts of propane and dioxygen.  After stirring for two 
hours at room temperature, the propane hydroxylation products were derivatized to alkyl 
nitrites using a published method [18]. To the reaction mixture, 0.3 g of sodium nitrite and 
2 mL 10 µM chloroform in hexane was added and the mixture cooled on ice.  While on ice, 
0.2 mL concentrated sulfuric acid was added.  The flask was stoppered with a rubber 
stopper and stirred on ice for 15 minutes.  The reaction was rinsed into a separatory funnel 
with 20 mL of deionized water.  The organic phase was washed twice with 20 mL of water 
and analyzed by gas chromatography.  Control reactions were performed by repeating these 
steps without the substrate, to correct for background levels of propanol. All reactions were 
carried out in triplicate. 
Propanol formation rates were measured in two different ways.  For the data presented in 
Chapter 2, rates were measured in 4 mL reactions containing 1 µM P450 and propane 
saturated 0.1M potassium phosphate buffer, pH 8 which were initiated with 500 µM 
NADPH.   Aliquots of this mixture (933 µL) were removed at 20 s intervals and quenched 
with 67 µL of 6 N HCl containing 3 mM 1-pentanol internal standard (200 µM final 
concentration).  The samples were analyzed by GC-FID (see below).  For the data 
presented in all other chapters, propane hydroxylation reactions were carried out in 5 mL 
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reactions were carried out in 20 mL glass vials as described above similarly to those 
described for propane. For rate determination, the reaction was stopped after 1 min by 
adding 200 µL of sulfuric acid. 50 µL of 5 mM 1-butanol was added to the reaction 
mixture as an internal standard. Propanol and 1-butanol were subsequently derivatized to 
their corresponding alkyl nitrites as described above Control reactions were performed 
without substrate did not contain detectable amounts of propanols. All reactions were 
performed in triplicate.  
  
G.4. Ethane Reactions (Chapter 6) 
Ethane reactions were carried out in 20 mL glass vials similarly to those described for 
propane. An NADPH regeneration system was used because commercially-available 
NADPH contains 2-3% ethanol. A 5.0 mL reaction mixture contained 100 to 500 nM 
purified protein in 0.1 M potassium phosphate buffer (pH 8.0) saturated with ethane and 
dioxygen. 300 µL of the regeneration system (1.66 mM NADP+, 167 U/mL isocitrate 
dehydrogenase, 416 mM isocitrate) was added. The vial was immediately topped with a 
septum, pressurized with 20 psi of ethane and stirred at 25°C. For determination of total 
turnover, the reaction was allowed to proceed for 12 hours.  For rate determination, the 
reaction was stopped at 0, 15 and 30 min. 50 µL of 5 mM 1-butanol was added to the 
reaction mixture as an internal standard. Ethanol and 1-butanol were subsequently 
derivatized to their corresponding alkyl nitrites according to a published procedure [18]. 
Control reactions were performed without substrate and with inactivated protein (the 
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protein was inactivated by adding 200 µL sulfuric acid before initiation of the reaction).  
Reaction buffer saturated with ethane and oxygen did not contain an ethanol concentration 
above this background of ~ 1.0 µM.  All reactions were carried out in triplicate.  
 
H. Fatty Acid Hydroxylation Reactions (Chapter 4) 
For the determination of total turnover numbers and regioselectivity, reactions (1 mL) 
with lauric acid and palmitic acid were performed for 3 hours at 25°C in 2 mL 
microcentrifuge tubes.  The reactions were carried out in Tris-HCl buffer (0.1 M, pH 8.2, 
0.650 mL), containing purified protein (25 nM).  Substrate (sodium salt of the fatty acids 
(20 mM), dissolved in sodium carbonate (50 mM) at 80°C, 0.1 mL) was added to the 
reaction to give 2 mM total substrate.  To initiate the reaction, NADPH (0.25 mL, 2 mM) 
was added and mixed.  The reaction was terminated and acidified by adding HCl (14 µL, 
6N).  An internal standard of 10-hydroxycapric acid in dimethylsulfoxide (10 µL, 10 
mM) was added to each reaction.  The products were extracted by adding ethyl acetate 
(0.5 mL).  The tube was vortexed and then centrifuged at 10,000 g for 2 minutes in a 
microcentrifuge.  The ethyl acetate layer was removed with a pipet and dried using a 
Savant Speed Vac at medium heat for 30 minutes.  The residue was derivitized by adding 
0.1 mL of a 50:50 pyrimidine:(bis-trimethylsilyltrifluoroacetamide with 1% TMSCl) and 
reacting at 80°C for 20 minutes.  The derivatization solution was injected directly into the 
GC for product analysis. All reactions were carried out in triplicate. 
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Authentic standards for hydroxylated fatty acids were available only for 12-hydroxylauric 
acid and 16-hydroxypalmitic acid, which were used to quantify all hydroxyl-fatty acids of 
the same chain length.  The ω-1, ω-2 and w-3 hydroxy-fatty acids were identified relative 
to the product retention times from reactions with wild-type P450 BM-3 for which the 
relative amounts of product regioisomers is well established [19,20].  
 
I. Hydroxylation Reactions of 2-Cyclopentanelbenzoxazole (Chapter 5) 
Hydroxylation reactions of 2-cyclopentanelbenzoxazole 2 for the determination of 
enantioselectivity and total turnover number of were carried out similarly to those 




Hydroxylation reactions were performed in 20 mL glass vials and stirred at low speed 
using magnetic stirring bars. The 5 mL reaction mixture containing purified protein (25 nM 
of mutant protein or 100 nM of wt), 1 mM substrate 2, and 1% ethanol in potassium 
phosphate buffer (0.1 M, pH 8.0) was initiated by the addition of  500 µL NADPH (10 
mM). After 12 hours of stirring at room temperature, a 1.5 mL aliquot of the reaction was 
removed from the vial and quenched with 300 µL of chloroform in a 2 mL microcentrifuge 
tube. An internal standard containing 15 µL coumarin (20 mM in ethanol) was added to the 
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tube. The tube was vortexed and then centrifuged at 10,000 g for 2 minutes in a 
microcentrifuge. The chloroform layer was removed with a pipette and analyzed by gas 
chromatography to determine total turnover numbers and product distributions. Control 
reactions performed by repeating these steps without the addition of substrate revealed no 
detectable background levels of these specific products. All reactions were carried out in at 
least triplicate 
To determine formation rates of 3 (measured at 21°C), 5 mL reactions containing 100 nM 








Aliquots (1.4 mL) were removed from the reaction at 20 second intervals for one minute 
and quenched in 2 mL microcentrifuge tubes containing 300 µL chloroform, 100 µL 6 N 
HCl, and 14 µL 20 mM coumarin in ethanol. The tubes were vortexed and centrifuged at 
~10,000 g for 2 minutes to separate the layers. The chloroform layer was removed and 





J. Gas Chromatography 
Identification and quantification of analytes were performed using purchased standards 
and 5-point calibration curves with internal standards.  All samples were injected at a 
volume of 1.0 µL and analyses were performed at least in triplicate.  
 
J.1. Linear Alkane Oxidation Products (C5 to C10) (Chapters 2-4, 6) 
Analyses of hydroxylation products of linear alkanes were performed on a Hewlett Packard 
5890 Series II Plus gas chromatograph with a flame ionization detector (FID) and fitted 
with a HP-7673 autosampler system. Direct analysis of hexane, heptane, octane, nonane, 
and decane hydroxylation products was performed on an HP-5 capillary column 
(crosslinked 5% phenyl methyl siloxane, 30 m length, 0.32 mm ID, 0.25 µm film 
thickness) connected to the FID detector.  A typical temperature program for separating the 
alcohol products is 250°C injector, 300°C detector, 50°C oven for 3 minutes, then 
10°C/minute gradient to 200°C, 25°C/minute gradient to 250°C, then 250°C for 3 minutes.   
Overoxidation products of alkanes were analyzed on a Hewlett Packard 6890 Series gas 
chromatography System coupled to a Hewlett Packard 5973 Mass Selective Detector.  
The alcohol, aldehyde, acid and diol products were separated using an INNOWax 
capillary column (Agilent Technologies, 30 m length, 0.25 mm ID, 0.25 µm film 
thickness) with the temperature program of 250°C injector, 60°C oven for 1 minutes, then 
10°C/minute gradient to 250°C, then 250°C for 2 minutes. 
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J.2. Chiral Analysis of Alkane Reactions (Chapter 2 and 6) 
The (-)-menthyl chloroformate-derivatized chiral products were separated as 
diastereomers on a CycloSil-B chiral capillary column (Agilent Technologies, 30 m 
length, 0.32 mm ID, 0.25 µm film thickness) connected to the FID detector [21].  Each 
pair of diastereomers required a different temperature program for full resolution, but a 
typical program is as follows: chiral octanol analysis - 250°C injector, 300°C detector, 
100°C oven for 1 minute, then 10°C/minute gradient to 190°C, hold at 190°C for 10 
minutes, 10°C/minute gradient to 250°C, then 250°C for 3 minutes.  
 
J.3. Gaseous Alkane (C1 to C4) Oxidation Products  (Chapters 2,3 and 6) 
Analysis of the alkyl nitrite derivatives of methanol, ethanol and propanol was performed 
on a Hewlett-Packard 5890 Series II Plus gas chromatograph (Hewlett-Packard, San 
Fernando, CA, U.S.A) with an electron capture detector (ECD) using an HP-1 column 
(Agilent Technologies; 30m length, 0.53 mm ID, 2.65 µM film thickness) or an HP-1 
capillary column (Agilent Technologies; crosslinked 1% phenyl methyl siloxane, 30 m 
length, 0.32 mm ID, 0.25 µm film thickness) [18]. The temperature program was: 60°C 
injector, 150°C detector, 35° oven for 3 min, 10°C/min gradient to 60°C, 25°C/min 
gradient to 200°C, and then 200°C for 5 min. 
For propane oxidation rates described in Chapter 2, A GC/FID fitted with an HP FFAP 
(cross-linked FFAP, 30 m length, 0.25 mm ID, 0.25 µm film thickness) using the 
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temperature program:  250°C injector, 300°C detector, 50°C oven for 3 minutes, then 
10°C/minute gradient to 200°C, 25°C/minute gradient to 220°C, then 220°C for 3 minutes.  
 
J.4. Fatty Acid Hydroxylation Products (Chapter 4) 
Trimethylsilyl-derivatized fatty acids and their hydroxylated products were analyzed by 
injecting 1 µl onto an HP-5 capillary column (crosslinked 5% phenyl methyl siloxane, 30 
m length, 0.32 mm ID, 0.25 µm film thickness) connected to the FID detector.  A typical 
temperature program for separating the derivatized products is 250°C injector, 300°C 
detector, 150°C oven for 1 minutes, then 10°C/minute gradient to 250°C, then 250°C for 
5 minutes.  Authentic standards for 12-hydroxylauric acid and 16-hydroxypalmitic acid 
were used to identify the ω-hydroxy-fatty acids, while the ω-1, ω-2 and ω-3 hydroxy-
fatty acids were identified based on reactions with wild-type P450 BM-3 for which the 
hydroxylation pattern is known [19,20].  Products were verified according to the retention 
time and fragmentation pattern of the known ω, ω-1, ω-2, and ω-3 controls by GC-MS 
using a Varian Star 3400cx gas chromatograph with an HP-5 capillary column 
(crosslinked 5% phenyl methyl siloxane, 30 m length, 0.25 mm ID, 0.25 µm film 
thickness) connected to a Varian Saturn 2000 GC/MS detector using the following 
temperature program: 250°C injector, 150°C oven for 2 minutes, then 10°C/minute 
gradient to 250°C, then 250°C for 5 minutes. 
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J.5. Hydroxylation Reactions of 2-Cyclopentylbenzoxazole (Chapter 5) 
Analysis of the hydroxylation products of 2-cyclopentanebenzoxazole 2 was performed 
using authentic standards and a 5-point calibration curve with coumarin as an internal 
standard. The injection volume was 1 µL. Analysis was performed on a Hewlett-Packard 
5890 Series II Plus gas chromatograph connected to a FID detector using a CycloSil-B 
column (J&W Scientific, 30 m length, 0.320 mm ID, 0.25 µm film thickness) for chiral 
analysis or a HP-5MS column (Agilent Technologies, 30 m length, 0.25 mm ID, 0.25 µM 
film thickness) for the determination of rates and total turnover numbers. The temperature 
program for the CycloSil-B column was: 100°C injector, 250°C detector, 100° oven for 3 
min, 10°C/min gradient to 170°C, 170°C for 10 min, 25°C/min gradient to 200°C, and then 
200°C for 8 min. The temperature program for the HP-5MS column was: 100°C injector, 
250°C detector, 100° oven for 3 min, 10°C/min gradient to 210°C, 25°C/min gradient to 
250°C, and then 250°C for 3 min. 
 
K. Overoxidation of Ethanol by BM-3 Variant 53-5H (Chapter 6) 
Ethanol (20 µM) was used as the substrate under the reaction conditions described above 
(section G.4).  No decrease in ethanol concentration was observed within experimental 
error (± 3 µM) over the course of the reaction. NMR (Varian Mercury 300 MHz) 
spectroscopy was used to monitor reactions of 53-5H with singly 13C-labeled ethanol (HO-
13CH2CH3, 57 ppm). Concentrations of 13C-labeled ethanol as low as 50 µM in the 
presence of 10 µM P450 (in 0.1M potassium phosphate buffer, pH 8, with 10% deuterium 
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oxide added) could be detected using the 13C channel of the NMR. The longer relaxation 
rates of the carbonyl carbon atoms in acetaldehyde (206 ppm) and acetic acid (176 ppm) 
decrease their carbon NMR signal heights by 25-40% in our experiments, making their 
detection limit approximately 100 µM. Reactions using 10 µM 53-5H, 1 mM 13C-ethanol, 
100 µM NADP+, 50 mM isocitrate, and 10 U/mL isocitrate dehydrogenase were stirred 12 
hours at room temperature. Deuterium oxide (10% final concentration) was then added to 
each reaction, and NMR spectra (averaging ~20,000 scans each) were recorded. Control 
reactions using 50 nM of 53-5H from the same batch, 4 mM of octane, 100 µM NADP+, 50 
mM isocitrate, and 10 U/mL isocitrate dehydrogenase were also performed and the 
products characterized to verify that the P450 was fully active. No overoxidation products 
were detected in these experiments, indicating that, in the presence of 1 mM ethanol, 53-5H 
catalyzes less than 10 total turnovers of ethanol.  
 
L. Absorption Spectra of BM-3 Variants 1-12G, 53-5H and 35-E11 (Chapter 6) 
The absorption spectra were taken using a 3 µM solution of purified P450 in potassium 
phosphate buffer (0.1 M, pH 8.0) in a quartz cuvette.  Ethane was added either by 
bubbling ethane for 2 to 10 min at approximately one bubble sec-1, or by pressurizing the 
cuvette with ethane (20 psi).  The shift in equilibrium from low- (Amax at 418 nm) to 
high-spin (Amax at 390 nm) configuration of the ferric heme iron was measured. 
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M. Whole-Cell Reactions (Chapter 2) 
The procedure for whole-cell reactions of E. coli (DH5α) overexpressing mutants 9-10A-
A328V and 1-12G was only slightly modified from Witholt’s published method [22]. An 
overnight culture of cells (in 3 mL LB with 100 µg/mL ampicillin) was used to inoculate 
75 mL of M9 minimal medium containing 0.5% w/v glucose, 0.2 mM calcium chloride, 5 
mM MgSO4, and 100 µg/mL ampicillin. The culture was then shaken for 24 hours at 37°C 
and 250 rpm.  The cells were collected by centrifugation at 2200 g for 10 minutes and 
resuspended in 20 mL of 0.2 M potassium phosphate buffer pH 7.4 containing 0.5% 
glucose, 100 µg/mL ampicillin, 1 mM IPTG, and 0.5 mM δ-aminolevulinic acid, 5 mM 
alkane (from a 500 mM stock of alkane in dimethyl sulfoxide).   This mixture was shaken 
for 8 hours at 37°C and 250 rpm.  Product distributions were measured by gas 
chromatography after extracting this culture with 1 mL of chloroform.   Chiral analysis of 
the reaction products was performed after extracting the culture with 2 mL of CH2Cl2 and 
derivatizing the organic layer with (-)-menthyl chloroformate. 
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A p p e n d i x  A  













Enzymes used for biocatalysis applications need to be sufficiently stable in order to resist 
thermal denaturation under process conditions.    We engineered P450 BM-3 for improved 
alkane hydroxylation activity by introducing mutations and screening for improved 
activity, but mutations generally decrease the stability of a protein.  To avoid identifying 
highly unstable mutants, lysis of E. coli cells containing BM-3 variants was performed for 
one hour at 37oC.  The stability of improved mutants, however, was not determined.  Here 
we briefly examine the stabilities of the wild-type enzyme and selected variants.  
 
B. Results 
To characterize the thermostability of wild-type P450 BM-3 and the variants identified by 
screening mutant libraries, we performed three separate assays.  The fraction of folded 
heme domain remaining after heat-treatment was determined from the fraction of the 
ferrous heme-CO complex that retained the absorbance peak at 450 nm, which 
characterizes a properly-folded P450.  We also determined the fraction of remaining 
NADPH-driven activity after heat treatment by measuring the fraction of the protein tat 
retained measurable NADPH oxidation rates in presence of hexyl methyl ether.  This 
measurement provides information instability caused by altered heme-reductase 
interactions. 
Temperature-dependent inactivation of P450 BM-3 has been shown to be caused by the 
reductase domain, and more specifically on the dissociation of the FAD cofactor [1].  
Except for variant 35-E1l, which contains two mutations in the reductase domain, the 
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reductase domain was not altered during the course of work described in this thesis.  It is 
likely, however, that conformational changes in the heme domain due to its accumulated 
mutations have a destabilizing effect on the reductase domain.  To assess whether the 
reductase domain was destabilized, the fraction of active reductase domain after heat 
treatment was determined from the fraction of reductase domain that retained cytochrome c 
reductase activity.  The reductase portion of P450 BM-3 is able to perform this reaction 
independently from the heme domain.   
The data were fit to a two-state model, and the resulting calculated temperatures 
corresponding to half denaturation for the 15-min heat incubations are listed in Table A.1. 
The values are in good agreement to the midpoints of the melting curves.  According to this 
measure of stability, the variants obtained by random mutagenesis have lost significant 
stability.  The heme domain of mutant 9-10A, the last variant obtained from random 
mutagenesis experiments described in this thesis, is approximately 10 oC less stable than 
wild-type.  Mutations within the active site of 53-5H did not further decrease the stability.  
Mutations in the reductase domain of mutant 35-E11 also have no further destabilizing 
effects.  Although the variants (except for 35-E11) do not contain mutations in the 
reductase domain, this domain seems to have lost stability.  This is evident from the 
decreased NADPH oxidation and cytochrome c reduction activity.  Conformational 
changes in the reductase domain induced by the mutated heme domain could account for 
this effect.   
It has been proposed that the stability of a protein is important for its robustness to amino 
acid substitutions [2].  The important implication for directed evolution experiments is 
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that applying random mutagenesis to an unstable protein will yield libraries with mostly 
unfolded proteins.  The threshold of stability at which this becomes important for P450 
BM-3 has not been determined.  It may, however, become necessary to increase the 
stability before applying further rounds of mutagenesis to identify mutants with improved 
activity.  Directed evolution has proven to be effective method for increasing enzyme 
thermostability [3]. 
 
Table A.1. Thermostability parameters for wild-type P450 BM-3 and variants selected for 
improved alkane hydroxylation activity. 
 T50 for 15 min incubations [oC] [a]
BM-3 variant T50 heme [b] T50 NADPH oxidation [c] T50 cyt c reduction [d]
wt 54.8 ± 0.6 46.9 ± 0.3 43.7 ± 0.5 
139-3 54.7 ± 0.8 46.5 ± 0.1 n.a. [e]
J 49.6 ± 0.6 46.4± 0.1 n.a. [e]
9-10A 45.0 ± 0.7 44.4 ± 0.2 n.a. [e]
53-5H 44 ± 0.2 43.9 ± 0.2 34.9 ± 0.7 
35-E11 44.8 ± 0.2 43.6 ± 0.2 34.9 ± 0.3 
[a] Calculated by fitting the data to a two-state denaturation equation.  See Experimental 
section below for details. 
[b]  T50 heme is calculated from the percentage of 450 nm CO-binding peak of cytochrome 
P450 BM-3 variants remaining after 15-min incubations at varying temperatures 
[c] T50 NADPH oxidation is calculated from the percentage of NADPH oxidation activity of 
cytochrome P450 BM-3 variants in presence of hexyl methyl ether remaining after 15-min 
incubations at varying temperatures 
[d] T50 cyt c reduction is calculated from the percentage of cytochrome c reduction activity of 
cytochrome P450 BM-3 variants in presence of hexyl methyl ether remaining after 15-min 
incubations at varying temperatures. 
[e] T50 cyt c reduction values for 139-3, J, and 9-10A could not be calculated because their 
activities did not drop to zero at elevated temperature and a two-state denaturation model 






Purified protein (40 µL, 1 µM for NADPH oxidation assay, 25 nM for cytochrome c assay, 
25 µM for CO-binding assay) in potassium phosphate buffer (0.1 M, pH 8.0) was incubated 
for 15 min at 20 different temperatures ranging from 30 to 65oC in a 96-well PCR plate in a 
PCR machine (PTC 200 DNE Engine, MJ Research, Watertown, MA).  Samples were 
cooled to 4 oC for 5 min and then incubated at 25 oC prior to performing assays.  Each assay 
was performed in triplicate at each temperature. 
For the CO-binding assay, 30 µL of protein were added to 170 µL of 100 mM sodium 
hydrosulfite in potassium phosphate buffer (0.3 mM, pH 8.0). A baseline spectrum was 
taken before placing the plate into a chamber.  The chamber was evacuated and 
subsequently filled with carbon monoxide.  The plate was incubated for approximately 10 
minutes before removing it to record the difference spectrum from 400-500 nm using a 
Spectramax Plus microtiter plate reader (Molecular Devices, Sunnyvale, CA). 
For the NADPH depletion assay, 30 up of protein were added to 170 µL potassium 
phosphate buffer (0.1 M, pH 8.0).  Substrate (2 µL, 400 mM in ethanol) was added and the 
mixture was incubated for 2 min at room temperature before NADPH (50 µL, 0.8 mM) 
was added to initiate the reaction.  NADPH oxidation was monitored at 340 nM in a 
Spectramax Plus microtiter plate reader (Molecular Devices, Sunnyvale, CA). 
For the cytochrome c reduction assay, 30 up of protein was added to 170 µL potassium 
phosphate buffer (0.1 M, pH 8.0) containing 150 µM cytochrome c.  The reaction was 
initiated by addition of NADPH (50 µL, 0.5 mM) and cytochrome c reduction was 
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monitored at 550 nM using a Spectramax Plus microtiter plate reader (Molecular Devices, 
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A p p e n d i x  B  















Cytochrome P450 BM-3 (GenBank number J04832) is composed of 1048 amino acids 
(3144 bp).  The heme domain of cytochrome P450 BM-3 contains 471 amino acids (1413 
bp) while the reductase domain is comprised of 577 amino acids (1731 bp).  The P450 
BM-3 gene and the genes of P450 BM-3 mutants derived from this gene include a silent 
mutation to introduce a SacI site 130 bp upstream of the end of the heme domain.  The 
genes were cloned behind the double tac promoter of the expression vector pCWori 
(pBM3_WT18-6).  This plasmid was used for all cloning procedures as well as for 
protein expression. 
In random mutagenesis experiments targeting the heme domain, error prone PCR was 
applied to the region stretching from the BamHI site to the SacI site, thereby omitting the 
last 32 amino acids (96 bp) of the heme domain.  In random mutagenesis experiments 
targeting the reductase domain, error prone PCR was applied to the region stretching 
from the SacI to the EcoRI site.  
Figure B.1 lists the nucleotide sequence of full-length, wild-type cytochrome P450 BM-3. 
Figure B.2 lists the amino acid sequence of full-length, wild-type cytochrome P450 
BM-3. 
Figure B.3 lists the nucleotide sequence of the pCWori vector containing wild-type P450 
BM-3 (pBM3_WT18-6).  The two Ptac promoters in this vector begin at nucleotide 
positions 167 and 262 (refer to plasmid map in Figure B.4). 
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Figure B.4 shows the plasmid map of the pCWori vector containing wild-type P450 BM-
3 (pBM3_WT18-6).  
Table B.1 lists the mutations of P450 BM-3 mutants generated by random mutagenesis 
and recombination prior to my involvement in the project. 
Table B.2 lists P450 BM-3 mutants described in Chapter 2. 
Table B.3 lists single active site mutants of P450 BM-3 described in Chapter 3. 
Table B.4 lists amino acid substitutions of multiple active site mutants of P450 BM-3 
described in Chapter 3. 
Table B.5 lists amino acid substitutions of reductase mutants described in Chapter 5. 
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Figure B.1. Nucleotide sequence of full-length, wild-type cytochrome P450 BM-3. 
    1 ATGACAATTA AAGAAATGCC TCAGCCAAAA ACGTTTGGAG AGCTTAAAAA 
   51 TTTACCGTTA TTAAACACAG ATAAACCGGT TCAAGCTTTG ATGAAAATTG 
  101 CGGATGAATT AGGAGAAATC TTTAAATTCG AGGCGCCTGG TCGTGTAACG 
  151 CGCTACTTAT CAAGTCAGCG TCTAATTAAA GAAGCATGCG ATGAATCACG 
  201 CTTTGATAAA AACTTAAGTC AAGCGCTTAA ATTTGTACGT GATTTTGCAG 
  251 GAGACGGGTT ATTTACAAGC TGGACGCATG AAAAAAATTG GAAAAAAGCG 
  301 CATAATATCT TACTTCCAAG CTTCAGTCAG CAGGCAATGA AAGGCTATCA 
  351 TGCGATGATG GTCGATATCG CCGTGCAGCT TGTTCAAAAG TGGGAGCGTC 
  401 TAAATGCAGA TGAGCATATT GAAGTACCGG AAGACATGAC ACGTTTAACG 
  451 CTTGATACAA TTGGTCTTTG CGGCTTTAAC TATCGCTTTA ACAGCTTTTA 
  501 CCGAGATCAG CCTCATCCAT TTATTACAAG TATGGTCCGT GCACTGGATG 
  551 AAGCAATGAA CAAGCTGCAG CGAGCAAATC CAGACGACCC AGCTTATGAT 
  601 GAAAACAAGC GCCAGTTTCA AGAAGATATC AAGGTGATGA ACGACCTAGT 
  651 AGATAAAATT ATTGCAGATC GCAAAGCAAG CGGTGAACAA AGCGATGATT 
  701 TATTAACGCA TATGCTAAAC GGAAAAGATC CAGAAACGGG TGAGCCGCTT 
  751 GATGACGAGA ACATTCGCTA TCAAATTATT ACATTCTTAA TTGCGGGACA 
  801 CGAAACAACA AGTGGTCTTT TATCATTTGC GCTGTATTTC TTAGTGAAAA 
  851 ATCCACATGT ATTACAAAAA GCAGCAGAAG AAGCAGCACG AGTTCTAGTA 
  901 GATCCTGTTC CAAGCTACAA ACAAGTCAAA CAGCTTAAAT ATGTCGGCAT 
  951 GGTCTTAAAC GAAGCGCTGC GCTTATGGCC AACTGCTCCT GCGTTTTCCC 
 1001 TATATGCAAA AGAAGATACG GTGCTTGGAG GAGAATATCC TTTAGAAAAA 
 1051 GGCGACGAAC TAATGGTTCT GATTCCTCAG CTTCACCGTG ATAAAACAAT 
 1101 TTGGGGAGAC GATGTGGAAG AGTTCCGTCC AGAGCGTTTT GAAAATCCAA 
 1151 GTGCGATTCC GCAGCATGCG TTTAAACCGT TTGGAAACGG TCAGCGTGCG 
 1201 TGTATCGGTC AGCAGTTCGC TCTTCATGAA GCAACGCTGG TACTTGGTAT 
 1251 GATGCTAAAA CACTTTGACT TTGAAGATCA TACAAACTAC GAGCTCGATA 
 1301 TTAAAGAAAC TTTAACGTTA AAACCTGAAG GCTTTGTGGT AAAAGCAAAA 
 1351 TCGAAAAAAA TTCCGCTTGG CGGTATTCCT TCACCTAGCA CTGAACAGTC 
 1401 TGCTAAAAAA GTACGCAAAA AGGCAGAAAA CGCTCATAAT ACGCCGCTGC 
 1451 TTGTGCTATA CGGTTCAAAT ATGGGAACAG CTGAAGGAAC GGCGCGTGAT 
 1501 TTAGCAGATA TTGCAATGAG CAAAGGATTT GCACCGCAGG TCGCAACGCT 
 1551 TGATTCACAC GCCGGAAATC TTCCGCGCGA AGGAGCTGTA TTAATTGTAA 
 1601 CGGCGTCTTA TAACGGTCAT CCGCCTGATA ACGCAAAGCA ATTTGTCGAC 
 1651 TGGTTAGACC AAGCGTCTGC TGATGAAGTA AAAGGCGTTC GCTACTCCGT 
 1701 ATTTGGATGC GGCGATAAAA ACTGGGCTAC TACGTATCAA AAAGTGCCTG 
 1751 CTTTTATCGA TGAAACGCTT GCCGCTAAAG GGGCAGAAAA CATCGCTGAC 
 1801 CGCGGTGAAG CAGATGCAAG CGACGACTTT GAAGGCACAT ATGAAGAATG 
 1851 GCGTGAACAT ATGTGGAGTG ACGTAGCAGC CTACTTTAAC CTCGACATTG 
 1901 AAAACAGTGA AGATAATAAA TCTACTCTTT CACTTCAATT TGTCGACAGC 
 1951 GCCGCGGATA TGCCGCTTGC GAAAATGCAC GGTGCGTTTT CAACGAACGT 
 2001 CGTAGCAAGC AAAGAACTTC AACAGCCAGG CAGTGCACGA AGCACGCGAC 
 2051 ATCTTGAAAT TGAACTTCCA AAAGAAGCTT CTTATCAAGA AGGAGATCAT 
 2101 TTAGGTGTTA TTCCTCGCAA CTATGAAGGA ATAGTAAACC GTGTAACAGC 
 2151 AAGGTTCGGC CTAGATGCAT CACAGCAAAT CCGTCTGGAA GCAGAAGAAG 
 2201 AAAAATTAGC TCATTTGCCA CTCGCTAAAA CAGTATCCGT AGAAGAGCTT 
 2251 CTGCAATACG TGGAGCTTCA AGATCCTGTT ACGCGCACGC AGCTTCGCGC 
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 2301 AATGGCTGCT AAAACGGTCT GCCCGCCGCA TAAAGTAGAG CTTGAAGCCT 
 2351 TGCTTGAAAA GCAAGCCTAC AAAGAACAAG TGCTGGCAAA ACGTTTAACA 
 2401 ATGCTTGAAC TGCTTGAAAA ATACCCGGCG TGTGAAATGA AATTCAGCGA 
 2451 ATTTATCGCC CTTCTGCCAA GCATACGCCC GCGCTATTAC TCGATTTCTT 
 2501 CATCACCTCG TGTCGATGAA AAACAAGCAA GCATCACGGT CAGCGTTGTC 
 2551 TCAGGAGAAG CGTGGAGCGG ATATGGAGAA TATAAAGGAA TTGCGTCGAA 
 2601 CTATCTTGCC GAGCTGCAAG AAGGAGATAC GATTACGTGC TTTATTTCCA 
 2651 CACCGCAGTC AGAATTTACG CTGCCAAAAG ACCCTGAAAC GCCGCTTATC 
 2701 ATGGTCGGAC CGGGAACAGG CGTCGCGCCG TTTAGAGGCT TTGTGCAGGC 
 2751 GCGCAAACAG CTAAAAGAAC AAGGACAGTC ACTTGGAGAA GCACATTTAT 
 2801 ACTTCGGCTG CCGTTCACCT CATGAAGACT ATCTGTATCA AGAAGAGCTT 
 2851 GAAAACGCCC AAAGCGAAGG CATCATTACG CTTCATACCG CTTTTTCTCG 
 2901 CATGCCAAAT CAGCCGAAAA CATACGTTCA GCACGTAATG GAACAAGACG 
 2951 GCAAGAAATT GATTGAACTT CTTGATCAAG GAGCGCACTT CTATATTTGC 
 3001 GGAGACGGAA GCCAAATGGC ACCTGCCGTT GAAGCAACGC TTATGAAAAG 
 3051 CTATGCTGAC GTTCACCAAG TGAGTGAAGC AGACGCTCGC TTATGGCTGC 
 3101 AGCAGCTAGA AGAAAAAGGC CGATACGCAA AAGACGTGTG GGCTGGG 
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Figure B.2. Amino acid sequence of full-length, wild-type cytochrome P450 BM-3. 
    1 MTIKEMPQPK TFGELKNLPL LNTDKPVQAL MKIADELGEI FKFEAPGRVT 
   51 RYLSSQRLIK EACDESRFDK NLSQALKFVR DFAGDGLFTS WTHEKNWKKA 
  101 HNILLPSFSQ QAMKGYHAMM VDIAVQLVQK WERLNADEHI EVPEDMTRLT 
  151 LDTIGLCGFN YRFNSFYRDQ PHPFITSMVR ALDEAMNKLQ RANPDDPAYD 
  201 ENKRQFQEDI KVMNDLVDKI IADRKASGEQ SDDLLTHMLN GKDPETGEPL 
  251 DDENIRYQII TFLIAGHETT SGLLSFALYF LVKNPHVLQK AAEEAARVLV 
  301 DPVPSYKQVK QLKYVGMVLN EALRLWPTAP AFSLYAKEDT VLGGEYPLEK 
  351 GDELMVLIPQ LHRDKTIWGD DVEEFRPERF ENPSAIPQHA FKPFGNGQRA 
  401 CIGQQFALHE ATLVLGMMLK HFDFEDHTNY ELDIKETLTL KPEGFVVKAK 
  451 SKKIPLGGIP SPSTEQSAKK VRKKAENAHN TPLLVLYGSN MGTAEGTARD 
  501 LADIAMSKGF APQVATLDSH AGNLPREGAV LIVTASYNGH PPDNAKQFVD 
  551 WLDQASADEV KGVRYSVFGC GDKNWATTYQ KVPAFIDETL AAKGAENIAD 
  601 RGEADASDDF EGTYEEWREH MWSDVAAYFN LDIENSEDNK STLSLQFVDS 
  651 AADMPLAKMH GAFSTNVVAS KELQQPGSAR STRHLEIELP KEASYQEGDH 
  701 LGVIPRNYEG IVNRVTARFG LDASQQIRLE AEEEKLAHLP LAKTVSVEEL 
  751 LQYVELQDPV TRTQLRAMAA KTVCPPHKVE LEALLEKQAY KEQVLAKRLT 
  801 MLELLEKYPA CEMKFSEFIA LLPSIRPRYY SISSSPRVDE KQASITVSVV 
  851 SGEAWSGYGE YKGIASNYLA ELQEGDTITC FISTPQSEFT LPKDPETPLI 
  901 MVGPGTGVAP FRGFVQARKQ LKEQGQSLGE AHLYFGCRSP HEDYLYQEEL 
  951 ENAQSEGIIT LHTAFSRMPN QPKTYVQHVM EQDGKKLIEL LDQGAHFYIC 
 1001 GDGSQMAPAV EATLMKSYAD VHQVSEADAR LWLQQLEEKG RYAKDVWAG 
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Figure B.3. Nucleotide sequence of the pCWori vector containing wild-type cytochrome 
P450 BM-3 (pBM3_WT18-6). 
    1 ATGACAATTA AAGAAATGCC TCAGCCAAAA ACGTTTGGAG AGCTTAAAAA 
   51 TTTACCGTTA TTAAACACAG ATAAACCGGT TCAAGCTTTG ATGAAAATTG 
  101 CGGATGAATT AGGAGAAATC TTTAAATTCG AGGCGCCTGG TCGTGTAACG 
  151 CGCTACTTAT CAAGTCAGCG TCTAATTAAA GAAGCATGCG ATGAATCACG 
  201 CTTTGATAAA AACTTAAGTC AAGCGCTTAA ATTTGTACGT GATTTTGCAG 
  251 GAGACGGGTT ATTTACAAGC TGGACGCATG AAAAAAATTG GAAAAAAGCG 
  301 CATAATATCT TACTTCCAAG CTTCAGTCAG CAGGCAATGA AAGGCTATCA 
  351 TGCGATGATG GTCGATATCG CCGTGCAGCT TGTTCAAAAG TGGGAGCGTC 
  401 TAAATGCAGA TGAGCATATT GAAGTACCGG AAGACATGAC ACGTTTAACG 
  451 CTTGATACAA TTGGTCTTTG CGGCTTTAAC TATCGCTTTA ACAGCTTTTA 
  501 CCGAGATCAG CCTCATCCAT TTATTACAAG TATGGTCCGT GCACTGGATG 
  551 AAGCAATGAA CAAGCTGCAG CGAGCAAATC CAGACGACCC AGCTTATGAT 
  601 GAAAACAAGC GCCAGTTTCA AGAAGATATC AAGGTGATGA ACGACCTAGT 
  651 AGATAAAATT ATTGCAGATC GCAAAGCAAG CGGTGAACAA AGCGATGATT 
  701 TATTAACGCA TATGCTAAAC GGAAAAGATC CAGAAACGGG TGAGCCGCTT 
  751 GATGACGAGA ACATTCGCTA TCAAATTATT ACATTCTTAA TTGCGGGACA 
  801 CGAAACAACA AGTGGTCTTT TATCATTTGC GCTGTATTTC TTAGTGAAAA 
  851 ATCCACATGT ATTACAAAAA GCAGCAGAAG AAGCAGCACG AGTTCTAGTA 
  901 GATCCTGTTC CAAGCTACAA ACAAGTCAAA CAGCTTAAAT ATGTCGGCAT 
  951 GGTCTTAAAC GAAGCGCTGC GCTTATGGCC AACTGCTCCT GCGTTTTCCC 
 1001 TATATGCAAA AGAAGATACG GTGCTTGGAG GAGAATATCC TTTAGAAAAA 
 1051 GGCGACGAAC TAATGGTTCT GATTCCTCAG CTTCACCGTG ATAAAACAAT 
 1101 TTGGGGAGAC GATGTGGAAG AGTTCCGTCC AGAGCGTTTT GAAAATCCAA 
 1151 GTGCGATTCC GCAGCATGCG TTTAAACCGT TTGGAAACGG TCAGCGTGCG 
 1201 TGTATCGGTC AGCAGTTCGC TCTTCATGAA GCAACGCTGG TACTTGGTAT 
 1251 GATGCTAAAA CACTTTGACT TTGAAGATCA TACAAACTAC GAGCTCGATA 
 1301 TTAAAGAAAC TTTAACGTTA AAACCTGAAG GCTTTGTGGT AAAAGCAAAA 
 1351 TCGAAAAAAA TTCCGCTTGG CGGTATTCCT TCACCTAGCA CTGAACAGTC 
 1401 TGCTAAAAAA GTACGCAAAA AGGCAGAAAA CGCTCATAAT ACGCCGCTGC 
 1451 TTGTGCTATA CGGTTCAAAT ATGGGAACAG CTGAAGGAAC GGCGCGTGAT 
 1501 TTAGCAGATA TTGCAATGAG CAAAGGATTT GCACCGCAGG TCGCAACGCT 
 1551 TGATTCACAC GCCGGAAATC TTCCGCGCGA AGGAGCTGTA TTAATTGTAA 
 1601 CGGCGTCTTA TAACGGTCAT CCGCCTGATA ACGCAAAGCA ATTTGTCGAC 
 1651 TGGTTAGACC AAGCGTCTGC TGATGAAGTA AAAGGCGTTC GCTACTCCGT 
 1701 ATTTGGATGC GGCGATAAAA ACTGGGCTAC TACGTATCAA AAAGTGCCTG 
 1751 CTTTTATCGA TGAAACGCTT GCCGCTAAAG GGGCAGAAAA CATCGCTGAC 
 1801 CGCGGTGAAG CAGATGCAAG CGACGACTTT GAAGGCACAT ATGAAGAATG 
 1851 GCGTGAACAT ATGTGGAGTG ACGTAGCAGC CTACTTTAAC CTCGACATTG 
 1901 AAAACAGTGA AGATAATAAA TCTACTCTTT CACTTCAATT TGTCGACAGC 
 1951 GCCGCGGATA TGCCGCTTGC GAAAATGCAC GGTGCGTTTT CAACGAACGT 
 2001 CGTAGCAAGC AAAGAACTTC AACAGCCAGG CAGTGCACGA AGCACGCGAC 
 2051 ATCTTGAAAT TGAACTTCCA AAAGAAGCTT CTTATCAAGA AGGAGATCAT 
 2101 TTAGGTGTTA TTCCTCGCAA CTATGAAGGA ATAGTAAACC GTGTAACAGC 
 2151 AAGGTTCGGC CTAGATGCAT CACAGCAAAT CCGTCTGGAA GCAGAAGAAG 
 2201 AAAAATTAGC TCATTTGCCA CTCGCTAAAA CAGTATCCGT AGAAGAGCTT 
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 2251 CTGCAATACG TGGAGCTTCA AGATCCTGTT ACGCGCACGC AGCTTCGCGC 
 2301 AATGGCTGCT AAAACGGTCT GCCCGCCGCA TAAAGTAGAG CTTGAAGCCT 
 2351 TGCTTGAAAA GCAAGCCTAC AAAGAACAAG TGCTGGCAAA ACGTTTAACA 
 2401 ATGCTTGAAC TGCTTGAAAA ATACCCGGCG TGTGAAATGA AATTCAGCGA 
 2451 ATTTATCGCC CTTCTGCCAA GCATACGCCC GCGCTATTAC TCGATTTCTT 
 2501 CATCACCTCG TGTCGATGAA AAACAAGCAA GCATCACGGT CAGCGTTGTC 
 2551 TCAGGAGAAG CGTGGAGCGG ATATGGAGAA TATAAAGGAA TTGCGTCGAA 
 2601 CTATCTTGCC GAGCTGCAAG AAGGAGATAC GATTACGTGC TTTATTTCCA 
 2651 CACCGCAGTC AGAATTTACG CTGCCAAAAG ACCCTGAAAC GCCGCTTATC 
 2701 ATGGTCGGAC CGGGAACAGG CGTCGCGCCG TTTAGAGGCT TTGTGCAGGC 
 2751 GCGCAAACAG CTAAAAGAAC AAGGACAGTC ACTTGGAGAA GCACATTTAT 
 2801 ACTTCGGCTG CCGTTCACCT CATGAAGACT ATCTGTATCA AGAAGAGCTT 
 2851 GAAAACGCCC AAAGCGAAGG CATCATTACG CTTCATACCG CTTTTTCTCG 
 2901 CATGCCAAAT CAGCCGAAAA CATACGTTCA GCACGTAATG GAACAAGACG 
 2951 GCAAGAAATT GATTGAACTT CTTGATCAAG GAGCGCACTT CTATATTTGC 
 3001 GGAGACGGAA GCCAAATGGC ACCTGCCGTT GAAGCAACGC TTATGAAAAG 
 3051 CTATGCTGAC GTTCACCAAG TGAGTGAAGC AGACGCTCGC TTATGGCTGC 
 3101 AGCAGCTAGA AGAAAAAGGC CGATACGCAA AAGACGTGTG GGCTGGGTAA 
 3151 GAATTCATCG ATGATAAGCT GTCAAACATG AGCAGATCTG AGCCCGCCTA 
 3201 ATGAGCGGGC TTTTTTTTCA GATCTGCTTG AAGACGAAAG GGCCTCGTGA 
 3251 TACGCCTATT TTTATAGGTT AATGTCATGA TAATAATGGT TTCTTAGCGT 
 3301 CAAAGCAACC ATAGTACGCG CCCTGTAGCG GCGCATTAAG CGCGGCGGGT 
 3351 GTGGTGGTTA CGCGCAGCGT GACCGCTACA CTTGCCAGCG CCCTAGCGCC 
 3401 CGCTCCTTTC GCTTTCTTCC CTTCCTTTCT CGCCACGTTC GCCGGCTTTC 
 3451 CCCGTCAAGC TCTAAATCGG GGGCTCCCTT TAGGGTTCCG ATTTAGTGCT 
 3501 TTACGGCACC TCGACCCCAA AAAACTTGAT TTGGGTGATG GTTCACGTAG 
 3551 TGGGCCATCG CCCTGATAGA CGGTTTTTCG CCCTTTGACG TTGGAGTCCA 
 3601 CGTTCTTTAA TAGTGGACTC TTGTTCCAAA CTGGAACAAC ACTCAACCCT 
 3651 ATCTCGGGCT ATTCTTTTGA TTTATAAGGG ATTTTGCCGA TTTCGGCCTA 
 3701 TTGGTTAAAA AATGAGCTGA TTTAACAAAA ATTTAACGCG AATTTTAACA 
 3751 AAATATTAAC GTTTACAATT TCAGGTGGCA CTTTTCGGGG AAATGTGCGC 
 3801 GGAACCCCTA TTTGTTTATT TTTCTAAATA CATTCAAATA TGTATCCGCT 
 3851 CATGAGACAA TAACCCTGAT AAATGCTTCA ATAATATTGA AAAAGGAAGA 
 3901 GTATGAGTAT TCAACATTTC CGTGTCGCCC TTATTCCCTT TTTTGCGGCA 
 3951 TTTTGCCTTC CTGTTTTTGC TCACCCAGAA ACGCTGGTGA AAGTAAAAGA 
 4001 TGCTGAAGAT CAGTTGGGTG CACGAGTGGG TTACATCGAA CTGGATCTCA 
 4051 ACAGCGGTAA GATCCTTGAG AGTTTTCGCC CCGAAGAACG TTTTCCAATG 
 4101 ATGAGCACTT TTAAAGTTCT GCTATGTGGC GCGGTATTAT CCCGTGTTGA 
 4151 CGCCGGGCAA GAGCAACTCG GTCGCCGCAT ACACTATTCT CAGAATGACT 
 4201 TGGTTGAGTA CTCACCAGTC ACAGAAAAGC ATCTTACGGA TGGCATGACA 
 4251 GTAAGAGAAT TATGCAGTGC TGCCATAACC ATGAGTGATA ACACTGCGGC 
 4301 CAACTTACTT CTGACAACGA TCGGAGGACC GAAGGAGCTA ACCGCTTTTT 
 4351 TGCACAACAT GGGGGATCAT GTAACTCGCC TTGATCGTTG GGAACCGGAG 
 4401 CTGAATGAAG CCATACCAAA CGACGAGCGT GACACCACGA TGCCTGCAGC 
 4451 AATGGCAACA ACGTTGCGCA AACTATTAAC TGGCGAACTA CTTACTCTAG 
 4501 CTTCCCGGCA ACAATTAATA GACTGGATGG AGGCGGATAA AGTTGCAGGA 
 4551 CCACTTCTGC GCTCGGCCCT TCCGGCTGGC TGGTTTATTG CTGATAAATC 
 4601 TGGAGCCGGT GAGCGTGGGT CTCGCGGTAT CATTGCAGCA CTGGGGCCAG 
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 4651 ATGGTAAGCC CTCCCGTATC GTAGTTATCT ACACGACGGG GAGTCAGGCA 
 4701 ACTATGGATG AACGAAATAG ACAGATCGCT GAGATAGGTG CCTCACTGAT 
 4751 TAAGCATTGG TAACTGTCAG ACCAAGTTTA CTCATATATA CTTTAGATTG 
 4801 ATTTAAAACT TCATTTTTAA TTTAAAAGGA TCTAGGTGAA GATCCTTTTT 
 4851 GATAATCTCA TGACCAAAAT CCCTTAACGT GAGTTTTCGT TCCACTGAGC 
 4901 GTCAGACCCC GTAGAAAAGA TCAAAGGATC TTCTTGAGAT CCTTTTTTTC 
 4951 TGCGCGTAAT CTGCTGCTTG CAAACAAAAA AACCACCGCT ACCAGCGGTG 
 5001 GTTTGTTTGC CGGATCAAGA GCTACCAACT CTTTTTCCGA AGGTAACTGG 
 5051 CTTCAGCAGA GCGCAGATAC CAAATACTGT CCTTCTAGTG TAGCCGTAGT 
 5101 TAGGCCACCA CTTCAAGAAC TCTGTAGCAC CGCCTACATA CCTCGCTCTG 
 5151 CTAATCCTGT TACCAGTGGC TGCTGCCAGT GGCGATAAGT CGTGTCTTAC 
 5201 CGGGTTGGAC TCAAGACGAT AGTTACCGGA TAAGGCGCAG CGGTCGGGCT 
 5251 GAACGGGGGG TTCGTGCACA CAGCCCAGCT TGGAGCGAAC GACCTACACC 
 5301 GAACTGAGAT ACCTACAGCG TGAGCTATGA GAAAGCGCCA CGCTTCCCGA 
 5351 AGGGAGAAAG GCGGACAGGT ATCCGGTAAG CGGCAGGGTC GGAACAGGAG 
 5401 AGCGCACGAG GGAGCTTCCA GGGGGAAACG CCTGGTATCT TTATAGTCCT 
 5451 GTCGGGTTTC GCCACCTCTG ACTTGAGCGT CGATTTTTGT GATGCTCGTC 
 5501 AGGGGGGCGG AGCCTATGGA AAAACGCCAG CAACGCGGCC TTTTTACGGT 
 5551 TCCTGGCCTT TTGCTGGCCT TTTGCTCACA TGTTCTTTCC TGCGTTATCC 
 5601 CCTGATTCTG TGGATAACCG TATTACCGCC TTTGAGTGAG CTGATACCGC 
 5651 TCGCCGCAGC CGAACGACCG AGCGCAGCGA GTCAGTGAGC GAGGAAGCGG 
 5701 AAGAGCGCCT GATGCGGTAT TTTCTCCTTA CGCATCTGTG CGGTATTTCA 
 5751 CACCGCATAT ATGGTGCACT CTCAGTACAA TCTGCTCTGA TGCCGCATAG 
 5801 TTAAGCCAGT ATACACTCCG CTATCGCTAC GTGACTGGGT CATGGCTGCG 
 5851 CCCCGACACC CGCCAACACC CGCTGACGCG CCCTGACGGG CTTGTCTGCT 
 5901 CCCGGCATCC GCTTACAGAC AAGCTGTGAC CGTCTCCGGG AGCTGCATGT 
 5951 GTCAGAGGTT TTCACCGTCA TCACCGAAAC GCGCGAGGCA GAACGCCATC 
 6001 AAAAATAATT CGCGTCTGGC CTTCCTGTAG CCAGCTTTCA TCAACATTAA 
 6051 ATGTGAGCGA GTAACAACCC GTCGGATTCT CCGTGGGAAC AAACGGCGGA 
 6101 TTGACCGTAA TGGGATAGGT TACGTTGGTG TAGATGGGCG CATCGTAACC 
 6151 GTGCATCTGC CAGTTTGAGG GGACGACGAC AGTATCGGCC TCAGGAAGAT 
 6201 CGCACTCCAG CCAGCTTTCC GGCACCGCTT CTGGTGCCGG AAACCAGGCA 
 6251 AAGCGCCATT CGCCATTCAG GCTGCGCAAC TGTTGGGAAG GGCGATCGGT 
 6301 GCGGGCCTCT TCGCTATTAC GCCAGCTGGC GAAAGGGGGA TGTGCTGCAA 
 6351 GGCGATTAAG TTGGGTAACG CCAGGGTTTT CCCAGTCACG ACGTTGTAAA 
 6401 ACGACGGCCA GTGAATCCGT AATCATGGTC ATAGCTGTTT CCTGTGTGAA 
 6451 ATTGTTATCC GCTCACAATT CCACACAACA TACGAGCCGG AAGCATAAAG 
 6501 TGTAAAGCCT GGGGTGCCTA ATGAGTGAGC TAACTCACAT TAATTGCGTT 
 6551 GCGCTCACTG CCCGCTTTCC AGTCGGGAAA CCTGTCGTGC CAGCTGCATT 
 6601 AATGAATCGG CCAACGCGCG GGGAGAGGCG GTTTGCGTAT TGGGCGCCAG 
 6651 GGTGGTTTTT CTTTTCACCA GTGAGACGGG CAACAGCTGA TTGCCCTTCA 
 6701 CCGCCTGGCC CTGAGAGAGT TGCAGCAAGC GGTCCACGCT GGTTTGCCCC 
 6751 AGCAGGCGAA AATCCTGTTT GATGGTGGTT AACGGCGGGA TATAACATGA 
 6801 GCTGTCTTCG GTATCGTCGT ATCCCACTAC CGAGATATCC GCACCAACGC 
 6851 GCAGCCCGGA CTCGGTAATG GCGCGCATTG CGCCCAGCGC CATCTGATCG 
 6901 TTGGCAACCA GCATCGCAGT GGGAACGATG CCCTCATTCA GCATTTGCAT 
 6951 GGTTTGTTGA AAACCGGACA TGGCACTCCA GTCGCCTTCC CGTTCCGCTA 
 7001 TCGGCTGAAT TTGATTGCGA GTGAGATATT TATGCCAGCC AGCCAGACGC 
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 7051 AGACGCGCCG AGACAGAACT TAATGGGCCC GCTAACAGCG CGATTTGCTG 
 7101 GTGACCCAAT GCGACCAGAT GCTCCACGCC CAGTCGCGTA CCGTCTTCAT 
 7151 GGGAGAAAAT AATACTGTTG ATGGGTGTCT GGTCAGAGAC ATCAAGAAAT 
 7201 AACGCCGGAA CATTAGTGCA GGCAGCTTCC ACAGCAATGG CATCCTGGTC 
 7251 ATCCAGCGGA TAGTTAATGA TCAGCCCACT GACGCGTTGC GCGAGAAGAT 
 7301 TGTGCACCGC CGCTTTACAG GCTTCGACGC CGCTTCGTTC TACCATCGAC 
 7351 ACCACCACGC TGGCACCCAG TTGATCGGCG CGAGATTTAA TCGCCGCGAC 
 7401 AATTTGCGAC GGCGCGTGCA GGGCCAGACT GGAGGTGGCA ACGCCAATCA 
 7451 GCAACGACTG TTTGCCCGCC AGTTGTTGTG CCACGCGGTT GGGAATGTAA 
 7501 TTCAGCTCCG CCATCGCCGC TTCCACTTTT TCCCGCGTTT TCGCAGAAAC 
 7551 GTGGCTGGCC TGGTTCACCA CGCGGGAAAC GGTCTGATAA GAGACACCGG 
 7601 CATACTCTGC GACATCGTAT AACGTTACTG GTTTCACATT CACCACCCTG 
 7651 AATTGACTCT CTTCCGGGCG CTATCATGCC ATACCGCGAA AGGTTTTGCG 
 7701 CCATTCGATG GTGTCCTGGC ACGACAGGTT TCCCGACTGG AAAGCGGGCA 
 7751 GTGAGCGCAA CGCAATTAAT GTGAGTTAGC TCACTCATTA GGCACCCCAG 
 7801 GCTTTACACT TTATGCTTCC GGCTCGTATA ATGTGTGGAA TTGTGAGCGG 
 7851 ATAACAATTT CACACAGGAA ACAGGATCGA TCCATCGATG AGCTTACTCC 
 7901 CCATCCCCCT GTTGACAATT AATCATCGGC TCGTATAATG TGTGGAATTG 
 7951 TGAGCGGATA ACAATTTCAC ACAGGAAACA GGATCAGCTT ACTCCCCATC 
 8001 CCCCTGTTGA CAATTAATCA TCGGCTCGTA TAATGTGTGG AATTGTGAGC 
 8051 GGATAACAAT TTCACACAGG AAACAGGATC CATCGATGCT TAGGAGGTCA 
 8101 T 
 
 223




















Table B.1. P450 BM-3 variants generated by random mutagenesis and recombination 




substitution Amino acid substitution of mutants 
Variant 35-4 139-3 139-37 A B L J 
Reference [1,2] [2,3] [2] [2] [2] [2] [2,4] 
E5 A15G     E [a]   
V78 T236C A A A A A A A 
K99 A297G     K [a]   
F107 C324T  F [a] F [a] F [a] F [a] F [a] F [a]
A112 A336G      A [a]  
H138 C415T  Y      
G157 G472T    C    
N159 C480T   N [a]     
F162 T487C      L  
D168 G505A      N  
T175 C527T  I I I I I I 
V178 G535A  I      
A184 553-555 [b]    I I   
A184 C554T  V V   V V 
N186 A559G   D     
R203 C612T   R [a]     
F205 T617G       C 
D217 A653T   V     
D223 T669A    E E   
S226 C681G       R 
G227 G682A    S S   
H236 709-711 [c]    R    
H236 T711G Q Q Q  Q Q Q 
E252 A758G G G G G G G G 
R255 C766A  S     S 
V281 T845C    A    
A290 C872T  V V V V V V 
A295 G886A  T      
P303 A912C   P [a]     
Q308 A924G     Q [a]   
A328 C986T        
L353 C1060G  V V V V V V 
G396 G1189A   M     
E372 A1119G       E [a]
Q397 G1194A  Q [a]      
T411A A1234G      A  
P525P G1575C     P [a]   
[a] Synonymous mutation 
[b] A184I DNA mutation was GCA to ATA 
[c] H236R DNA mutation was CAT to CGG 
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substitution Amino acid substitution of mutants 
  J 9-10A 9-10A-A82L 
9-10A-
A328V 1-12G 
Reference [2,4] [2,4] [2,4] [2,4] [2,4] 
R47 C142T  C C C C 
V78 T236C A A A A A 
A82 247-249 [2]   L  L 
K94 A284T  I I I I 
F107 C324T F [a] F [a] F [a] F [a] F [a]
P142 C427T  S S S S 
T175 C527T I I I I I 
A184 C554T V V V V V 
F205 T617G C C C C C 
S226 C681G R R R R R 
H236 T711G Q Q Q Q Q 
E252 A758G G G G G G 
R255 C766A S S S S S 
A290 C872T V V V V V 
A328 C986T    V V 
L353 C1060G V V V V V 
E372 A1119G E [a] E [a] E [a] E [a] E [a]
 
[a] Synonymous mutation 
[b] A82L DNA mutation was GCA to CTT 
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Table B.3. Variants of P450 BM-3 containing single active site mutations as described in 
Chapter 3. 
Name DNA position DNA substitutions [a] Amino acid substitution [a]
9-10A-L75I 226-228 CTT→ATT L75I 
9-10A-L75W 226-228 CTT→TGG L75W 
9-10A-A78T 235-237 GCA→ACA A78T 
9-10A-A78F 235-237 GCA→TTC A78F 
9-10A-A78S 235-237 GCA→TCC A78S 
9-10A-A82T 247-249 GCA→ACA A82T 
9-10A-A82S 247-249 GCA→TCA A82S 
9-10A-A82F 247-249 GCA→TTC A82F 
9-10A-A82I 247-249 GCA→ATC A82I 
9-10A-A82C 247-249 GCA→TGC A82C 
9-10A-A82G 247-249 GCA→GGG A82G 
9-10A-F87I 262-264 TTT→ATC F87I 
9-10A-F87V 262-264 TTT→GTG F87V 
9-10A-F87L 262-264 TTT→TTG F87L 
9-10A-T88C 265-267 ACA→TGT T88C 
9-10A-T260L 781-783 ACA→CTC T260L 
9-10A-T260S 781-783 ACA→TCA T260S 
9-10A-T260N 781-783 ACA→AAC T260N 
9-10A-A328F 985-987 GCT→TTC A328F 
9-10A-A328M 985-987 GCT→ATG A328M 
9-10A-A328L 985-987 GCT→CTC A328L 
 
[a] Mutations are relative to 9-10A (see Table B.2 for details).  Wild-type P450 BM-3 has a 




Table B.4. Variants of P450 BM-3 containing multiple active site mutations as described in 
Chapters 3, 4, and 5. 
Mutant Reference A75 [a] A78 [a] A82 [a] F87 [a] A328 [a]
77-9H   T G  L 
1-7D  I F G  L 
68-8F    F G  L 
49-9B      G V L 
35-7F    F S   L 
1-5G  I F S   L 
13-7C    T     L 
49-1A    T G V L 
2-4B  I T     L 
12-10C     G V V 
11-8E       V L 
41-5B   F G  V 
29-3E   F G  F 
7-11D     F  V 
29-10E     F  F 
53-5H [5]  F S  F 
 
[a] Mutations are relative to 9-10A (see Table B.2 for details).  Wild-type P450 BM-3 has a 
valine at position 78. 
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substitution Amino acid substitution of mutants 
Variant 53-5H-E464G [a] 35-E11 [a]
Reference [5] [5] 
E464 A1394G G G 
I710 T2132C  T 
L771 A2313G  L [b]
 
[a] only mutations in the reductase domain are listed.  Heme domain mutations are those 
listed for 53-5H in Table B.4. 
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The activity profiles of the saturation mutagenesis libraries are plotted in figure C.1.  For 
each profile, the activity of each of the 174 library members was normalized to the 
average 9-10A activity and is plotted in descending order.  Mutants with greater than 
20% of 9-10A’s activity (dashed line) were considered active.  The coefficient of 
variance of the screen was determined to be 13% based on activities of 16 parental clones 
cultured in the same 96-well plates under identical conditions.  The screen was performed 
in 96-well plate format in which each well of the microtiter plates containing E. coli cell 
lysate grown from a single colony was screened for activity.  Eight wells in each plate 
were filled with mutant 9-10A for comparison and one well was left empty as a negative 
control.  Please refer to Chapter 8 for experimental details. 
































































































































































































































































A p p e n d i x  D  












The following section lists the experimental procedures for the synthesis of substrates and 
product standards as well as for whole cell biotransformations described in Chapter 5.  This 
work was performed by Dieter F. Münzer, Sabine Feichtenhofer, Anna de Raadt and Anton 
Glieder at the Technical University of Graz, Austria.  
 
A. Instrumentation 
All chemicals were purchased from Sigma-Aldrich, Fluka or Merck.  If required, chemicals 
and solvents were purified according to Perrin and Armarego [1].  Optical rotations were 
measured on a Perkin Elmer Polarimeter 341.  1H and 13C NMR were recorded on a 
Gemini 200 (Varian) or UNITY / INOVA 500 (Varian).  HETCOR, DEPT and COSY 
experiments were carried out as required.  CDCl3 was used as solvent and as internal 
standard.  Before use, the CDCl3 was filtered through a short plug of basic alumina to 
remove traces of acid.  The minor isomer is given in italics.  Chiral HPLC was determined 
with an Agilent 1100 Series HPLC system containing column unity, degasser, quaternary 
pump, autosampler, UV and RI detector.  A Lichrosorb SJ 60, 10 µm normal phase 
precolumn was used.  LC was performed on Silica gel 60 (Merck, 70 - 230 mesh) using 
mixtures of ethyl acetate and petroleum ether unless otherwise stated.  GC analysis was 
carried out on an Agilent 6890 N network GC system with a 7683 series autosampler, FID 
and a Agilent 19091J-413 HP 5 column (30 m).  TLC was performed on Silica gel 60 F254 
aluminium plates (Merck) and compounds detected with UV (254 nm) and dipping into 
either reagent A (1 g vanillin, 140 mL ethanol or methanol, 20 mL concentrated H2SO4) or 
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reagent B (10% H2SO4, 10% (NH4)6Mo7O24 × 4 H2O and 0.8% Ce(SO4)2 × 4 H2O in 
water).  The TLC plates were then developed by heating with a heat gun.  Mixtures of 
petroleum ether/ethyl acetate were used as eluent.  Centrifugation was carried out with a 
Beckman Coulter Avanti J-20 XP centrifuge with a JA-10 rotor.  For the 
biotransformations a Memmert BE 600 incubator was used. 
 




The biotransformation substrate 2 was synthesized using published methods [2-4]. 
 
C. Synthesis of Product Standards 
For the identification of the peaks in HPLC and GC, for example for the determination of 













The title compound was obtained in 34% yield from reacting racemic 3-
oxocyclopentanecarboxylic acid (1.07 g, 8.35 mmol) with 2-aminophenol (0.91 g, 8.35 
mmol) as described (Method B) in the published synthesis for benzoxazoles [2-4].  The 
desired ketone 5 was purified by column chromatography (pet. ether : ethyl acetate = 
5:1 to 3:1).  Physical data are identical to literature [2-4]. 
 
E. Synthesis of Product 3 Standards 
For the determination of ee/de values of product 3 obtained from the biohydroxylation, 









(S,S)-3 (79% ee, 95% de, reference 1) was obtained from biohydroxylation of 2 with 
Sphingomonas sp. HXN-200 [5,6].  The absolute configuration of this sample was 
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determined by comparing optical rotation ([α]  = +20.1°, c = 2.1 in CH20D 2Cl2) to the 
published value [2-4]. 
A mixture of all four diastereoisomers of 3, [(S,R)-3 and (R,S)-3] : [(S,S)-3 and (R,R)-
3 = 5:1 (NMR), reference 2], was also required for reference purposes.  The mixture 
was obtained by reducing racemic ketone 5 with NaBH4 in methanol.  Accordingly, 
1.5 eq of NaBH4 were suspended in 2 mL of methanol.  After 30 seconds, a solution 
of 80 mg (0.40 mmol) of ketone 5 in 1 mL of methanol was added to the stirred 
suspension.  After five minutes the reaction was complete (TLC).  To the reaction 
mixture, 5 mL of CH2Cl2 were added, the solution was washed with equal amounts of 
5% aqueous HCl, saturated aqueous NaHCO3 and water, dried over Na2SO4, filtered 
and concentrated down under reduced pressure.  Column chromatography (pet. ether : 
ethyl acetate = 2:1) gave 65 mg of 3 (80% yield) as a colourless syrup. 
1H-NMR (CDCl3): δ = 1.71-2.46 (m, 7H), 3.49, 3.72 (m, p, 1H), 4.46, 4.58 (2 × bm, 
1H), 7.28, 7.45, 7.63 (3 × m, 2H, 1H, 1H).  13C-NMR (CDCl3): δ = 29.0, 30.1, 35.1, 
35.8, 36.7, 37.3, 40.4, 40.9, 73.4, 73.5, 110.4, 110.5, 119.6, 124.2, 124.4, 124.6, 
124.7, 141.2, 150.9, 170.3, 171.3. 
A mixture of (S,S)-3 and (S,R)-3 (reference 3) was also prepared.  The mixture was 
obtained by the oxidation of reference 1 with pyridinium chlorochromate (PCC) in 
CH2Cl2 and subsequent reduction of the isolated ketone 5 to alcohol 3 with NaBH4 in 
methanol.  For the oxidation, 1.5 eq of PCC were suspended in 1 mL of CH2Cl2 and a 
solution of 45 mg (0.22 mmol) of 3 (79% ee, 95% de) in 1 mL of CH2Cl2 was added.  
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The colour of the reaction mixture changed from brown to dark grey.  After 1 h the 
reaction was complete (TLC); the reaction mixture was immediately put onto silica 
gel and, after column chromatography (pet. ether : ethyl acetate = 1:1), 36 mg (81% 
yield) of ketone 5 were obtained as white crystals.  Physical data were identical to 
literature [2-4]. Subsequently, 25 mg of 5 were reduced as described for reference 2.  
20 mg (80% yield) of the desired mixture were obtained.  In this case, 
chromatography was not necessary. 
 
F. Cultivation of BM-3 mutants for whole cell biotransformations 
The following mutants were tested: 35-4, 139-3, 139-29, 139-37, A, B, J, L, 9-10A, 9-10A-
A328V, 9-10A-A-82L, 1-12G as well as the wild-type (see Appendix B for mutations).  E. 
coli DH5α, transformed with these plasmids, was used for the biotransformations.  All 
experiments were conducted in parallel.  All mutants were cultivated and stored on LBamp 
agar plates.  For the stage 1 cultures 10 mL Greiner tubes were used.  2 mL LB medium (10 
g tryptone, 5 g yeast extract and 5 g NaCl.  These were dissolved in distilled H2O and made 
up to 1L) together with 100mg/L ampicillin were inoculated with the respective E. coli 
cells which had been previously grown on agar.  These stage 1 cultures were then 
incubated over night (18.5 h) at 100 rpm and 30°C.  For stage 2 cultures 1L Erlenmeyer 
flasks were used.  150 mL TB medium (solution 1: 12 g tryptone, 24 g yeast extract and 4 
mL glycerine.  These were dissolved in distilled H2O and made up to 900 mL of solution 2: 
100 mL buffer consisting of 0.17 M KH2PO4 and 0.72 M K2HPO4.  Each solution was 
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sterilised separately and then mixed.  The pH value should lie between 6 and 8.) together 
with 100 mg/L ampicillin and, in one run, 1.5 mL/L trace element solution (0.5 g 
CaCl2×2H2O, 0.18 g ZnSO4×7H2O, 0.1 g MnSO4×H2O, 20.1 g Na2-EDTA, 16.7 g 
FeCl3×6H2O, 0.16 g CuSO4×5H2O, 0.18 g CoCl2×6H2O in 1L distilled H2O) were 
inoculated with 1 mL stage 1 culture.  They were then incubated at 100 rpm and 30°C for 
8h.  
 
G. Substrate addition 
After the previously mentioned 8h, substrate 2 (3 mM) was dissolved in EtOH (84 mg 2 in 
1 mL abs. EtOH) and this added to the stage 2 culture.  In addition, 50 mg/L ampicillin was 
also added.  After incubation for a further 15h, additional ampicillin (50 mg/L) was added.  
Each experiment was stopped (see the following section) after a final 21h of incubation. 
 
H. Sample processing and purification 
Each experiment was stopped by the following procedure: the respective culture was 
centrifuged (4400 g) and the supernatant liquid extracted three times with ethyl acetate.  
The organic phases were collected, dried with Na2SO4, filtered and concentrated down 
under reduced pressure.  The crude extracts were purified with column chromatography 
(pet. ether : ethyl acetate; 10:1 followed by 2:1).  During chromatography, priority was 
placed on not influencing the de of 3. 
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I. Analytics 
The determination of the ee/de of the products 3 from the whole cell biotransformation was 
achieved with reference compounds/mixtures (all 4 diastereoisomers of 3) and chiral HPLC 
(Daicel Chiralpak AD-H, 1mL/min, n-heptane:ethanol = 95.5:4.5, 230 nm; retention times: 
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